STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 126121

TO: Ben Sackey **Location: REM/5B31/5C18** **Art Unit: 1626** **Tuesday, July 13, 2004** **Case Serial Number: 10/655876**	**From: Noble Jarrell** **Location: Biotech-Chem Library** **Rem 1B71** **Phone: 272-2556** **Noble.jarrell@uspto.gov**

Search Notes

```
=> d his

     (FILE 'HOME' ENTERED AT 13:20:30 ON 13 JUL 2004)

     FILE 'HCAPLUS' ENTERED AT 13:20:37 ON 13 JUL 2004
               ACT SAC876APP/A
               ---------
L1   (        171)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHENG P"/AU OR "CHENG P T"/A
L2   (         30)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHENG PETER"/AU OR "CHENG PE
L3   (         14)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("DEVASTHALE P V"/AU OR "DEVAS
L4   (         61)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("JEON Y"/AU OR "JEON Y H"/AU
L5   (          9)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHEN SEAN"/AU OR "CHEN SEAN
L6   (        350)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHEN S S"/AU OR "CHEN S Y"/A
L7   (        576)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ZHANG HAO"/AU OR "ZHANG HAO
L8   (       1962)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ZHANG H"/AU OR "ZHANG H B"/A
L9   (         22)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L1 OR L2 OR L3 OR L4 OR L5 OR
L10            15 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9 AND ?OBES?/BI
               ---------
               ACT SAC876CS/A
               ---------
L11  (        171)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHENG P"/AU OR "CHENG P T"/A
L12  (         30)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHENG PETER"/AU OR "CHENG PE
L13  (         14)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("DEVASTHALE P V"/AU OR "DEVAS
L14  (         61)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("JEON Y"/AU OR "JEON Y H"/AU
L15  (          9)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHEN SEAN"/AU OR "CHEN SEAN
L16  (        350)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("CHEN S S"/AU OR "CHEN S Y"/A
L17  (        576)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ZHANG HAO"/AU OR "ZHANG HAO
L18  (       1962)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ZHANG H"/AU OR "ZHANG H B"/A
L19  (       5301)SEA FILE=HCAPLUS ABB=ON  PLU=ON  (BRISTOL (1A) (MYER? OR MEYER?
L20  (          2)SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("BRISTOL MAYERS SQUIBB CO"/CS
L21            29 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L11 OR L12 OR L13 OR L14 OR L
               ---------

     FILE 'REGISTRY' ENTERED AT 13:21:24 ON 13 JUL 2004
               ACT SAC876SSS/A
               ---------
L22               STR
L23             0 SEA FILE=REGISTRY SSS SAM L22
               ---------
L24               STR L22
L25             2 L24
L26           692 L24 FULL
                  SAVE TEMP L26 SAC876FUL/A
L27               STR L24
L28               STR L27
L29               STR L27
L30            33 L29 SAM SUB=L26
L31               STR L29
L32            33 L31 SAM SUB=L26
L33               STR L31
L34            33 L33  SUB=L26 SAM
L35           681 L33 FULL SUB=L26
                  SAVE TEMP L35 SAC876SUB1/A

     FILE 'HCAPLUS' ENTERED AT 14:28:20 ON 13 JUL 2004
L36            10 L35
L37             3 L11-18 AND L36
L38             3 L19-20 AND L36
L39             3 L37-38
L40             7 L36 NOT L39
```

```
L41           2 L40 AND (PY<=1999 OR AY<=1999 OR PRY<=1999 OR AD<19990922 OR PD

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:32:36 ON 13 JUL 2004
L42           9 L35

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:34:15 ON 13 JUL 2004
                 E CHENG P/AU
L43          22 E27,E32-33
                 E DEVASTHALE P/AU
L44           9 E4
                 E JEON Y/AU
L45          38 E30-31
                 E CHEN S/AU
L46          19 E37-38,E7
                 E ZHANG H/AU
L47          34 E28
L48        1393 (BRISTOL (1A) (MYER? OR M!YER?) (1A) SQUIBB?)/CS,PA
L49           7 L42 AND L43-47
L50           3 L42 AND L48
L51           3 L49 AND L50
L52           7 L49-50
L53           2 L42 NOT L52
L54           0 L53 AND (PY<=1999 OR AY<=1999 OR PRY<=1999 OR AD<19990922 OR PD

     FILE 'HCAOLD' ENTERED AT 14:39:20 ON 13 JUL 2004
L55           0 L35

     FILE 'REGISTRY' ENTERED AT 14:44:20 ON 13 JUL 2004
L56        2455 C23H26N2O4
L57           4 L56 AND L26

     FILE 'STNGUIDE' ENTERED AT 14:47:00 ON 13 JUL 2004

     FILE 'REGISTRY' ENTERED AT 14:47:17 ON 13 JUL 2004
L58           1 L57 AND ETHYL ESTER

     FILE 'HCAPLUS' ENTERED AT 14:47:42 ON 13 JUL 2004
L59           2 L58
L60           2 L59 AND L11-18
L61           2 L59 AND L19-20
L62           2 L60-61

     FILE 'USPATFULL, USPAT2' ENTERED AT 14:48:47 ON 13 JUL 2004
L63           6 L58
L64           6 L63 AND L43-47
L65           3 L63 AND L48
L66           6 L64-65

     FILE 'HCAOLD' ENTERED AT 14:50:25 ON 13 JUL 2004
L67           0 L58

     FILE 'HCAPLUS' ENTERED AT 15:11:24 ON 13 JUL 2004
L68          34 L10 OR L21

=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:12:14 ON 13 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 13 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 12 Jul 2004 (20040712/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d all 168 tot

L68 ANSWER 1 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:465510 HCAPLUS
ED Entered STN: 10 Jun 2004
TI Thyroid receptor ligands. Part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta
AU Hangeland, Jon J.; Doweyko, Arthur M.; Dejneka, Tamara; Friends, Todd J.; **Devasthale, Pratik**; Mellstrom, Karin; Sandberg, Johnny; Grynfarb, Marlena; Sack, John S.; Einspahr, Howard; Faernegardh, Mathias; Husman, Bolette; Ljunggren, Jan; Koehler, Konrad; Sheppard, Cheryl; Malm, Johan; Ryono, Denis E.
CS Pharmaceutical Research Institute, **Bristol-Myers Squibb**, Princeton, NJ, 08543, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3549-3553
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 2, 28
AB A set of thyromimetics having improved selectivity for TR-.beta.1 were prepared by replacing the 3'-iso-Pr group of 2 and 3 with substituents having increased steric bulk. From this limited SAR study, the most potent and selective compds. identified were derived from 2 and contained a 3'-Ph moiety bearing small hydrophobic groups meta to the biphenyl link. X-ray crystal data of 15c complexed with TR-.beta.1 LBD shows methionine 442 to be displaced by the bulky R3' Ph Et amide side chain. Movement of this amino acid side chain provides an expanded pocket for the bulky side chain while the ligand-receptor complex retains full agonist activity.
ST thyroid receptor ligand thyromimetic structure activity prepn crystal structure
IT INDEXING IN PROGRESS
IT Crystal structure
(of a thyromimetic with thyroid hormone receptor beta)
IT Structure-activity relationship
(structure activity relationships of thyromimetics with selectivity for thyroid hormone receptor beta)
IT Thyroid hormones
RL: PAC (Pharmacological activity); BIOL (Biological study)
(structure activity relationships of thyromimetics with selectivity for

thyroid hormone receptor beta)
IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.; structure activity relationships of thyromimetics with selectivity for thyroid hormone receptor beta)
IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.1; structure activity relationships of thyromimetics with selectivity for thyroid hormone receptor beta)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Barkhem, T; J Steroid Biochem Mol Biol 1991, V38, P667 HCAPLUS
(2) Borngraeber, S; PNAS 2003, V100, P15358 HCAPLUS
(3) Brent, G; Endocrinology: Basic and Clinical Principles 1997
(4) Carlsson, B; J Med Chem 2002, V45, P623 HCAPLUS
(5) Dow, R; Bioorg Med Chem Lett 2003, V13, P379 HCAPLUS
(6) Forrest, D; Semin Cancer Biol 1994, V5, P167 HCAPLUS
(7) Grover, G; PNAS 2003, V100, P10067 HCAPLUS
(8) Ishiyama, T; J Org Chem 1995, V60, P7508 HCAPLUS
(9) Johansson, C; Am J Physiol 1999, V276, PH2006 HCAPLUS
(10) Jones, T; Acta Cryst 1991, VA47(part 2), P110
(11) Lazar, M; Endocr Rev 1993, V14, P184 HCAPLUS
(12) McMartin, C; J Comput-Aided Mol Des 1997, V11, P333 HCAPLUS
(13) Navaza, J; Acta Cryst 1994, VA50, P157 HCAPLUS
(14) Nguyen, N; J Med Chem 2002, V45, P3310 HCAPLUS
(15) Otwinowski, Z; Methods in Enzymology 1997, V276, P307 HCAPLUS
(16) Trost, S; Endocrinology 2000, V141, P3057 HCAPLUS
(17) Underwood, A; Nature 1986, V324, P425 HCAPLUS
(18) Webb, P; J Steroid Biochem Mol Biol 2003, V83, P59
(19) Wilkstrom, L; EMBO J 1998, V17, P455
(20) Winn, M; Acta Cryst 2001, VD57, P122 HCAPLUS
(21) Woltz, J; J Org Chem 1955, V20, P210
(22) Ye, L; J Med Chem 2003, V46, P1580 HCAPLUS
(23) Yokoyama, N; J Med Chem 1995, V38, P695 HCAPLUS

L68 ANSWER 2 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:465505 HCAPLUS
ED Entered STN: 10 Jun 2004
TI BMS-201620: a selective beta 3 agonist
AU Washburn, W. N.; Sun, C.-Q.; Bisacchi, G.; Wu, G.; **Cheng, P. T.**; Sher, P. M.; Ryono, D.; Gavai, A. V.; Poss, K.; Girotra, R. N.; McCann, P. J.; Mikkilineni, A. B.; Dejneka, T. C.; Wang, T. C.; Merchant, Z.; Morella, M.; Arbeeny, C. M.; Harper, T. W.; Slusarchyk, D. A.; Skwish, S.; Russell, A. D.; Allen, G. T.; Tesfamariam, B.; Frohlich, B. H.; Abboa-Offei, B. E.; Cap, M.; Waldron, T. L.; George, R. J.; Young, D.; Dickinson, K. E.; Seymour, A. A.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3525-3529
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
CC 34 (Amino Acids, Peptides, and Proteins)
AB A series of N-(4-hydroxy-3-methylsulfonanilidoethanol)arylglycinamides were prepared and evaluated for their human .beta.3 adrenergic receptor agonist activity. SAR studies led to the identification of BMS-201620 (39), a potent .beta.3 full agonist (Ki=93 nM, 93% activation). Based on its favorable safety profile, BMS-201620 was chosen for clin. evaluation.
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE
(1) Amos, A; Diabet Med 1997, V14, PS7
(2) Anon; Unpublished work communicated by Dr Peter Slugg
(3) Bray, G; Nature 2000, V404, P672 HCAPLUS
(4) Crast, L; US 3517023 1970 HCAPLUS
(5) de Souza, C; Curr Pharm Des 2001, V7, P1433 HCAPLUS
(6) Emorine, L; Science 1989, V245, P1118 HCAPLUS
(7) Friedman, J; Nature 2000, V404, P632 HCAPLUS
(8) Gavai, A; Bioorg Med Chem Lett 2001, V11, P3041 HCAPLUS
(9) Kordik, C; J Med Chem 1999, V42, P181 HCAPLUS
(10) Lipworth, B; Eur J Clin Pharmacol 1989, V37, P297 HCAPLUS
(11) Lowell, B; J Biol Chem 2003, V278, P29385 HCAPLUS
(12) Sher, P; J Med Chem Res 1997, V7, P109 HCAPLUS
(13) Tesfamariam, B; Br J Pharmacol 1994, V112, P55 HCAPLUS
(14) Washburn, W; Bioorg Med Chem Lett 2001, V11, P3035 HCAPLUS
(15) Weber, A; Annu Rep Med Chem 1998, V33, P193 HCAPLUS
(16) Weyer, C; Diabet Metab 1999, V25, P11 HCAPLUS
(17) Weyer, C; Drug Dev Res 2000, V51, P80 HCAPLUS
(18) Yanovski, S; N Engl J Med 2002, V346, P591 HCAPLUS

L68 ANSWER 3 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41231 HCAPLUS
DN 140:111429
ED Entered STN: 18 Jan 2004
TI Preparation of substituted heterocyclic derivatives useful as **antidiabetic** and **antiobesity** agents
IN **Cheng, Peter T. W.**; **Chen, Sean**; **Devasthale, Pratik**; Ding, Charles Z.; Herpin, Timothy F.; Wu, Shung; **Zhang, Hao**; Wang, Wei; Ye, Xiang-Yang
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 543 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004004665	A2	20040115	WO 2003-US22149	20030702
	WO 2004004665	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004063700	A1	20040401	US 2003-616365	20030708
PRAI	US 2002-394508P	P	20020709		

OS MARPAT 140:111429
GI



I

AB The title compds. (I) [Z1 = (CH2)q, CO; Z2 = (CH2)p, CO; D = CH, CO, (CH2)m (where m = 0-3; p = 1, 2; q = 0-2); n = 0-2; Q = C, N; A = (CH2)x (where x = 1-5); A = (CH2)x1 (where x1 = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere in the chain; or A = -(CH2)x2-O-(CH2)x3- (where X2, X3 = 0 to 5, provided that at least one of x2 and x3 is other than 0); B = a bond or (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6 = C, N, O, or S and at least one of X2-X6 is C; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halogen, (un)substituted amino; R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, etc.; E = CH, N; Z = (CH2)x5 (where x5 is 0, i.e. a single or a double bond, 1, 2), or Z is (CH2)x6 (where x6 = 2-5), where (CH2)x6 includes an alkenyl (C:C) bond embedded within the chain or Z = -(CH2)x7-O-(CH2)x8- (where x7, x8 = 0-4); (CH2)x to (CH2)x8, (CH2)m, (CH2)n, (CH2)p and (CH2)q may be optionally substituted; Y = CO2R4 (where R4 = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR4a)R5 [where R4a = H, a prodrug ester; R5 = alkyl or aryl, or a phosphonic acid of the structure P(O)(OR4a)2]] including all stereoisomers, prodrug esters, and pharmaceutically acceptable salts thereof are prepared These compds., e.g. cis-1-ethoxycarbonyl-4-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl]pyrrolidin-3-ylacetic acid and cis-1-(6-trifluoromethylpyrimidin-2-yl)-4-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]phenyl]pyrrolidine-3-carboxylic acid, modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) levels, and thus are particularly useful in the treatment of **diabetes** and **obesity**, especially Type 2 **diabetes**, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, **obesity**, atherosclerosis, and related diseases employing such substituted acid derivs. alone or in combination with another **antidiabetic** agent and/or a hypolipidemic agent and/ or other therapeutic agents. Disclosed is a method for treating **diabetes**, especially Type 2 **diabetes**, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, **obesity**, hypertriglyceridemia, inflammation, Syndrome X, **diabetic** complications, dysmetabolic syndrome, atherosclerosis, and related diseases, which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound I. Also disclosed is a method for treating early malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions including fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and osteoporosis and proliferative diseases such as psoriasis, which comprises administering to a patient in need of treatment

a therapeutically effective amount of the compound I.

ST heterocycle prepn **antidiabetic antiobesity**; oxazolylethoxyphenylpyrrolidineacetic acid prepn **antidiabetic antiobesity**; oxazolylethoxyphenylpyrimidinylpyrrolidinecarboxylic acid prepn **antidiabetic antiobesity**; pyrimidinylpyrrolidinecarboxylic acid oxazolylethoxyphenyl prepn **antidiabetic antiobesity**; pyrrolidineacetic acid oxazolylethoxyphenyl prepn **antidiabetic antiobesity**; hyperglycemia hyperinsulinemia hyperlipidemia **obesity** atherosclerosis treatment heterocycle prepn

IT Intestine, disease
(Crohn's; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Metabolism, animal
(disorder, dysmetabolic syndrome; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Mammary gland, neoplasm
(ductal or lobular carcinoma; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated levels; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Stomach, disease
(gastric ulceritis; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Adipose tissue, neoplasm
(liposarcoma; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT **Diabetes** mellitus
(non-insulin-dependent; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Antiulcer agents
Atherosclerosis
Cytotoxic agents
Diabetes mellitus
Human
Hyperglycemia
Hypertriglyceridemia
Hypolipemic agents

Inflammation
Lung, neoplasm
Obesity
Osteoporosis
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Disease, animal
(proliferative; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Prostate gland, neoplasm
(prostatic intraepithelial neoplasia; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Disease, animal
(syndrome X; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 56-03-1, Biguanide 58-32-2, Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chloropropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 4205-91-8, Clonidine monohydrochloride 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89750-14-1, Glucagon-like peptide I 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS-962 144701-48-4, Telmisartan 147511-69-1, Itavastatin 152755-31-2, LY295427 159183-92-3, L750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 163222-33-1, Ezetimibe 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 168273-06-1, Rimonabant 169319-62-4, CGS 30440 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4 199113-98-9, Balaglitazone 199914-96-0, YM-440 213252-19-8, KRP297 244081-42-3, AJ9677 251565-85-2, AR-H 039242 251572-86-8, P32/98 287714-41-4, Visastatin 335149-08-1, L895645 335149-14-9, R-119702 335149-15-0, KAD1129 335149-19-4, GW-409544 335149-23-0, NVP-DPP-728A 335149-24-1, ATL-962 335149-25-2, CP331648 416839-88-8, Axokine 430433-17-3, Glipyride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapy; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 56-81-5, Glycerol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated levels; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(insulin resistance or hyperinsulinemia; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 647002-99-1P 647003-00-7P 647003-01-8P 647003-02-9P 647003-04-1P
647003-05-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 646998-60-9P 646998-64-3P 646998-66-5P 646998-69-8P 646998-72-3P
646998-73-4P 646998-75-6P 646998-77-8P 646998-79-0P 646998-80-3P
646998-83-6P 646998-84-7P 646998-86-9P 646998-88-1P 646998-90-5P
646998-92-7P 646998-93-8P 646998-94-9P 646998-96-1P 646998-98-3P
646999-00-0P 646999-02-2P 646999-04-4P 646999-06-6P 646999-08-8P
646999-10-2P 646999-11-3P 646999-12-4P 646999-13-5P 646999-14-6P
646999-15-7P 646999-16-8P 646999-17-9P 646999-18-0P 646999-19-1P
646999-20-4P 646999-21-5P 646999-22-6P 646999-23-7P 646999-24-8P
646999-25-9P 646999-26-0P 646999-27-1P 646999-28-2P 646999-30-6P
646999-31-7P 646999-32-8P 646999-33-9P 646999-34-0P 646999-35-1P
646999-36-2P 646999-37-3P 646999-38-4P 646999-39-5P 646999-40-8P
646999-41-9P 646999-42-0P 646999-43-1P 646999-44-2P 646999-45-3P
646999-46-4P 646999-47-5P 646999-48-6P 646999-49-7P 646999-50-0P
646999-51-1P 646999-52-2P 646999-53-3P 646999-54-4P 646999-55-5P
646999-56-6P 646999-57-7P 646999-58-8P 646999-59-9P 646999-60-2P
646999-61-3P 646999-62-4P 646999-63-5P 646999-64-6P 646999-65-7P
646999-67-9P 646999-68-0P 646999-69-1P 646999-70-4P 646999-71-5P
646999-72-6P 646999-73-7P 646999-74-8P 646999-75-9P 646999-76-0P
646999-77-1P 646999-78-2P 646999-79-3P 646999-80-6P 646999-81-7P
646999-82-8P 646999-83-9P 646999-84-0P 646999-85-1P 646999-86-2P
646999-87-3P 646999-88-4P 646999-89-5P 646999-90-8P 646999-91-9P
646999-92-0P 646999-93-1P 646999-94-2P 646999-95-3P 646999-96-4P
646999-97-5P 646999-98-6P 646999-99-7P 647000-00-8P 647000-01-9P
647000-02-0P 647000-03-1P 647000-04-2P 647000-05-3P 647000-06-4P
647000-07-5P 647000-08-6P 647000-09-7P 647000-10-0P 647000-11-1P
647000-12-2P 647000-13-3P 647000-14-4P 647000-15-5P 647000-16-6P
647000-17-7P 647000-18-8P 647000-19-9P 647000-20-2P 647000-21-3P
647000-22-4P 647000-23-5P 647000-24-6P 647000-25-7P 647000-26-8P
647000-27-9P 647000-28-0P 647000-29-1P 647000-30-4P 647000-31-5P
647000-32-6P 647000-33-7P 647000-34-8P 647000-35-9P 647000-36-0P
647000-37-1P 647000-38-2P 647000-39-3P 647000-40-6P 647000-41-7P
647000-42-8P 647000-43-9P 647000-44-0P 647000-45-1P 647000-46-2P
647000-47-3P 647000-48-4P 647000-49-5P 647000-50-8P 647000-51-9P
647000-52-0P 647000-53-1P 647000-54-2P 647000-55-3P 647000-56-4P
647000-57-5P 647000-58-6P 647000-59-7P 647000-60-0P 647000-61-1P
647000-62-2P 647000-63-3P 647000-64-4P 647000-65-5P 647000-66-6P
647000-67-7P 647000-68-8P 647000-69-9P 647000-70-2P 647000-71-3P
647000-72-4P 647000-73-5P 647000-74-6P 647000-76-8P 647000-77-9P
647000-78-0P 647000-79-1P 647000-80-4P 647000-81-5P 647000-82-6P
647000-83-7P 647000-84-8P 647000-85-9P 647000-86-0P 647000-87-1P
647000-88-2P 647000-89-3P 647000-90-6P 647000-91-7P 647000-92-8P
647000-93-9P 647000-94-0P 647000-95-1P 647000-96-2P 647000-97-3P

647000-98-4P 647000-99-5P 647001-00-1P 647001-01-2P 647001-02-3P
647001-03-4P 647001-04-5P 647001-05-6P 647001-06-7P 647001-07-8P
647001-08-9P 647001-09-0P 647001-10-3P 647001-11-4P 647001-12-5P
647001-13-6P 647001-14-7P 647001-15-8P 647001-16-9P 647001-17-0P
647001-18-1P 647001-19-2P 647001-20-5P 647001-21-6P 647001-22-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 647001-23-8P 647001-24-9P 647001-25-0P 647001-26-1P 647001-27-2P
647001-28-3P 647001-29-4P 647001-30-7P 647001-31-8P 647001-32-9P
647001-33-0P 647001-34-1P 647001-35-2P 647001-36-3P 647001-37-4P
647001-38-5P 647001-39-6P 647001-40-9P 647001-41-0P 647001-42-1P
647001-43-2P 647001-44-3P 647001-45-4P 647001-46-5P 647001-47-6P
647001-48-7P 647001-49-8P 647001-50-1P 647001-51-2P 647001-52-3P
647001-53-4P 647001-54-5P 647001-55-6P 647001-56-7P 647001-57-8P
647001-58-9P 647001-59-0P 647001-60-3P 647001-61-4P 647001-62-5P
647001-63-6P 647001-64-7P 647001-65-8P 647001-66-9P 647001-67-0P
647001-68-1P 647001-69-2P 647001-70-5P 647001-71-6P 647001-72-7P
647001-73-8P 647001-74-9P 647001-75-0P 647001-76-1P 647001-77-2P
647001-78-3P 647001-79-4P 647001-80-7P 647001-81-8P 647001-82-9P
647001-83-0P 647001-84-1P 647001-85-2P 647001-86-3P 647001-87-4P
647001-88-5P 647001-89-6P 647001-90-9P 647001-91-0P 647001-92-1P
647001-93-2P 647001-94-3P 647001-95-4P 647001-96-5P 647001-97-6P
647001-98-7P 647001-99-8P 647002-00-4P 647002-01-5P 647002-02-6P
647002-03-7P 647002-04-8P 647002-05-9P 647002-06-0P 647002-07-1P
647002-08-2P 647002-09-3P 647002-10-6P 647002-11-7P 647002-12-8P
647002-13-9P 647002-14-0P 647002-15-1P 647002-16-2P 647002-17-3P
647002-18-4P 647002-19-5P 647002-20-8P 647002-21-9P 647002-22-0P
647002-23-1P 647002-24-2P 647002-25-3P 647002-27-5P 647002-28-6P
647002-29-7P 647002-30-0P 647002-31-1P 647002-32-2P 647002-33-3P
647002-34-4P 647002-35-5P 647002-36-6P 647002-37-7P 647002-38-8P
647002-39-9P 647002-40-2P 647002-41-3P 647002-42-4P 647002-43-5P
647002-44-6P 647002-45-7P 647002-46-8P 647002-47-9P 647002-49-1P
647002-50-4P 647002-51-5P 647002-52-6P 647002-53-7P 647002-54-8P
647002-55-9P 647002-56-0P 647002-57-1P 647002-58-2P 647002-59-3P
647002-60-6P 647002-61-7P 647002-62-8P 647002-63-9P 647002-64-0P
647002-65-1P 647002-66-2P 647002-67-3P 647002-68-4P 647002-69-5P
647002-70-8P 647002-71-9P 647002-72-0P 647002-73-1P 647002-74-2P
647002-75-3P 647002-76-4P 647002-77-5P 647002-78-6P 647002-79-7P
647002-80-0P 647002-81-1P 647002-82-2P 647002-83-3P 647002-84-4P
647002-85-5P 647002-86-6P 647002-87-7P 647002-88-8P 647002-89-9P
647002-90-2P 647002-91-3P 647002-92-4P 647002-93-5P 647002-94-6P
647002-95-7P 647002-96-8P 647002-97-9P 647002-98-0P 647003-03-0P
647003-06-3P 647003-07-4P 647003-08-5P 647003-09-6P 647003-10-9P
647003-11-0P 647003-12-1P 647003-13-2P 647003-14-3P 647003-15-4P
647003-16-5P 647003-17-6P 647003-18-7P 647003-19-8P 647003-20-1P
647003-21-2P 647003-22-3P 647003-23-4P 647003-24-5P 647003-25-6P
647003-26-7P 647003-27-8P 647003-28-9P 647003-29-0P 647003-30-3P
647003-31-4P 647003-32-5P 647003-33-6P 647003-34-7P 647003-35-8P
647003-36-9P 647003-37-0P 647003-38-1P 647003-39-2P 647003-40-5P
647003-41-6P 647003-42-7P 647003-43-8P 647003-44-9P 647003-45-0P
647003-46-1P 647003-47-2P 647003-48-3P 647003-49-4P 647003-50-7P
647003-51-8P 647003-52-9P 647003-53-0P 647003-54-1P 647003-55-2P
647003-56-3P 647003-57-4P 647003-58-5P 647003-59-6P 647003-60-9P
647003-61-0P 647003-62-1P 647003-63-2P 647003-64-3P 647003-65-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 647003-66-5P 647003-67-6P 647003-68-7P 647003-69-8P 647003-70-1P
647003-71-2P 647003-72-3P 647003-93-8P 647004-00-0P 647004-07-7P
647004-67-9P 647007-28-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 647004-06-6P 647005-23-0P 647005-27-4P 647005-28-5P 647005-47-8P
647005-49-0P 647005-50-3P 647006-01-7P 647006-03-9P 647006-37-9P
647006-38-0P 647006-51-7P 647006-52-8P 647007-34-9P 647007-35-0P
647007-43-0P 647007-44-1P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 94594-90-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 334-88-3P, Diazomethane 1201-68-9P 3272-96-6P 6129-15-3P
17944-68-2P 24764-91-8P 27492-46-2P 36187-69-6P 39514-19-7P
40019-44-1P 53215-95-5P 57668-34-5P 58608-98-3P 61389-68-2P
85136-12-5P 92427-80-0P 93102-05-7P 94938-02-0P 94938-03-1P
96013-77-3P 96013-95-5P 103788-59-6P 114564-74-8P 116381-09-0P
121484-76-2P 129649-12-3P 131362-25-9P 136058-69-0P 160721-23-3P
161670-81-1P 166253-36-7P 167147-68-4P 175204-39-4P 175204-40-7P
177259-98-2P 185679-37-2P 227029-27-8P 244152-94-1P 255876-57-4P
331746-05-5P 331746-50-0P 433289-57-7P 433289-59-9P 440365-13-9P
476458-89-6P 477541-29-0P 477541-33-6P 477774-06-4P 477774-28-0P
477774-29-1P 477774-36-0P 478540-87-3P 518343-85-6P 585569-20-6P
585569-21-7P 585569-22-8P 585569-23-9P 585569-24-0P 645392-01-4P
645392-34-3P 647003-73-4P 647003-74-5P 647003-75-6P 647003-76-7P
647003-77-8P 647003-78-9P 647003-79-0P 647003-80-3P 647003-81-4P
647003-82-5P 647003-83-6P 647003-84-7P 647003-85-8P 647003-86-9P
647003-87-0P 647003-88-1P 647003-89-2P 647003-90-5P 647003-92-7P
647003-94-9P 647003-95-0P 647003-96-1P 647003-97-2P 647003-98-3P
647003-99-4P 647004-01-1P 647004-02-2P 647004-03-3P 647004-04-4P
647004-05-5P 647004-08-8P 647004-09-9P 647004-10-2P 647004-11-3P
647004-12-4P 647004-13-5P 647004-14-6P 647004-15-7P 647004-16-8P
647004-17-9P 647004-18-0P 647004-19-1P 647004-20-4P 647004-21-5P
647004-22-6P 647004-23-7P 647004-24-8P 647004-25-9P 647004-26-0P
647004-28-2P 647004-29-3P 647004-30-6P 647004-31-7P 647004-32-8P
647004-33-9P 647004-34-0P 647004-35-1P 647004-36-2P 647004-37-3P
647004-38-4P 647004-39-5P 647004-40-8P 647004-41-9P 647004-42-0P
647004-43-1P 647004-44-2P 647004-45-3P 647004-46-4P 647004-47-5P
647004-48-6P 647004-49-7P 647004-50-0P 647004-51-1P 647004-53-3P
647004-54-4P 647004-55-5P 647004-56-6P 647004-57-7P 647004-58-8P
647004-59-9P 647004-60-2P 647004-61-3P 647004-62-4P 647004-63-5P
647004-64-6P 647004-65-7P 647004-66-8P 647004-68-0P 647004-69-1P
647004-70-4P 647004-71-5P 647004-72-6P 647004-73-7P 647004-74-8P
647004-75-9P 647004-76-0P 647004-77-1P 647004-78-2P 647004-79-3P
647004-80-6P 647004-81-7P 647004-82-8P 647004-83-9P 647004-84-0P
647004-85-1P 647004-86-2P 647004-87-3P 647004-88-4P 647004-89-5P
647004-90-8P 647004-91-9P 647004-92-0P 647004-93-1P 647004-94-2P
647004-95-3P 647004-96-4P 647004-97-5P 647004-98-6P 647004-99-7P
647005-00-3P 647005-01-4P 647005-02-5P 647005-03-6P 647005-04-7P
647005-05-8P 647005-06-9P 647005-07-0P 647005-08-1P 647005-09-2P

647005-10-5P 647005-11-6P 647005-12-7P 647005-13-8P 647005-14-9P
647005-15-0P 647005-16-1P 647005-17-2P 647005-18-3P 647005-19-4P
647005-20-7P 647005-21-8P 647005-22-9P 647005-24-1P 647005-25-2P
647005-26-3P 647005-29-6P 647005-30-9P 647005-31-0P 647005-32-1P
647005-33-2P 647005-34-3P 647005-35-4P 647005-36-5P 647005-37-6P
647005-38-7P 647005-39-8P 647005-40-1P 647005-41-2P 647005-42-3P
647005-43-4P 647005-44-5P 647005-45-6P 647005-46-7P 647005-48-9P
647005-51-4P 647005-52-5P 647005-53-6P 647005-54-7P 647005-55-8P
647005-56-9P 647005-57-0P 647005-58-1P 647005-59-2P 647005-60-5P
647005-61-6P 647005-62-7P 647005-63-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 647005-64-9P 647005-65-0P 647005-66-1P 647005-67-2P 647005-68-3P
647005-69-4P 647005-70-7P 647005-71-8P 647005-72-9P 647005-73-0P
647005-74-1P 647005-75-2P 647005-76-3P 647005-77-4P 647005-78-5P
647005-79-6P 647005-80-9P 647005-81-0P 647005-82-1P 647005-83-2P
647005-84-3P 647005-85-4P 647005-86-5P 647005-87-6P 647005-88-7P
647005-89-8P 647005-90-1P 647005-91-2P 647005-92-3P 647005-94-5P
647005-95-6P 647005-96-7P 647005-97-8P 647005-98-9P 647005-99-0P
647006-00-6P 647006-02-8P 647006-05-1P 647006-06-2P 647006-07-3P
647006-08-4P 647006-09-5P 647006-10-8P 647006-11-9P 647006-12-0P
647006-13-1P 647006-14-2P 647006-16-4P 647006-17-5P 647006-18-6P
647006-19-7P 647006-20-0P 647006-21-1P 647006-22-2P 647006-23-3P
647006-24-4P 647006-25-5P 647006-26-6P 647006-27-7P 647006-28-8P
647006-29-9P 647006-30-2P 647006-31-3P 647006-32-4P 647006-33-5P
647006-34-6P 647006-35-7P 647006-36-8P 647006-39-1P 647006-40-4P
647006-41-5P 647006-42-6P 647006-43-7P 647006-44-8P 647006-45-9P
647006-46-0P 647006-47-1P 647006-48-2P 647006-49-3P 647006-50-6P
647006-53-9P 647006-54-0P 647006-55-1P 647006-56-2P 647006-57-3P
647006-58-4P 647006-59-5P 647006-60-8P 647006-61-9P 647006-62-0P
647006-63-1P 647006-64-2P 647006-65-3P 647006-66-4P 647006-67-5P
647006-68-6P 647006-69-7P 647006-70-0P 647006-71-1P 647006-72-2P
647006-73-3P 647006-74-4P 647006-75-5P 647006-76-6P 647006-77-7P
647006-78-8P 647006-79-9P 647006-80-2P 647006-81-3P 647006-82-4P
647006-83-5P 647006-84-6P 647006-85-7P 647006-86-8P 647006-87-9P
647006-88-0P 647006-89-1P 647006-90-4P 647006-91-5P 647006-92-6P
647006-93-7P 647006-94-8P 647006-95-9P 647006-96-0P 647006-97-1P
647006-98-2P 647006-99-3P 647007-00-9P 647007-01-0P 647007-02-1P
647007-03-2P 647007-04-3P 647007-05-4P 647007-06-5P 647007-07-6P
647007-08-7P 647007-09-8P 647007-10-1P 647007-11-2P 647007-12-3P
647007-13-4P 647007-14-5P 647007-15-6P 647007-16-7P 647007-17-8P
647007-18-9P 647007-19-0P 647007-20-3P 647007-21-4P 647007-22-5P
647007-23-6P 647007-24-7P 647007-25-8P 647007-26-9P 647007-27-0P
647007-29-2P 647007-30-5P 647007-31-6P 647007-32-7P 647007-33-8P
647007-36-1P 647007-37-2P 647007-38-3P 647007-39-4P 647007-40-7P
647007-41-8P 647007-42-9P 647007-45-2P 647007-46-3P 647007-47-4P
647007-48-5P 647007-49-6P 647007-50-9P 647007-51-0P 647007-52-1P
647007-53-2P 647007-54-3P 647007-55-4P 647007-56-5P 647007-57-6P
647007-58-7P 647007-59-8P 647007-60-1P 647007-61-2P 647007-63-4P
647007-64-5P 647007-65-6P 647007-66-7P 647007-67-8P 647007-68-9P
647007-69-0P 647007-70-3P 647007-71-4P 647007-72-5P 647007-73-6P
647007-74-7P 647007-75-8P 647007-77-0P 647007-79-2P 647007-80-5P
647007-81-6P 647007-82-7P 647012-33-7P 647015-46-1P 647832-88-0P
647832-89-1P 647832-90-4P 647832-91-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 50-00-0, Formaldehyde, reactions 57-71-6, 2,3-Butanedione monooxime 67-56-1, Methanol, reactions 70-25-7, 1-Methyl-3-nitro-1-nitrosoguanidine 75-36-5, Acetyl chloride 77-78-1, Dimethyl sulfate 79-04-9 79-22-1, Methyl chloroformate 88-10-8, Diethylaminocarbonyl chloride 98-09-9, Benzenesulfonyl chloride 98-80-6, Phenylboronic acid 98-88-4, Benzoyl chloride 99-76-3, 4-Hydroxybenzoic acid methyl ester 100-07-2, 4-Methoxybenzoyl chloride 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 100-52-7, Benzaldehyde, reactions 100-63-0, Phenylhydrazine 100-83-4, 3-Hydroxybenzaldehyde 103-71-9, Phenyl isocyanate, reactions 103-80-0, Benzeneacetyl chloride 104-94-9, p-Anisidine 106-93-4, 1,2-Dibromoethane 107-13-1, Acrylonitrile, reactions 107-14-2, Chloroacetonitrile 107-21-1, Ethylene glycol, reactions 107-22-2, Glyoxal 108-23-6, Isopropyl chloroformate 108-24-7, Acetic anhydride 108-86-1, Bromobenzene, reactions 109-61-5, n-Propyl chloroformate 109-90-0, Ethyl isocyanate 122-01-0, 4-Chlorobenzoyl chloride 123-08-0, 4-Hydroxybenzaldehyde 124-63-0, Methanesulfonyl chloride 141-75-3, Butyryl chloride 149-87-1, DL-Pyroglutamic acid 312-94-7, 2-Trifluoromethylbenzoyl chloride 329-15-7, 4-Trifluoromethylbenzoyl chloride 375-72-4, 1,1,2,2,3,3,4,4,4-Nonafluoro-1-butanesulfonyl fluoride 431-35-6, Bromotrifluoroacetone 462-27-1, 2-Fluoroethyl chloroformate 501-53-1, Benzyl chloroformate 501-97-3, 3-(4-Hydroxyphenyl)propionic acid 540-38-5, 4-Iodophenol 541-41-3, Ethyl chloroformate 543-27-1, Isobutyl chloroformate 592-34-7, n-Butyl chloroformate 594-44-5, Ethanesulfonyl chloride 615-18-9, 2-Chlorobenzoxazole 616-38-6, Dimethyl carbonate 618-46-2, 3-Chlorobenzoyl chloride 620-24-6, 3-Hydroxybenzyl alcohol 621-54-5, 3-(3-Hydroxyphenyl)propionic acid 623-47-2, Ethyl propynoate 627-11-2, 2-Chloroethyl chloroformate 628-12-6, 2-Methoxyethyl chloroformate 630-08-0, Carbon monoxide, reactions 674-82-8, Diketene 874-60-2, 4-Methylbenzoyl chloride 917-54-4, Methyllithium 917-95-3, 2-Nitroso-2-methylpropane 922-67-8, Methyl propynoate 933-88-0, 2-Methylbenzoyl chloride 937-62-2, 4-Methylphenyl chloroformate 1011-37-6, 5-Chloromethyl-3-phenylisoxazole 1066-54-2, Trimethylsilylacetylene 1118-02-1, Trimethylsilyl isocyanate 1423-26-3, 3-Trifluoromethylphenylboronic acid 1679-18-1, 4-Chlorophenylboronic acid 1700-37-4, 3-Benzyloxybenzaldehyde 1710-98-1, 4-tert-Butylbenzoyl chloride 1711-05-3, 3-Methoxybenzoyl chloride 1711-06-4, 3-Methylbenzoyl chloride 1722-12-9, 2-Chloropyrimidine 1765-93-1, 4-Fluorophenylboronic acid 1822-94-2, 5-Chloromethyl-3-phenyl-[1,2,4]oxadiazole 1885-14-9, Phenyl chloroformate 2251-65-2, 3-Trifluoromethylbenzoyl chloride 2293-75-6, 2-Methoxyphenyl chloroformate 2344-80-1, Chloromethyltrimethylsilane 2393-23-9, 4-Methoxybenzylamine 2605-67-6, Methoxycarbonylmethylenetriphenylphosphorane 2719-27-9, Cyclohexanecarbonyl chloride 2920-38-9, 4-Biphenylcarbonitrile 2937-50-0, Allyl chloroformate 3282-30-2, Pivaloyl chloride 3483-82-7, N-Benzoyl-L-tyrosine ethyl ester 3934-20-1, 2,4-Dichloropyrimidine 4210-32-6, 4-tert-Butylbenzonitrile 4285-42-1, N-Methyl-N-phenylcarbamoyl chloride 4397-53-9, 4-Benzyloxybenzaldehyde 4457-32-3, 4-Nitrobenzyl chloroformate 4774-14-5, 2,6-Dichloropyrazine 4949-44-4, Ethyl propionylacetate 5424-21-5, 2,4-Dichloro-6-methylpyrimidine 5470-11-1, Hydroxylamine hydrochloride 7065-46-5, 3,3-Dimethylbutanoyl chloride 7497-61-2, 3-(3-Hydroxyphenyl)propionic acid methyl ester 7693-41-6, 4-Methoxyphenyl chloroformate 7693-44-9, 4-Bromophenyl chloroformate 7693-45-0, 4-Chlorophenyl chloroformate 7693-50-7, 2-Naphthyl chloroformate 7803-49-8, Hydroxylamine, reactions 10401-11-3, 3-Hydroxyphenylacetylene 10442-39-4, Tetrabutylammonium cyanide 13045-13-1, 3-Chloro-5-hydroxy-2-pentanone 13398-94-2, 2-(3-Hydroxyphenyl)ethanol 13831-03-3, tert-Butyl propiolate 14210-25-4, 5-Chloro-1-phenyltetrazole 14731-10-3 16205-84-8, Ethyl

3-trimethylsilylpropynoate 18107-18-1, Trimethylsilyldiazomethane 18162-48-6, tert-Butyldimethylsilyl chloride 19358-41-9, 2-Chlorophenyl chloroformate 19438-10-9, 3-Hydroxybenzoic acid methyl ester 20412-38-8, 2,2-Dimethylpropyl chloroformate 21615-34-9, 2-Methoxybenzoyl chloride 23795-02-0 24424-99-5, Di-tert-butyl dicarbonate 25054-53-9, 3,4-Methylenedioxybenzoyl chloride 26628-22-8, Sodium azide 31140-40-6, 4-Methoxycarbonylphenyl chloroformate 32779-36-5, 2-Chloro-5-bromopyrimidine 32807-28-6, Methyl 4-chloroacetoacetate 33034-67-2, 2-Chloro-4-trifluoromethylpyrimidine 35000-38-5, tert-Butyl (triphenylphosphoranylidene)acetate 35718-08-2, Propargyl chloroformate 36637-44-2, 4-(2-Tetrahydropyranyloxy)phenylmagnesium bromide 36823-88-8, 4-Trifluoromethoxybenzoyl chloride 38377-38-7, 4-Fluorophenyl chloroformate 39545-31-8, 2-Chlorobenzyl chloroformate 51067-38-0, 4-Phenoxyphenylboronic acid 52763-21-0, Ethyl 1-benzyl-3-oxo-4-piperidine carboxylate hydrochloride 68282-47-3, 4-Formyl-2-phenylimidazole 86270-03-3, 3-Trifluoromethoxybenzoyl chloride 87199-18-6, 3-Hydroxyphenylboronic acid 88738-78-7, Bis(2,2,2-trifluoroethyl) (methoxycarbonylmethyl)phosphonate 95668-29-4, 3-Trifluoromethylphenyl chloroformate 98946-18-0, tert-Butyl 2,2,2-trichloroacetimidate 103788-65-4 107539-52-6, 4-tert-Butyldimethylsilyloxyphenylmagnesium bromide 108448-77-7 111196-81-7, 2-Chloro-5-ethylpyrimidine 123324-71-0, p-tert-Butylphenylboronic acid 129714-97-2, 3,5-Difluorobenzoyl chloride 163105-89-3, 6-Methoxy-3-pyridylboronic acid 179915-71-0 183742-23-6 189032-84-6, 3-Methoxyphenylmagnesium chloride 211115-05-8 218278-58-1 312693-16-6, 3-Methoxybenzylzinc chloride 312693-17-7 647007-76-9 647007-78-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 13036-57-2P 103788-61-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reactant; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

L68 ANSWER 4 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:41224 HCAPLUS
DN 140:111417
ED Entered STN: 18 Jan 2004
TI Preparation of substituted heterocyclic derivatives useful as **antidiabetic** and **antiobesity** agents
IN **Cheng, Peter T. W.**; **Chen, Sean**; Ding, Charles Z.; Herpin, Timothy F.
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004004655	A2	20040115	WO 2003-US21331	20030708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004063762 A1 20040401 US 2003-616283 20030708
PRAI US 2002-394553P P 20020709
OS MARPAT 140:111417
GI



I

AB Compds. having general structure (I) [Q = C, N; A = (un)substituted (CH2)x (where x = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A = (un)substituted -(CH2)x2-O-(CH2)x3- (where x2, x3 = 0-5, provided that at least one of x2 and x3 is other than 0); B = a bond, (un)substituted (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6= C, N, O, or S, provided that at least one of X2-X6 is N; and at least one of X2, X3, X4, X5 and X6 is C; R1 = H, alkyl; R2, R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, etc.; Y = CO2R (where R = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR4a)R5 [where R4a = H, a prodrug ester; R5 = alkyl, aryl, or a phosphonic acid of the structure P(O)(OR4a)2]] including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof are prepared These compds. such as N-[[4-(1,2,3-triazol-4-ylmethoxy)benzyl](4-methoxypheoxycarbonyl)amino]acetic acid N-[[4-[2-(1,2,3-triazol-4-yl)ethoxy]benzyl](4-methoxypheoxycarbonyl)amino]acetic acid, N-[[1-[4-(2- or 4-imidazolylmethoxy)phenyl]isopentyl](4-methoxypheoxycarbonyl)amino]acetic acid, N-[[1-[4-(1,2,4-oxadiazol-3-ylmethoxy)phenyl]isopentyl](4-methoxypheoxycarbonyl)amino]acetic acid, N-[[4-(1,2,4-oxadiazol-3-ylmethoxy)phenethyl](isobutoxycarbonyl)amino]acetic acid derivs. modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) and thus are particularly useful in the treatment of **diabetes** and **obesity**, especially Type 2 **diabetes**, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, **obesity**, atherosclerosis, and related diseases.

ST triazole imidazole oxadiazole prepn **antiobesity** **antidiabetic**; heterocycle prepn **antiobesity** **antidiabetic**; hyperglycemia hyperinsulinemia hyperlipidemia atherosclerosis treatment heterocycle prepn; triazolylmethoxybenzylmethoxy pheoxycarbonylaminoacetic acid prepn **antiobesity** **antidiabetic**; triazolylethoxybenzylmethoxypheoxycarbonylaminoaceti

c acid prepn **antiobesity antidiabetic**;
imidazolylmethoxyphenylisopentylmethoxypheoxycarbonylaminoacetic acid prepn **antiobesity antidiabetic**;
oxadiazolylmethoxyphenylisopentylmethoxypheoxycarbonylaminoacetic acid prepn **antiobesity antidiabetic**;
oxadiazolylmethoxyphenethylisobutoxycarbonylamino acetic acid prepn **antiobesity antidiabetic**

IT Intestine, disease
(Crohn's; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Metabolism, animal
(disorder, dysmetabolic syndrome; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Mammary gland, neoplasm
(ductal carcinoma; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated blood levels; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Mammary gland, neoplasm
(fibroadenoma; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Stomach, disease
(gastric ulceritis; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Adipose tissue, neoplasm
(liposarcoma; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Carcinoma
(lobular; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT **Diabetes** mellitus
(non-insulin-dependent; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Antiulcer agents
Atherosclerosis
Cytotoxic agents
Diabetes mellitus
Human

Hyperglycemia
Hypertriglyceridemia
Hypolipemic agents
Inflammation
Lung, neoplasm
Neoplasm
Obesity
Osteoporosis
Ovary, neoplasm
Psoriasis
Stomach, neoplasm
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Heterocyclic compounds
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Disease, animal
(proliferative; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Prostate gland, neoplasm
(prostatic intraepithelial neoplasia (PIN); preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT Disease, animal
(syndrome X; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 56-03-1, Biguanide 58-32-2, Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chloropropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 943-45-3D, Fibric acid, derivs. 4205-91-8, Clonidine monohydrochloride 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 89750-14-1, Glucagon-like peptide I 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS-962 144701-48-4, Telmisartan 147511-69-1 152755-31-2, LY295427 159183-92-3, L750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 163222-33-1, Ezetimibe 166518-60-1, Avasimibe 168273-06-1, Rimonabant 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4 199113-98-9, Balaglitazone 199914-96-0, YM-440 213252-19-8, KRP297 244081-42-3, AJ9677 251572-86-8, P32/98 287714-41-4 335149-08-1, L895645 335149-14-9, R-119702 335149-15-0, KAD1129 335149-17-2, ARHO 39242 335149-19-4, GW-409544 335149-23-0, NVP-DPP-728A 335149-24-1, ATL-962 335149-25-2, CP331648 416839-88-8, Axokine 430433-17-3,

Glipyride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 56-81-5, Glycerol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated blood levels; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 645392-65-0P, (R)-(+)-[1-[4-(tert-Butyldimethylsilyloxy)phenyl]ethylamino] acetic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 13322-19-5P 645390-64-3P 645390-65-4P 645390-66-5P 645390-67-6P
645390-68-7P 645390-69-8P 645390-70-1P 645390-71-2P 645390-72-3P
645390-73-4P 645390-74-5P 645390-75-6P 645390-76-7P 645390-77-8P
645390-78-9P 645390-79-0P 645390-80-3P 645390-81-4P 645390-82-5P
645390-83-6P 645390-84-7P 645390-85-8P 645390-86-9P 645390-87-0P
645390-88-1P 645390-89-2P 645390-90-5P 645390-91-6P 645390-92-7P
645390-93-8P 645390-94-9P 645390-95-0P 645390-96-1P 645390-97-2P
645390-98-3P 645390-99-4P 645391-00-0P 645391-01-1P 645391-02-2P
645391-03-3P 645391-04-4P 645391-05-5P 645391-06-6P 645391-07-7P
645391-08-8P 645391-09-9P 645391-10-2P 645391-11-3P 645391-12-4P
645391-13-5P 645391-14-6P 645391-15-7P 645391-16-8P 645391-17-9P
645391-18-0P 645391-19-1P 645391-20-4P 645391-21-5P 645391-22-6P
645391-23-7P 645391-24-8P 645391-25-9P 645391-26-0P 645391-27-1P
645391-28-2P 645391-29-3P 645391-30-6P 645391-31-7P 645391-32-8P
645391-33-9P 645391-34-0P 645391-35-1P 645391-36-2P 645391-37-3P
645391-38-4P 645391-39-5P 645391-40-8P 645391-41-9P 645391-42-0P
645391-43-1P 645391-44-2P 645391-45-3P 645391-46-4P 645391-47-5P
645391-50-0P 645391-53-3P 645399-36-6P 645399-38-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 100-83-4, 3-Hydroxybenzaldehyde 123-08-0, 4-Hydroxybenzaldehyde
151-50-8, Potassium cyanide 5680-79-5, Glycine methyl ester hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 22300-56-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 1201-68-9P 2411-77-0P 3272-96-6P 13322-02-6P 13322-20-8P
17944-68-2P 26787-75-7P 36187-69-6P 94938-02-0P 94938-03-1P
96013-95-5P 99280-78-1P 114564-74-8P 116381-09-0P 143589-99-5P
161670-81-1P 196810-82-9P 255876-57-4P 331746-09-9P 385383-45-9P
440365-13-9P 645391-55-5P 645391-57-7P 645391-59-9P 645391-61-3P
645391-62-4P 645391-63-5P 645391-64-6P 645391-65-7P 645391-66-8P
645391-67-9P 645391-68-0P 645391-69-1P 645391-70-4P 645391-71-5P
645391-72-6P 645391-73-7P 645391-74-8P 645391-75-9P 645391-76-0P
645391-77-1P 645391-78-2P 645391-79-3P 645391-80-6P 645391-81-7P
645391-82-8P 645391-83-9P 645391-84-0P 645391-85-1P 645391-86-2P
645391-87-3P 645391-89-5P 645391-91-9P 645391-93-1P 645391-94-2P
645391-96-4P 645391-99-7P 645392-01-4P 645392-03-6P 645392-05-8P
645392-07-0P 645392-08-1P 645392-10-5P 645392-12-7P 645392-13-8P
645392-14-9P 645392-15-0P 645392-16-1P 645392-17-2P 645392-18-3P
645392-19-4P 645392-20-7P 645392-21-8P 645392-22-9P 645392-23-0P
645392-24-1P 645392-25-2P 645392-26-3P 645392-27-4P 645392-28-5P
645392-29-6P 645392-30-9P 645392-31-0P 645392-32-1P 645392-33-2P

645392-34-3P 645392-35-4P 645392-36-5P 645392-37-6P 645392-38-7P
645392-40-1P 645392-43-4P 645392-45-6P 645392-47-8P 645392-49-0P
645392-52-5P 645392-54-7P 645392-56-9P 645392-58-1P 645392-61-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 74-88-4, Iodomethane, reactions 75-21-8, Ethylene oxide, reactions 77-78-1, Dimethyl sulfate 79-22-1, Methyl chloroformate 96-32-2, Methyl bromoacetate 98-88-4, Benzoyl chloride 106-93-4, 1,2-Dibromoethane 107-14-2, Chloroacetonitrile 124-63-0, Methanesulfonyl chloride 501-53-1, Benzyl chloroformate 543-27-1, Isobutyl chloroformate 670-95-1, 4-Phenylimidazole 874-60-2, p-Toluoyl chloride 874-90-8, 4-Methoxybenzonitrile 926-62-5, Isobutylmagnesium bromide 1535-73-5, 3-Trifluoromethoxyaniline 1888-75-1, Isopropyllithium 4949-44-4, Ethyl propionylacetate 5470-11-1, Hydroxylamine hydrochloride 7803-49-8, Hydroxylamine, reactions 10442-39-4, Tetrabutylammonium cyanide 18107-18-1, Trimethylsilyldiazomethane 18162-48-6, tert-Butyldimethylsilyl chloride 22038-86-4, (R)-(+)-1-(4-Methoxyphenyl)ethylamine 22818-40-2, D-4-Hydroxyphenylglycine 26628-22-8, Sodium azide 32807-28-6, Methyl 4-chloroacetoacetate 41851-59-6, (S)-1-(4-Methoxyphenyl)ethylamine 68282-47-3, 4-Formyl-2-phenylimidazole 82796-69-8, (S)-1-(3-Methoxyphenyl)ethylamine 157141-27-0, Cyanomethylenetributylphosphorane
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance or hyperinsulinemia; preparation of substituted heterocyclic derivs. as **antidiabetic** and **antiobesity** agents)

L68 ANSWER 5 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:855758 HCAPLUS
DN 139:364829
ED Entered STN: 31 Oct 2003
TI Preparation of heterocyclo inhibitors of potassium channel function
IN Lloyd, John; **Jeon, Yoon T.**; Finlay, Heather; Yan, Lin; Beaudoin, Serge; Gross, Michael F.
PA **Bristol-Myers Squibb** Company, USA; Icagen, Inc.
SO PCT Int. Appl., 330 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003088908	A2	20031030	WO 2003-US11807	20030416
	WO 2003088908	A3	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004110793 A1 20040610 US 2003-417355 20030416
PRAI US 2002-374279P P 20020419
OS MARPAT 139:364829
GI



I



II

AB The title compds. [I; m, p = 0-3 (provided that the sum of m and p is at least 2); Q = NR1, O, S, SO, SO2; R1 = H, C(:W)NR6R7, SO2NR6R7, OCONR6R7, etc.; R2 = heteroaryl, heteroarylalkyl, aryl, etc.; J = a bond, alkylene; R3 = R5, OR5, SO2R5, etc.; R5 = CN, heteroaryl, aryl, etc.; R6, R7 = H, alkyl, OH, etc.; W = (un)substituted NH, N(CO2H), N(CN), N(SO2H), CH(NO2); Rx = H, alkyl, hydroxyalkyl, aryl, etc.], useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur) in the prevention and treatment of arrhythmia and IKur-associated conditions, were prepared E.g., a multi-step synthesis of II [starting from bis(2-chloroethyl)amine], was given. Pharmaceutical composition comprising the compound I is claimed.

ST heterocycle piperidine prepn inhibitor potassium channel antiarrhythmic
IT Endothelin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ET antagonists; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)
IT Antidiabetic agents
(HMG-CoA reductase inhibitors; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)
IT Anticoagulants
Antihypertensives
Platelet aggregation inhibitors
(addnl. therapeutic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)
IT Angiotensin receptor antagonists
(angiotensin II; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)
IT Heart, disease
(arrhythmia; preparation of substituted piperidines as inhibitors of potassium channel function)
IT Heart, disease

(atrial arrhythmia, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Heart, disease
(atrial fibrillation, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Heart, disease
(atrial flutter, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Ion channel blockers
(calcium, addnl. therapeutic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Glycosides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(cardiac, addnl. therapeutic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Lung, disease
(chronic obstructive, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Mental disorder
(cognitive, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis, cardiac glycoside; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Cognition
Immunity
(disorder, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Headache
(migraine, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mineralocorticoid receptor antagonists; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Ion channel blockers
(potassium; preparation of substituted piperidines as inhibitors of potassium channel function)

IT Antiarrhythmics
Human
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT Anticonvulsants
Antimigraine agents
Cognition enhancers
Immunomodulators
(preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic

agent)

IT Esophagus, disease
(reflux esophagitis, treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Thyroid gland
(thyroid mimetics; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Anti-inflammatory agents
Inflammation
(treatment of inflammatory disease; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Diabetes mellitus
Digestive tract, disease
Epilepsy
Gastrointestinal motility
(treatment of; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT Adrenoceptor antagonists
(.beta.-, antihypertensives; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 62571-86-2, Captopril 75847-73-3, Enalapril 76547-98-3, Lisinopril
81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril
85441-61-8, Quinapril 87333-19-5, Ramipril 98048-97-6, Fosinopril
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACE inhibitor; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 19764-93-3 75330-75-5, Lovastatin 79902-63-9, Simvastatin
81093-37-0, Pravastatin 134523-00-5, Atorvastatin 147098-20-2, ZD-4522
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMG-CoA reductase inhibitor; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 37250-24-1, HMG-CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMG-CoA reductase inhibitors; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 50-78-2, Aspirin 113665-84-2, Clopidogrel 143443-90-7, Ifetroban
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-platelet agents; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 52-53-9, Verapamil 3930-20-9, Sotalol 42399-41-7, Diltiazem
115256-11-6, Dofetilide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiarrhythmic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 81-81-2, Warfarin 9005-49-6, Heparin, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticoagulant; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 10238-21-8, Glyburide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biguanide/glyburide combination as antidiabetic; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 56-03-1, Biguanide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biguanides and biguanide/glyburide as antidiabetics; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 630-60-4, Ouabain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac glycoside; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 65312-43-8, Factor VIIa
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(factor VIIa inhibitors as antithrombotic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 9002-05-5, Factor Xa
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(factor Xa inhibitors as antithrombotic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 9015-82-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, antihypertensives; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 82707-54-8, Vasopeptidase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; antihypertensives; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 52-01-7, Spironolactone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mineralocorticoid receptor antagonist; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 619277-67-7P 619280-89-6P 619280-93-2P 619288-37-8P 619291-07-5P
619291-08-6P 619292-14-7P 619292-30-7P 619292-31-8P 619292-35-2P
619292-97-6P 619294-69-8P 619295-32-8P 619295-33-9P 619295-41-9P
619295-47-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 94308-71-1P 95128-61-3P 619277-72-4P 619277-78-0P 619277-83-7P
619277-88-2P 619277-93-9P 619277-98-4P 619278-03-4P 619278-09-0P
619278-15-8P 619278-20-5P 619278-25-0P 619278-31-8P 619278-36-3P
619278-40-9P 619278-45-4P 619278-50-1P 619278-54-5P 619278-59-0P
619278-64-7P 619278-69-2P 619278-74-9P 619278-79-4P 619278-84-1P
619278-89-6P 619278-94-3P 619278-99-8P 619279-04-8P 619279-08-2P
619279-16-2P 619279-21-9P 619279-25-3P 619279-29-7P 619279-33-3P
619279-38-8P 619279-45-7P 619279-48-0P 619279-52-6P 619279-56-0P
619279-60-6P 619279-64-0P 619279-68-4P 619279-72-0P 619279-76-4P
619279-80-0P 619279-84-4P 619279-88-8P 619279-92-4P 619279-96-8P
619280-00-1P 619280-04-5P 619280-08-9P 619280-12-5P 619280-16-9P
619280-20-5P 619280-24-9P 619280-28-3P 619280-32-9P 619280-37-4P

619280-41-0P 619280-45-4P 619280-49-8P 619280-53-4P 619280-57-8P
619280-61-4P 619280-65-8P 619280-69-2P 619280-73-8P 619280-77-2P
619280-81-8P 619280-85-2P 619280-97-6P 619281-01-5P 619281-05-9P
619281-09-3P 619281-13-9P 619281-17-3P 619281-21-9P 619281-25-3P
619281-29-7P 619281-33-3P 619281-39-9P 619281-44-6P 619281-47-9P
619281-50-4P 619281-53-7P 619281-56-0P 619281-59-3P 619281-62-8P
619281-65-1P 619281-68-4P 619281-71-9P 619281-74-2P 619281-77-5P
619281-80-0P 619281-83-3P 619281-86-6P 619281-89-9P 619281-92-4P
619281-95-7P 619281-98-0P 619282-01-8P 619282-04-1P 619282-07-4P
619282-10-9P 619282-13-2P 619282-16-5P 619282-19-8P 619282-22-3P
619282-25-6P 619282-28-9P 619282-31-4P 619282-34-7P 619282-37-0P
619282-40-5P 619282-43-8P 619282-46-1P 619282-49-4P 619282-53-0P
619282-57-4P 619282-60-9P 619282-63-2P 619282-66-5P 619282-69-8P
619282-72-3P 619282-75-6P 619282-78-9P 619282-81-4P 619282-84-7P
619282-87-0P 619282-91-6P 619282-95-0P 619282-98-3P 619283-01-1P
619283-04-4P 619283-07-7P 619283-10-2P 619283-13-5P 619283-16-8P
619283-19-1P 619283-22-6P 619283-25-9P 619283-28-2P 619283-31-7P
619283-34-0P 619283-37-3P 619283-39-5P 619283-42-0P 619283-44-2P
619283-47-5P 619283-50-0P 619283-53-3P 619283-56-6P 619283-59-9P
619283-62-4P 619283-64-6P 619283-67-9P 619283-70-4P 619283-73-7P
619283-76-0P 619283-79-3P 619283-82-8P 619283-85-1P 619283-88-4P
619283-91-9P 619283-94-2P 619283-97-5P 619284-00-3P 619284-03-6P
619284-05-8P 619284-08-1P 619284-11-6P 619284-14-9P 619284-17-2P
619284-20-7P 619284-23-0P 619284-25-2P 619284-28-5P 619284-31-0P
619284-34-3P 619284-37-6P 619284-40-1P 619284-43-4P 619284-46-7P
619284-49-0P 619284-52-5P 619284-55-8P 619284-58-1P 619284-61-6P
619284-64-9P 619284-67-2P 619284-70-7P 619284-73-0P 619284-76-3P
619284-79-6P 619284-82-1P 619284-85-4P 619284-88-7P 619284-91-2P
619284-94-5P 619284-98-9P 619285-02-8P 619285-06-2P 619285-10-8P
619285-14-2P 619285-18-6P 619285-21-1P 619285-24-4P 619285-27-7P
619285-30-2P 619285-33-5P 619285-36-8P 619285-39-1P 619285-42-6P
619285-45-9P 619285-48-2P 619285-51-7P 619285-54-0P 619285-57-3P
619285-60-8P 619285-63-1P 619285-66-4P 619285-69-7P 619285-72-2P
619285-75-5P 619285-78-8P 619285-81-3P 619285-84-6P 619285-87-9P
619285-90-4P 619285-93-7P 619285-96-0P 619285-99-3P 619286-02-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 619286-05-4P 619286-08-7P 619286-11-2P 619286-14-5P 619286-17-8P
619286-20-3P 619286-23-6P 619286-26-9P 619286-29-2P 619286-32-7P
619286-35-0P 619286-38-3P 619286-41-8P 619286-44-1P 619286-47-4P
619286-50-9P 619286-53-2P 619286-56-5P 619286-59-8P 619286-62-3P
619286-65-6P 619286-68-9P 619286-71-4P 619286-74-7P 619286-77-0P
619286-80-5P 619286-83-8P 619286-86-1P 619286-89-4P 619286-92-9P
619286-95-2P 619286-97-4P 619287-00-2P 619287-03-5P 619287-05-7P
619287-07-9P 619287-10-4P 619287-12-6P 619287-14-8P 619287-16-0P
619287-18-2P 619287-20-6P 619287-22-8P 619287-24-0P 619287-26-2P
619287-29-5P 619287-31-9P 619287-33-1P 619287-35-3P 619287-37-5P
619287-39-7P 619287-41-1P 619287-43-3P 619287-45-5P 619287-47-7P
619287-49-9P 619287-51-3P 619287-53-5P 619287-55-7P 619287-57-9P
619287-59-1P 619287-61-5P 619287-63-7P 619287-65-9P 619287-67-1P
619287-69-3P 619287-71-7P 619287-73-9P 619287-75-1P 619287-77-3P
619287-79-5P 619287-81-9P 619287-83-1P 619287-85-3P 619287-87-5P
619287-89-7P 619287-91-1P 619287-93-3P 619287-95-5P 619287-97-7P
619287-99-9P 619288-01-6P 619288-03-8P 619288-05-0P 619288-07-2P
619288-09-4P 619288-11-8P 619288-13-0P 619288-15-2P 619288-17-4P
619288-19-6P 619288-21-0P 619288-23-2P 619288-25-4P 619288-27-6P
619288-29-8P 619288-31-2P 619288-33-4P 619288-35-6P 619288-39-0P

619288-41-4P 619288-43-6P 619288-45-8P 619288-47-0P 619288-49-2P
619288-51-6P 619288-53-8P 619288-55-0P 619288-57-2P 619288-59-4P
619288-61-8P 619288-63-0P 619288-65-2P 619288-67-4P 619288-69-6P
619288-71-0P 619288-73-2P 619288-75-4P 619288-77-6P 619288-79-8P
619288-81-2P 619288-83-4P 619288-85-6P 619288-87-8P 619288-89-0P
619288-91-4P 619288-93-6P 619288-95-8P 619288-97-0P 619288-99-2P
619289-01-9P 619289-03-1P 619289-05-3P 619289-07-5P 619289-09-7P
619289-11-1P 619289-13-3P 619289-15-5P 619289-17-7P 619289-19-9P
619289-21-3P 619289-23-5P 619289-25-7P 619289-27-9P 619289-29-1P
619289-31-5P 619289-33-7P 619289-35-9P 619289-37-1P 619289-39-3P
619289-41-7P 619289-43-9P 619289-45-1P 619289-47-3P 619289-49-5P
619289-51-9P 619289-53-1P 619289-55-3P 619289-57-5P 619289-59-7P
619289-61-1P 619289-63-3P 619289-65-5P 619289-67-7P 619289-69-9P
619289-71-3P 619289-73-5P 619289-75-7P 619289-77-9P 619289-79-1P
619289-81-5P 619289-83-7P 619289-86-0P 619289-88-2P 619289-89-3P
619289-90-6P 619289-91-7P 619289-92-8P 619289-93-9P 619289-94-0P
619289-95-1P 619289-96-2P 619289-97-3P 619289-98-4P 619289-99-5P
619290-00-5P 619290-01-6P 619290-02-7P 619290-03-8P 619290-04-9P
619290-05-0P 619290-06-1P 619290-07-2P 619290-08-3P 619290-09-4P
619290-10-7P 619290-11-8P 619290-12-9P 619290-13-0P 619290-14-1P
619290-15-2P 619290-16-3P 619290-17-4P 619290-18-5P 619290-19-6P
619290-20-9P 619290-21-0P 619290-22-1P 619290-23-2P 619290-24-3P
619290-25-4P 619290-26-5P 619290-27-6P 619290-28-7P 619290-29-8P
619290-30-1P 619290-31-2P 619290-32-3P 619290-33-4P 619290-34-5P
619290-35-6P 619290-36-7P 619290-37-8P 619290-38-9P 619290-39-0P
619290-40-3P 619290-41-4P 619290-42-5P 619290-43-6P 619290-44-7P
619290-45-8P 619290-46-9P 619290-47-0P 619290-48-1P 619290-49-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 619290-50-5P 619290-51-6P 619290-52-7P 619290-53-8P 619290-54-9P
619290-55-0P 619290-56-1P 619290-57-2P 619290-58-3P 619290-59-4P
619290-60-7P 619290-61-8P 619290-62-9P 619290-63-0P 619290-64-1P
619290-65-2P 619290-66-3P 619290-67-4P 619290-68-5P 619290-69-6P
619290-70-9P 619290-71-0P 619290-72-1P 619290-73-2P 619290-74-3P
619290-75-4P 619290-76-5P 619290-77-6P 619290-78-7P 619290-79-8P
619290-80-1P 619290-81-2P 619290-82-3P 619290-83-4P 619290-84-5P
619290-85-6P 619290-86-7P 619290-87-8P 619290-88-9P 619290-89-0P
619290-90-3P 619290-91-4P 619290-92-5P 619290-93-6P 619290-94-7P
619290-95-8P 619290-96-9P 619290-97-0P 619290-98-1P 619290-99-2P
619291-00-8P 619291-01-9P 619291-02-0P 619291-03-1P 619291-04-2P
619291-05-3P 619291-06-4P 619291-09-7P 619291-10-0P 619291-11-1P
619291-12-2P 619291-13-3P 619291-14-4P 619291-15-5P 619291-16-6P
619291-17-7P 619291-18-8P 619291-19-9P 619291-20-2P 619291-21-3P
619291-22-4P 619291-23-5P 619291-24-6P 619291-25-7P 619291-26-8P
619291-27-9P 619291-28-0P 619291-29-1P 619291-30-4P 619291-31-5P
619291-32-6P 619291-33-7P 619291-34-8P 619291-35-9P 619291-36-0P
619291-37-1P 619291-38-2P 619291-39-3P 619291-40-6P 619291-41-7P
619291-42-8P 619291-43-9P 619291-44-0P 619291-45-1P 619291-46-2P
619291-47-3P 619291-48-4P 619291-49-5P 619291-50-8P 619291-51-9P
619291-52-0P 619291-53-1P 619291-54-2P 619291-55-3P 619291-56-4P
619291-57-5P 619291-58-6P 619291-59-7P 619291-60-0P 619291-61-1P
619291-62-2P 619291-63-3P 619291-64-4P 619291-65-5P 619291-66-6P
619291-67-7P 619291-68-8P 619291-69-9P 619291-70-2P 619291-71-3P
619291-72-4P 619291-73-5P 619291-74-6P 619291-75-7P 619291-76-8P
619291-77-9P 619291-78-0P 619291-79-1P 619291-80-4P 619291-81-5P
619291-82-6P 619291-83-7P 619291-84-8P 619291-85-9P 619291-86-0P
619291-87-1P 619291-88-2P 619291-89-3P 619291-90-6P 619291-91-7P

619291-92-8P 619291-93-9P 619291-94-0P 619291-95-1P 619291-96-2P
619291-97-3P 619291-98-4P 619291-99-5P 619292-00-1P 619292-01-2P
619292-02-3P 619292-03-4P 619292-04-5P 619292-05-6P 619292-06-7P
619292-07-8P 619292-08-9P 619292-09-0P 619292-10-3P 619292-11-4P
619292-12-5P 619292-13-6P 619292-15-8P 619292-16-9P 619292-17-0P
619292-18-1P 619292-19-2P 619292-20-5P 619292-21-6P 619292-22-7P
619292-23-8P 619292-24-9P 619292-25-0P 619292-26-1P 619292-27-2P
619292-28-3P 619292-29-4P 619292-32-9P 619292-33-0P 619292-34-1P
619292-36-3P 619292-37-4P 619292-38-5P 619292-39-6P 619292-40-9P
619292-41-0P 619292-42-1P 619292-43-2P 619292-44-3P 619292-45-4P
619292-46-5P 619292-47-6P 619292-48-7P 619292-49-8P 619292-50-1P
619292-51-2P 619292-52-3P 619292-53-4P 619292-54-5P 619292-55-6P
619292-56-7P 619292-57-8P 619292-58-9P 619292-59-0P 619292-60-3P
619292-62-5P 619292-64-7P 619292-66-9P 619292-67-0P 619292-68-1P
619292-69-2P 619292-70-5P 619292-71-6P 619292-72-7P 619292-73-8P
619292-74-9P 619292-75-0P 619292-76-1P 619292-77-2P 619292-78-3P
619292-79-4P 619292-80-7P 619292-81-8P 619292-82-9P 619292-83-0P
619292-84-1P 619292-85-2P 619292-86-3P 619292-87-4P 619292-88-5P
619292-89-6P 619292-90-9P 619292-91-0P 619292-92-1P 619292-93-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 619292-94-3P 619292-95-4P 619292-96-5P 619292-98-7P 619292-99-8P
619293-00-4P 619293-01-5P 619293-02-6P 619293-03-7P 619293-04-8P
619293-05-9P 619293-06-0P 619293-07-1P 619293-08-2P 619293-09-3P
619293-10-6P 619293-11-7P 619293-12-8P 619293-13-9P 619293-14-0P
619293-15-1P 619293-16-2P 619293-17-3P 619293-18-4P 619293-19-5P
619293-20-8P 619293-21-9P 619293-22-0P 619293-23-1P 619293-24-2P
619293-25-3P 619293-26-4P 619293-27-5P 619293-28-6P 619293-29-7P
619293-30-0P 619293-31-1P 619293-32-2P 619293-33-3P 619293-34-4P
619293-35-5P 619293-36-6P 619293-37-7P 619293-38-8P 619293-39-9P
619293-40-2P 619293-41-3P 619293-42-4P 619293-43-5P 619293-44-6P
619293-45-7P 619293-46-8P 619293-47-9P 619293-48-0P 619293-49-1P
619293-50-4P 619293-51-5P 619293-52-6P 619293-53-7P 619293-54-8P
619293-55-9P 619293-56-0P 619293-57-1P 619293-58-2P 619293-59-3P
619293-60-6P 619293-61-7P 619293-62-8P 619293-63-9P 619293-64-0P
619293-65-1P 619293-66-2P 619293-67-3P 619293-68-4P 619293-69-5P
619293-70-8P 619293-71-9P 619293-72-0P 619293-73-1P 619293-74-2P
619293-75-3P 619293-76-4P 619293-77-5P 619293-78-6P 619293-79-7P
619293-80-0P 619293-82-2P 619293-83-3P 619293-84-4P 619293-85-5P
619293-86-6P 619293-87-7P 619293-88-8P 619293-89-9P 619293-90-2P
619293-91-3P 619293-92-4P 619293-93-5P 619293-94-6P 619293-95-7P
619293-96-8P 619293-97-9P 619293-98-0P 619293-99-1P 619294-00-7P
619294-01-8P 619294-02-9P 619294-03-0P 619294-04-1P 619294-05-2P
619294-06-3P 619294-07-4P 619294-08-5P 619294-09-6P 619294-10-9P
619294-11-0P 619294-12-1P 619294-13-2P 619294-14-3P 619294-15-4P
619294-16-5P 619294-17-6P 619294-18-7P 619294-19-8P 619294-20-1P
619294-21-2P 619294-22-3P 619294-23-4P 619294-24-5P 619294-25-6P
619294-26-7P 619294-27-8P 619294-28-9P 619294-29-0P 619294-30-3P
619294-31-4P 619294-33-6P 619294-34-7P 619294-36-9P 619294-38-1P
619294-40-5P 619294-42-7P 619294-44-9P 619294-46-1P 619294-48-3P
619294-49-4P 619294-50-7P 619294-51-8P 619294-52-9P 619294-54-1P
619294-56-3P 619294-58-5P 619294-59-6P 619294-60-9P 619294-61-0P
619294-63-2P 619294-65-4P 619294-66-5P 619294-67-6P 619294-68-7P
619294-70-1P 619294-71-2P 619294-72-3P 619294-73-4P 619294-74-5P
619294-75-6P 619294-76-7P 619294-77-8P 619294-78-9P 619294-79-0P
619294-80-3P 619294-81-4P 619294-82-5P 619294-83-6P 619294-84-7P
619294-85-8P 619294-86-9P 619294-87-0P 619294-88-1P 619294-89-2P

619294-90-5P 619294-91-6P 619294-92-7P 619294-93-8P 619294-94-9P
619294-95-0P 619294-96-1P 619294-97-2P 619294-98-3P 619294-99-4P
619295-00-0P 619295-01-1P 619295-02-2P 619295-03-3P 619295-04-4P
619295-05-5P 619295-06-6P 619295-07-7P 619295-08-8P 619295-09-9P
619295-10-2P 619295-11-3P 619295-12-4P 619295-13-5P 619295-14-6P
619295-15-7P 619295-16-8P 619295-17-9P 619295-18-0P 619295-19-1P
619295-20-4P 619295-21-5P 619295-22-6P 619295-23-7P 619295-24-8P
619295-25-9P 619295-26-0P 619295-27-1P 619295-28-2P 619295-29-3P
619295-30-6P 619295-31-7P 619295-34-0P 619295-35-1P 619295-36-2P
619295-37-3P 619295-38-4P 619295-39-5P 619295-40-8P 619295-42-0P
619295-43-1P 619295-44-2P 619295-45-3P 619295-46-4P 619295-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 619295-49-7P 619295-50-0P 619295-51-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 93-97-0, Benzoic anhydride 100-46-9, Benzylamine, reactions 103-71-9, Phenyl isocyanate, reactions 107-07-3, 2-Chloroethanol, reactions 108-91-8, Cyclohexylamine, reactions 334-22-5, Bis(2-chloroethyl)amine 349-88-2, 4-Fluorobenzenesulfonyl chloride 364-74-9, 2,5-Difluoronitrobenzene 393-52-2, 2-Fluorobenzoyl chloride 446-48-0, 2-Fluorobenzyl bromide 459-31-4, 3-(4-Fluorophenyl)propionic acid 498-94-2, Piperidine-4-carboxylic acid 501-00-8, 3-Fluorophenylacetonitrile 541-41-3, Ethyl chloroformate 579-75-9, o-Anisic acid 589-08-2, N-Methylphenethylamine 622-95-7, 4-Chlorobenzyl bromide 645-45-4, Hydrocinnamoyl chloride 701-27-9, 3-Fluorobenzenesulfonyl chloride 939-87-7, trans-2-Phenylcyclopropanecarbonyl chloride 1189-71-5, Sulfuryl chloride isocyanate 1493-27-2, 2-Fluoronitrobenzene 1722-12-9, 2-Chloropyrimidine 1924-77-2, 2-Phenylbenzylamine 2947-61-7, 4-Methylbenzyl cyanide 4395-98-6, 4-Cyanopiperidine 5424-01-1, 3-Aminopyrazine-2-carboxylic acid 6850-57-3, 2-Methoxybenzylamine 10147-36-1, Propylsulfonyl chloride 13623-94-4, 1,1-Bis(methylthio)-2-nitroethylene 19493-44-8, 1-Chloroisoquinoline 20893-30-5, 2-Thiopheneacetonitrile 21615-34-9, o-Anisoyl chloride 25115-74-6 51304-58-6 56243-25-5, 1-Benzyl-4-phenylpiperidine-4-carbonitrile 64353-29-3, 2-(4-Ethylphenyl)ethylamine 71258-18-9 79463-77-7, Diphenyl N-cyanocarbonimidate 80466-79-1, 3,5-Dimethylisoxazole-4-sulfonyl chloride 83949-32-0 112471-14-4 116943-62-5 352275-00-4 489471-89-8 619296-15-0 619296-16-1 619296-17-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 704-05-2P 53986-10-0P 56134-07-7P 84176-77-2P 84358-13-4P
118753-70-1P 158144-79-7P 158144-82-2P 167262-68-2P 178803-90-2P
181641-61-2P 181642-08-0P 181642-34-2P 198554-64-2P 266341-44-0P
266341-45-1P 401567-10-0P 619295-52-2P 619295-53-3P 619295-54-4P
619295-55-5P 619295-56-6P 619295-57-7P 619295-58-8P 619295-59-9P
619295-60-2P 619295-61-3P 619295-62-4P 619295-63-5P 619295-64-6P
619295-65-7P 619295-66-8P 619295-67-9P 619295-68-0P 619295-69-1P
619295-70-4P 619295-71-5P 619295-72-6P 619295-73-7P 619295-74-8P
619295-75-9P 619295-76-0P 619295-77-1P 619295-78-2P 619295-79-3P
619295-80-6P 619295-81-7P 619295-82-8P 619295-83-9P 619295-84-0P
619295-85-1P 619295-86-2P 619295-87-3P 619295-88-4P 619295-89-5P

619295-90-8P 619295-91-9P 619295-92-0P 619295-93-1P 619295-94-2P
619295-96-4P 619295-97-5P 619295-98-6P 619295-99-7P 619296-00-3P
619296-01-4P 619296-02-5P 619296-03-6P 619296-04-7P 619296-05-8P
619296-06-9P 619296-07-0P 619296-08-1P 619296-09-2P 619296-10-5P
619296-11-6P 619296-12-7P 619296-13-8P 619296-14-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted piperidines as inhibitors of potassium channel function)

IT 105857-23-6, TPA
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tPA as antithrombotic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 9002-04-4, Thrombin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thrombin inhibitors as antithrombotic agent; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

IT 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vasopepsidase inhibitor; preparation of substituted piperidines as inhibitors of potassium channel function for use in combination with at least one addnl. therapeutic agent)

L68 ANSWER 6 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:656421 HCAPLUS
DN 139:197489
ED Entered STN: 22 Aug 2003
TI Preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents
IN **Cheng, Peter T.**; **Zhang, Hao**; Hariharan, Narayanan
PA USA
SO U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-444
ICS A61K031-4439; A61K031-427; A61K031-422; C07D417-02; C07D417-14; C07D413-14; C07D413-02
NCL 514333000; 514340000; 514341000; 514342000; 514367000; 514375000; 514397000; 546256000; 546269700; 546271400
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003158232	A1	20030821	US 2002-294525	20021114
	US 2003092736	A1	20030515	US 2002-153454	20020522
PRAI	US 2001-294380P	P	20010530		
	US 2002-153454	A2	20020522		

OS MARPAT 139:197489
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; .gtoreq.1 of x2, x3 .noteq. 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-.gamma. (PPAR.gamma.) and stimulators of peroxisome proliferator activated receptor-.alpha. (PPAR.alpha.). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPAR.alpha. and to PPAR.gamma. ligand binding domains with IC50 = 69 nM.

ST azolecarboxylate prepn **antidiabetic antiobesity** agent; PPAR agonist antagonist azolecarboxylate prepn

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AP-2 (activator protein 2), inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(Crohn's, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(EDG-2 (endothelial differentiation gene 2); preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT High-mobility group proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(HMGIC; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(I-FABP (intestinal fatty acid-binding protein); preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, upregulators, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Liver
(abnormality treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adipophilin; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiotensin II, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Ion channel blockers
(calcium, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Antihypertensives
(coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine-transporting, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fatty acid; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Skin
(keratinocyte; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adipose tissue, neoplasm

(liposarcoma, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT **Antidiabetic** agents
Antiobesity agents
Cardiovascular agents
Human
Platelet aggregation inhibitors
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Cardiovascular system, disease
Diabetes mellitus
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Obesity
Osteoporosis
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
(treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Stomach, disease
(ulcer, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., stimulators; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptor antagonists
(.beta.-, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptor agonists
(.beta.3-, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., inhibitors; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477773-71-0P 477773-72-1P 477773-73-2P 477773-74-3P 477773-75-4P
477773-76-5P 477773-77-6P 477773-78-7P 477773-79-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477773-70-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 54870-28-9, Meglitinide 89750-14-1, Glucagon-like peptide I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(coadministration; preparation of azolecarboxylic acids useful as

antidiabetic and **antiobesity** agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 58-32-2, Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 4205-91-8, Clonidine hydrochloride 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 143443-90-7, Ifetroban 144288-97-1, Ts-962 145599-86-6, Cerivastatin 152755-31-2, Ly295427 159183-92-3, 1750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, Cgs 30440 170861-63-9, Jtt-501 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4 199113-98-9 199914-96-0, Ym-440 213252-19-8, Krp297 244081-42-3, Aj9677 251572-86-8, p32/98 287714-41-4, Visastatin 335149-08-1, 1895645 335149-14-9, r-119702 335149-15-0, Kad1129 335149-17-2, Arho39242 335149-19-4, Gw-409544 335149-23-0, Nvp-dpp-728a 335149-24-1, Atl-962 335149-25-2, Cp331648 416839-88-8, Axokine 430433-17-3, Glipyride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 943-45-3, Fibric acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(derivs., coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 9001-62-1, Lipase 9015-82-1 9027-63-8, ACAT 9028-35-7, HMG-CoA reductase 9029-60-1, Lipoxygenase 9033-06-1, Glucosidase 9077-14-9, Squalene synthetase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 57-71-6 62-53-3, Benzenamine, reactions 98-80-6 100-39-0 100-46-9, Benzenemethanamine, reactions 100-63-0 105-34-0 123-08-0 501-94-0 536-89-0 539-44-6 621-37-4 622-37-7 674-82-8, Ketene dimer 824-94-2 1003-09-4 2033-24-1 3034-53-5 4693-91-8 6834-42-0 10564-55-3 13254-27-8 14199-15-6 20570-96-1 103788-65-4 244152-94-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 27492-46-2P 36397-19-0P 36963-39-0P 42058-59-3P 75140-48-6P 103788-59-6P 103788-61-0P 179248-84-1P 192213-57-3P 226956-10-1P 227029-27-8P 244149-78-8P 244151-17-5P 477773-80-1P 477773-81-2P 477773-82-3P 477773-83-4P 477773-84-5P 477773-85-6P 477773-86-7P 477773-87-8P 477773-88-9P 477773-89-0P 477773-90-3P 477773-91-4P 477773-92-5P 477773-93-6P 477773-94-7P 477773-95-8P 477773-96-9P 477773-97-0P 477773-98-1P 477773-99-2P 477774-00-8P 477774-01-9P

477774-02-0P 477774-03-1P 477774-04-2P 477774-05-3P 477774-06-4P
477774-07-5P 477774-08-6P 477774-09-7P 477774-10-0P 477774-11-1P
477774-12-2P 477774-13-3P 477774-14-4P 477774-15-5P 477774-16-6P
477774-17-7P 477774-18-8P 477774-19-9P 477774-20-2P 477774-21-3P
477774-22-4P 477774-23-5P 477774-24-6P 477774-25-7P 477774-26-8P
477774-27-9P 477774-28-0P 477774-29-1P 477774-30-4P 477774-31-5P
477774-32-6P 477774-33-7P 477774-34-8P 477774-35-9P 477774-36-0P
477774-37-1P 477774-38-2P 477774-39-3P 477774-40-6P 477774-41-7P
477774-42-8P 477774-43-9P 477774-44-0P 477774-45-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 9015-94-5, Renin, biological studies 9075-65-4, Glycerol phosphate dehydrogenase 11002-13-4, Angiotensinogen 140208-23-7, PAI-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 585569-37-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477774-47-3P 477774-48-4P 477774-49-5P 477774-50-8P 477774-51-9P
477774-52-0P 477774-53-1P 477774-54-2P 477774-55-3P 477774-56-4P
477774-57-5P 477774-58-6P 477774-59-7P 477774-60-0P 477774-61-1P
477774-62-2P 477774-63-3P 477774-64-4P 477774-65-5P 477774-66-6P
477774-67-7P 477774-68-8P 477774-69-9P 477774-70-2P 477774-71-3P
477774-72-4P 477774-73-5P 477774-74-6P 477774-75-7P 477774-76-8P
477774-77-9P 477774-78-0P 477774-79-1P 477774-80-4P 477774-81-5P
477774-82-6P 477774-83-7P 477774-84-8P 477774-85-9P 477774-86-0P
477774-87-1P 477774-88-2P 477774-89-3P 477774-90-6P 477774-91-7P
477774-92-8P 477774-95-1P 585569-09-1P 585569-11-5P 585569-19-3P
585569-27-3P 585569-42-2P 585569-45-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 100-83-4, 3-Hydroxybenzaldehyde 621-54-5, 3-(3-Hydroxyphenyl)propanoic acid 2881-83-6, Ethyl 4-methoxybenzoylacetate 10401-11-3, 3-Hydroxyphenylacetylene 10516-71-9, 3-(3-Methoxyphenyl)propionic acid 36635-61-7, Tosylmethyl isocyanide 88738-78-7 142933-69-5 477774-96-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 40478-49-7P 53215-95-5P 61389-68-2P 93102-05-7P 128133-59-5P
477774-93-9P 477774-94-0P 585569-10-4P 585569-12-6P 585569-13-7P
585569-14-8P 585569-15-9P 585569-16-0P 585569-17-1P 585569-18-2P
585569-20-6P 585569-21-7P 585569-22-8P 585569-23-9P 585569-24-0P
585569-25-1P 585569-26-2P 585569-28-4P 585569-29-5P 585569-30-8P
585569-31-9P 585569-32-0P 585569-33-1P 585569-34-2P 585569-35-3P
585569-36-4P 585569-38-6P 585569-39-7P 585569-40-0P 585569-41-1P
585569-43-3P 585569-44-4P 585569-46-6P 585569-47-7P 585569-48-8P
585569-49-9P 585569-50-2P 585569-51-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolecarboxylic acids useful as **antidiabetic** and

antiobesity agents)

L68 ANSWER 7 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:634929 HCAPLUS
ED Entered STN: 15 Aug 2003
TI Thyromimetics with improved selectivity for the thyroid hormone receptor beta
AU Hangeland, Jon J.; Dejneka, Tamara; Friends, Todd J.; **Devasthale, Pratik**; Mellstrom, Karin; Sandberg, Johnny; Grynfarb, Marlena; Sheppard, Cheryl; Malm, Johan; Ryono, Denis E.
CS Hopewell Discovery Chemistry, **Bristol-Myers Squibb**, Princeton, NJ, 08543, USA
SO Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003 (2003), MEDI-321 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69EKY9
DT Conference; Meeting Abstract
LA English
AB A set of thyromimetics having improved selectivity for the beta isoform of the thyroid hormone receptor (TR) were prepared by replacing the 3'-iso-Pr group of 2 and 3 with substituents having increased steric bulk. Three series were investigated: 3'-phenyls and related heterocycles derived from 2 and 3'-amides and 3'-phenoxys derived from 3. From this SAR study, the most potent and selective compds. identified were derived from 2 and contained a 3'-Ph moiety bearing small hydrophobic groups meta to the biphenyl link. This study also suggests the portion of the TR receptor binding pocket interacting with the 3'-moiety to be flexible while still permitting the receptor to adopt an agonist conformation.

L68 ANSWER 8 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:610206 HCAPLUS
DN 139:164542
ED Entered STN: 08 Aug 2003
TI Preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions
IN Lloyd, John; **Jeon, Yoon T.**; Finlay, Heather; Yan, Lin; Gross, Michael F.; Beaudoin, Serge
PA **Bristol-Myers Squibb** Company, USA; Icagen, Inc.
SO PCT Int. Appl., 312 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 24-1 (Alicyclic Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003063797	A2	20030807	WO 2003-US3170	20030131

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

NE, SN, TD, TG
US 2004072880 A1 20040415 US 2003-356158 20030131
PRAI US 2002-353884P P 20020201
OS MARPAT 139:164542
GI



AB Claimed are novel cycloalkyl compds. (shown as I; variables defined below; e.g. cis- and trans-N-(4-hydroxy-1-thiophen-2-ylcyclohexylmethyl)-2-methoxybenzamide and trans-N-[[4-[N'-cyano-N''-ethyl-N-(furan-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide) useful as inhibitors of K channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which was linked to the ultra-rapidly activating delayed rectifier K+ current IKur; no data), methods of using such compds. in the prevention and treatment of arrhythmia and IKur-associated conditions, and pharmaceutical compns. containing such compds. For I: dashed line = an optional double bond, provided that R1a is absent when a double bond is present; m and p = 0-3; R1 = H, NR8C(:W)NR6R7 (W = NR8a2, NCO2R8a2, NC(O)R8a2, NCN, NSO2R8a2), NR8SO2NR6R7, etc.; R1a = H, RX; or R1 and R1a together form oxo; or R1 and R1a together with the C atom to which they are attached combine to form an (un)substituted spiro-fused heterocyclo group; or R1 and R1a together combine to form :CR8R9. R2 is heteroaryl, (heteroaryl)alkyl, aryl, (aryl)alkyl, heterocyclo, (heterocyclo)alkyl, alkyl, alkenyl or cycloalkyl; J is a bond, C1-4 alkylene or C1-4 alkenylene; R3 = R5 (R5 = NR6aR7a, heteroaryl, (heteroaryl)alkyl, aryl, arylalkyl, alkyl, etc.), OR5, C(:Z1)R5, OC(:Z1)R5, C(:Z1)OR5, NR8a1C(:Z1)R5, etc.; RX is one or more optional substituents, attached to any available ring carbon atom; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, >600 example prepns. are included.

ST cycloalkyl compd prepn inhibitor potassium channel function arrhythmia drug; pharmaceutical compn cycloalkyl compd inhibitor potassium channel function

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TPA (tissue protein antigen); combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Angiotensin receptor antagonists
(angiotensin II; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Endothelin receptors
Mineralocorticoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Heart, disease

(arrhythmia; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Heart, disease
(atrial fibrillation; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Heart, disease
(atrial flutter; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Ion channel blockers
(calcium; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Lung, disease
(chronic obstructive; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Mental disorder
(cognitive; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Anticoagulants
Antihypertensives
Platelet aggregation inhibitors
(combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(digitalis; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Cognition
Immunity
(disorder; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Esophagus, disease
(esophagitis, reflux; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Thyroid gland
(mimetics; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Digestive tract, disease
(motility disorder; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Anti-inflammatory agents
Antiarrhythmics
Anticonvulsants
Antidiabetic agents
Cognition enhancers

Combinatorial library
Diabetes mellitus
Digestive tract, disease
Drug delivery systems
Epilepsy
Gastrointestinal motility
Human
Immunomodulators
Inflammation
(preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Potassium channel
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(voltage-gated Kv1.5, inhibitors; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT Adrenoceptor antagonists
(.beta.-; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 50-78-2, Aspirin 52-01-7, Spironolactone 52-53-9, Verapamil 56-03-1D, Biguanide, derivs. 81-81-2, Warfarin 630-60-4, Ouabain 3930-20-9, Sotalol 9005-49-6D, Heparin, derivs. 10238-21-8D, Glyburide, combinations with biguanide 42399-41-7, Diltiazem 62571-86-2, Captopril 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81872-10-8, Zofenopril 82924-03-6, Pentopril 83435-66-9, Delapril 85441-61-8, Quinapril 87333-19-5, Ramipril 88768-40-5, Cilazapril 98048-97-6, Fosinopril 107724-20-9, Eplerenone 111223-26-8 113665-84-2, Clopidogrel 115256-11-6, Dofetilide 134523-00-5, Atorvastatin 143443-90-7, Ifetroban 147511-69-1 160135-92-2, Gemopatrilat 167305-00-2, Omapatrilat 171870-23-8, Lanoteplase 191588-94-0, Tenecteplase 287714-41-4, Rosuvastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577034-05-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]trifluoroacetamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577034-09-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,3-dimethoxybenzamide 577034-12-9P, cis-N-[[4-(N'-Methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]-2-Phenoxypyridin-3-carboxamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577036-92-1P, cis-3-Trifluoromethyl-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577036-93-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]thiophene-2-carboxamide 577036-94-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,5-difluorobenzamide 577036-95-4P,

N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]benzodioxol-5-carboxamide 577036-96-5P
577036-97-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]benzoylaminoacetamide 577036-98-7P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2-ethylthiopyridine-3-carboxamide 577036-99-8P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2,4-dichloropyridine-3-carboxamide 577037-00-4P
577037-01-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-1-(4-chlorophenyl)cyclopentanecarboxamide
577037-02-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-chloro-1,3-dimethylpyrido[3,2-d]pyrazole-5-
carboxamide 577037-03-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]am
ino]-1-phenylcyclohexyl]methyl]-1-phenyl-5-propylpyrazole-4-carboxamide
577037-04-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2-(4-chlorophenoxy)pyridine-3-carboxamide
577037-05-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-methyl-2-butenamide 577037-06-0P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]furan-2-carboxamide 577037-07-1P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-ethoxy-3-oxopropanamide 577037-08-2P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-methylbenzamide 577037-09-3P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-fluorobenzamide 577037-10-6P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3,5-dimethylisoxazole-4-carboxamide
577037-11-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-cyanobenzamide 577037-12-8P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-methoxybenzamide 577037-13-9P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-methoxybenzamide 577037-14-0P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-ethoxybenzamide 577037-15-1P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-ethoxybenzamide 577037-16-2P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3,5-dimethoxybenzamide 577037-17-3P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2-methyl-5-tert-butylfuran-3-carboxamide
577037-18-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-4-pentylbenzamide 577037-19-5P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide
577037-20-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-1-oxo-2,2,5,7-tetramethylindan-4-carboxamide
577037-21-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-3-(2-chlorophenyl)-5-methylisoxazole-4-
carboxamide 577037-22-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]am
ino]-1-phenylcyclohexyl]methyl]2,3-dihydrobenzo[b]furan-5-carboxamide
577037-23-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2-amino-3-chlorobenzamide 577037-24-2P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2,3-dihydroxybenzamide 577037-25-3P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]indole-6-carboxamide 577037-26-4P,
N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-
phenylcyclohexyl]methyl]-2-hydroxy-3-methylbenzamide 577037-27-5P,

N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-fluoro-6-hydroxybenzamide 577037-28-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,5-dihydroxybenzamide 577037-29-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]indole-5-carboxamide 577037-30-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,6-dihydroxybenzamide 577037-31-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-dimethylaminobenzamide 577037-32-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,3-dihydrobenzo[b]furan-6-carboxamide 577037-33-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-amino-6-hydroxybenzamide 577037-34-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methylthiobenzamide 577037-35-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577037-36-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,6-difluorobenzamide 577037-37-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,3-dimethylindole-6-carboxamide 577037-38-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-fluoro-2-hydroxybenzamide 577037-39-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3,4-dimethoxybenzamide 577037-40-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]quinoline-8-carboxamide 577037-41-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-4-amino-3-methoxybenzamide 577037-42-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-(1H-pyrrol-1-yl)benzamide 577037-43-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]benzimidazole-5-carboxamide 577037-44-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-amino-4,5-difluorobenzamide 577037-45-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-amino-4-methylbenzamide 577037-46-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]benzothiazole-6-carboxamide 577037-47-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-4-chloro-2-methoxybenzamide 577037-48-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,3-dihydro-3-oxoindazole-5-carboxamide 577037-49-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1,2,3-benzothiadiazole-5-carboxamide 577037-50-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxycarbonylbenzamide 577037-51-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-chloro-2-methoxybenzamide 577037-52-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-mercaptobenzamide 577037-53-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-amino-6-fluorobenzamide 577037-54-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-(R)-2-amino-3-methylbutanamide 577037-55-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]pyridine-3-carboxamide 577037-56-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]tetrahydrofuran-2-carboxamide 577037-57-1P,

N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3,3,3-trifluoropropanamide 577037-58-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]cyclobutanecarboxamide 577037-59-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,5-dihydropyrrole-2-carboxamide 577037-60-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]thiophene-2-acetamide 577037-61-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxybenzamide 577037-62-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methylpyridine-3-carboxamide 577037-63-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methylpyrazine-2-carboxamide 577037-64-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-6-hydroxypyridine-2-carboxamide 577037-65-1P 577037-66-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-(R)-2-(methylamino)propanamide 577037-67-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1-methylpyrrolidine-2-carboxamide 577037-68-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-4,5-dimethylfuran-2-carboxamide 577037-69-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1,2,3-thiadiazole-4-carboxamide 577037-70-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-6-oxo-1,6-dihydropyridazine-3-carboxamide 577037-71-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxypropanamide 577037-72-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methoxy-5-oxopentanamide 577037-73-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]pyrazine-2-carboxamide 577037-74-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-hydroxypyridine-2-carboxamide 577037-75-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-thiopheneacetamide 577037-76-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-methoxy-3-oxopropanamide 577037-77-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methyl-2-(methylamino)propanamide 577037-78-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-(R)-5-oxotetrahydrofuran-2-carboxamide 577037-79-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-(isopropylideneaminooxy)propanamide 577037-80-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-(pyridin-3-yl)propenamide 577037-81-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-(pyridin-4-yl)propenamide 577037-82-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-dimethylaminoacetamide 577037-83-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-(methylsulfonyl)acetamide 577037-84-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1-oxopyridine-2-carboxamide 577037-85-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methylpyrazole-3-carboxamide 577037-86-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methyl-1,2,3-thiadiazole-4-carboxamide 577037-87-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1,5-dimethylpyrazole-3-carboxamide 577037-88-8P

, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-(S)-5-oxotetrahydrofuran-2-carboxamide 577037-89-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]imidazole-4-carboxamide 577037-90-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-aminobenzamide 577037-91-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-6-methylpyridine-3-carboxamide 577037-92-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-hydroxypyrazine-2-carboxamide 577037-93-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]isoxazole-5-carboxamide 577037-94-6P, (R)-N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-oxopyrrolidine-2-carboxamide 577037-95-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-amino-2-methylpropanamide 577037-96-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1-aminocyclohexanecarboxamide 577037-97-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1-aminocyclopropanecarboxamide 577037-98-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-methylpyridine-4-carboxamide 577037-99-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-aminopyridine-3-carboxamide 577038-00-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]morpholine-3-carboxamide 577038-01-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-6-oxo-6H-pyran-3-carboxamide 577038-02-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-6-hydroxypyridine-3-carboxamide 577038-03-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxypyridine-3-carboxamide 577038-04-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,5-dimethylpyrrole-3-carboxamide 577038-05-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methylcyclopropanecarboxamide 577038-06-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]heptanamide 577038-07-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methylpropanamide 577038-08-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2,2-dimethyl-4-pentenamide 577038-09-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-4-methylpentanamide 577038-10-9P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]cyclopent-3-enecarboxamide 577038-11-0P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-ethylbutanamide 577038-12-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]piperidine-4-carboxamide 577038-13-2P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]pyrrole-2-carboxamide 577038-14-3P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-aminopyrazine-2-carboxamide 577038-15-4P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-(acetylamino)acetamide 577038-16-5P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-5-methylthiophene-2-carboxamide 577038-17-6P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-methylthiophene-2-carboxamide 577038-18-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-

phenylcyclohexyl]methyl]-3-(furan-3-yl)propenamide 577038-19-8P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-1-methylpyrrole-2-carboxamide 577770-99-1P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-3-(imidazol-4-yl)propenamide 577771-00-7P, N-[[cis-4-[[(Cyanoimino)(methylamino)methyl]amino]-1-phenylcyclohexyl]methyl]bicyclo[2.2.1]-5-heptene-2-carboxamide
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577032-40-7P, Trans-N-[[4-Hydroxy-1-(thiophen-2-yl)cyclohexyl]methyl]-2-methoxybenzamide 577032-44-1P, cis-N-[[4-Hydroxy-1-(thiophen-3-yl)cyclohexyl]methyl]-2-methoxybenzamide 577032-72-5P, cis-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-20-6P 577039-35-1P, 1-Isopropenylcyclohexanecarboxylic acid N-(3-phenylpropyl)amide 577039-42-0P, N-[(1-Isopropenylcyclohexyl)methyl]-2-methoxybenzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577032-39-4P, Cis-N-[[4-Hydroxy-1-(thiophen-2-yl)cyclohexyl]methyl]-2-methoxybenzamide 577032-45-2P, N-[[cis-1-(3-Ethyl-5-methylisoxazol-4-yl)-4-hydroxycyclohexyl]methyl]-2-methoxybenzamide 577032-46-3P, trans-N-[(1-Benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]-2-methoxybenzamide 577032-47-4P, cis-N-[(1-Benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]-2-methoxybenzamide 577032-48-5P, trans-2,5-Dimethylfuran-3-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-49-6P, cis-2,5-Dimethylfuran-3-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-50-9P, trans-5-Chloro-4-methoxythiophene-3-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-51-0P, cis-5-Chloro-4-methoxythiophene-3-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-52-1P, trans-Pyridine-2-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-53-2P, cis-Pyridine-2-carboxylic acid N-[(1-benzo[b]thiophen-3-yl-4-hydroxycyclohexyl)methyl]amide 577032-55-4P, Trans-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-2-ylcyclohexyl ester 577032-56-5P, cis-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-2-ylcyclohexyl ester 577032-57-6P, cis-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-3-ylcyclohexyl ester 577032-58-7P, trans-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-3-ylcyclohexyl ester 577032-59-8P, cis-Ethylcarbamic acid 4-(3-ethyl-5-methylisoxazol-4-yl)-4-[[(2-methoxybenzoyl)amino]methyl]cyclohexyl ester 577032-60-1P, trans-Ethylcarbamic acid 4-(3-ethyl-5-methylisoxazol-4-yl)-4-[[(2-methoxybenzoyl)amino]methyl]cyclohexyl ester 577032-61-2P, trans-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[(2-methoxybenzoyl)amino]methyl]cyclohexyl ester 577032-62-3P, cis-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[(2-methoxybenzoyl)amino]methyl]cyclohexyl ester 577032-63-4P, cis-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-pyridin-2-ylcyclohexyl ester 577032-64-5P, trans-Ethylcarbamic acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-pyridin-2-ylcyclohexyl ester 577032-65-6P, trans-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[[(2,5-

dimethylfuran-3-yl)carbonyl]amino]methyl]cyclohexyl ester 577032-66-7P, cis-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[[(2,5-dimethylfuran-3-yl)carbonyl]amino]methyl]cyclohexyl ester 577032-67-8P, trans-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[[(5-chloro-4-methoxythien-3-yl)carbonyl]amino]methyl]cyclohexyl ester 577032-68-9P, cis-Ethylcarbamic acid 4-benzo[b]thiophen-3-yl-4-[[[(5-chloro-4-methoxythien-3-yl)carbonyl]amino]methyl]cyclohexyl ester 577032-69-0P, Acetic acid cis-4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-3-ylcyclohexyl ester 577032-70-3P, Butyric acid trans-4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-3-ylcyclohexyl ester 577032-71-4P, cis-Butyric acid 4-[[(2-methoxybenzoyl)amino]methyl]-4-thiophen-3-ylcyclohexyl ester 577032-75-8P, cis-2-Methoxy-[[4-(N'-benzyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-76-9P, cis-2-Methoxy-N-[[4-(N',N'-diethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-77-0P, cis-2-Methoxy-N-[[4-(N',N'-dipropyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-78-1P, cis-2-Methoxy-N-[[4-(N'-propyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-79-2P, cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-80-5P, cis-2-Methoxy-N-[[4-(N'-hexyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-81-6P, cis-2-Methoxy-N-[[4-(N'-methyl-N'-benzyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-82-7P, cis-2-Methoxy-N-[[4-(N'-tert-butyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-83-8P, cis-2-Methoxy-N-[[4-(N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-84-9P, cis-2-Methoxy-N-[[4-(N'-cyanomethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-85-0P, cis-2-Methoxy-N-[[4-[[(cyanoimino)(azetidino)methyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577032-86-1P, cis-2-Methoxy-N-[[4-(N'-cyclopropyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-87-2P, cis-2-Methoxy-N-[[4-[N'-(2-hydroxyethyl)-N''-cyanoguanidino]-1-phenylcyclohexyl]methyl]benzamide 577032-88-3P, cis-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-89-4P, cis-N-[[4-[N'-((S)-2-Hydroxy-1-methylethyl)-N''-cyanoguanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577032-90-7P, cis-2-Methoxy-N-[[4-(N'-prop-2-ynyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-91-8P, cis-2-Methoxy-N-[[4-(N'-cyclopropylmethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-92-9P, cis-2-Methoxy-N-[[4-[[(cyanoimino)(pyrrolidino)methyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577032-93-0P, cis-2-Methoxy-N-[[4-(N'-methoxy-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-94-1P, cis-2-Methoxy-N-[[4-(N'-methylamino-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-95-2P, cis-2-Methoxy-N-[[4-(N',N'-dimethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-96-3P, trans-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-98-5P, trans-2-Methoxy-N-[[4-(N'-benzyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577032-99-6P, trans-2-Methoxy-N-[[4-(N',N'-diethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-00-2P, trans-2-Methoxy-N-[[4-(N',N'-dipropyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-01-3P, trans-2-Methoxy-N-[[4-(N'-propyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-02-4P, trans-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-03-5P, trans-2-Methoxy-N-[[4-(N'-hexyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-04-6P, trans-2-Methoxy-N-[[4-(N'-methyl-N'-benzyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-05-7P, trans-2-Methoxy-N-[[4-(N'-tert-butyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577033-06-8P, trans-N-[[4-(N,N'-Diethylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-07-9P, N-[[4-(N,N'-Diethylguanidino)-1-

phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-09-1P, trans-2-Methoxy-N-[[4-[[(ethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-11-5P, trans-2-Methoxy-N-[[4-[[[(methyl)(benzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-12-6P, trans-2-Methoxy-N-[[4-[[(tert-butylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-13-7P, trans-2-Methoxy-N-[[4-[[(phenylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-14-8P, trans-2-Methoxy-N-[[4-[[(diethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-15-9P, trans-2-Methoxy-N-[[4-[[(benzylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-16-0P, trans-2-Methoxy-N-[[4-[[(propylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-17-1P, trans-2-Methoxy-N-[[4-[[(dipropylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-18-2P, trans-2-Methoxy-N-[[4-[[(4-methylpiperazin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-19-3P, cis-2-Methoxy-N-[[4-[[[(4-anisyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-21-7P, cis-2-Methoxy-N-[[4-[[[(methyl)(benzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-22-8P, cis-2-Methoxy-N-[[4-[[(tert-butylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-23-9P, cis-2-Methoxy-N-[[4-[[(phenylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-24-0P, cis-2-Methoxy-N-[[4-[[(diethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-25-1P, cis-2-Methoxy-N-[[4-[[(benzylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-26-2P, cis-2-Methoxy-N-[[4-[[(ethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-27-3P, cis-2-Methoxy-N-[[4-[[(dipropylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-28-4P, cis-2-Methoxy-N-[[4-[[(propylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-29-5P, cis-2-Methoxy-N-[[4-[[(methylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-30-8P, cis-N-[[4-[[(4-Phenylpiperazin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-31-9P, cis-N-[[4-[[(4-Cyano-4-phenylpiperidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-32-0P, cis-N-[[4-[[(4-Methylpiperazin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-33-1P, cis-2-Methoxy-N-[[4-[[(Allylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-34-2P, cis-2-Methoxy-N-[[4-[[[(3-isoxazolyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-35-3P, cis-2-Methoxy-N-[[4-[[[(3-cyanophenyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-36-4P, cis-2-Methoxy-N-[[4-[[[(4-methylbenzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-37-5P, cis-2-Methoxy-N-[[4-[[[(5-methyl-1H-pyrazol-3-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-38-6P, cis-2-Methoxy-N-[[4-[[[(3-diethylaminopropyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-39-7P, cis-2-Methoxy-N-[[4-[[[(3-dimethylamino-2,2-dimethylpropyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-40-0P, cis-2-Methoxy-N-[[4-[[[(methyl)(2-hydroxyethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-41-1P, cis-2-Methoxy-N-[[4-[(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577033-42-2P, cis-N-[[4-[[(4-Ethylpiperidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-43-3P, cis-2-Methoxy-N-[[4-[[[(2-ethoxyethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-44-4P, cis-2-Methoxy-N-[[4-[[(indan-1-ylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-45-5P, cis-2-Methoxy-N-[[4-[[[(2,4-difluorobenzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-46-6P, cis-2-Methoxy-N-[[4-[[[bis(2-hydroxyethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-47-7P, cis-2-Methoxy-N-[[4-

[[[(methyl)[2-(pyridin-2-yl)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-48-8P, cis-2-Methoxy-N-[[4-[[[(pyridin-2-ylmethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-49-9P, cis-2-Methoxy-N-[[4-[[[(4-methylpyridin-2-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-50-2P, cis-2-Methoxy-N-[[4-[[[(3-fluorophenyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-51-3P, cis-2-Methoxy-N-[[4-[[[(3-fluoro-4-methylphenyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-52-4P, cis-2-Methoxy-N-[[4-[[[(tetrazol-5-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-53-5P, cis-2-Methoxy-N-[[4-[[[(1H-pyrazol-3-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-54-6P 577033-55-7P, cis-N-[[4-[[(4-Acetyl-[1,4]diazepan-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-56-8P, cis-2-Methoxy-N-[[4-[[[(methyl)(propyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-57-9P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-58-0P, cis-2-Methoxy-N-[[4-[[[(2,2,2-trifluoroethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-59-1P, cis-2-Methoxy-N-[[4-[[[(4-fluorobenzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-60-4P, cis-2-Methoxy-N-[[4-[[[(2-methyl-2-propen-1-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-61-5P, cis-2-Methoxy-N-[[4-[[[(2-methylpropan-1-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-62-6P, cis-2-Methoxy-N-[[4-[[[[2-(imidazol-4-yl)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-63-7P, cis-N-[[4-[[[4-(4-Fluorophenyl)piperazin-1-yl]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-64-8P, cis-2-Methoxy-N-[[1-phenyl-4-[(piperazin-1-ylsulfonyl)amino]cyclohexyl]methyl]benzamide 577033-65-9P, cis-2-Methoxy-N-[[4-[[[(methyl)(2-dimethylaminoethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-66-0P, cis-2-Methoxy-N-[[4-[[[(cyclohexylmethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-67-1P, cis-2-Methoxy-N-[[4-[[[(pyridin-2-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-68-2P 577033-69-3P, cis-2-Methoxy-N-[[4-[[[[bis(hydroxymethyl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-70-6P, cis-2-Methoxy-N-[[4-[[[[1-(hydroxymethyl)-2-methylpropyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-71-7P, cis-2-Methoxy-N-[[4-[[[(2-hydroxy-1-methylethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-72-8P, cis-N-[[4-[[((R)-3-Hydroxypyrrolidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-73-9P, cis-2-Methoxy-N-[[4-[[[[(S)-2-hydroxypropyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-74-0P, cis-N-[[4-[[((S)-3-Hydroxypyrrolidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-75-1P, cis-2-Methoxy-N-[[4-[[[(methyl)(2-methoxyethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-76-2P, cis-2-Methoxy-N-[[4-[[[[(S)-2,3-dihydroxypropyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-77-3P, cis-N-[[4-[[(3-Hydroxypiperidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-78-4P, cis-N-[[4-[[((R)-2-Hydroxymethylpyrrolidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-79-5P, cis-N-[[4-[[((S)-2-Hydroxymethylpyrrolidin-1-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-80-8P, cis-2-Methoxy-N-[[4-[[[[[(R)-tetrahydrofuran-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-81-9P, cis-2-Methoxy-N-[[4-[[[[[(S)-tetrahydrofuran-2-

yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-82-0P, cis-2-Methoxy-N-[[4-[[[[1-(methoxymethyl)propyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-83-1P, cis-2-Methoxy-N-[[4-[[[[(3,4-dihydro-2H-pyran-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-84-2P, N-[[cis-4-[[(2,6-Dimethylmorpholin-4-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-85-3P, cis-2-Methoxy-N-[[4-[[[((R)-.alpha.-hydroxymethylbenzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-86-4P, cis-2-Methoxy-N-[[4-[[[((S)-.alpha.-hydroxymethylbenzyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-87-5P, cis-2-Methoxy-N-[[4-[[[((R)-2,3-dihydroxypropyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-88-6P, cis-2-Methoxy-N-[[4-[[[[4-[(ethoxycarbonyl)methyl]phenyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-89-7P, cis-2-Methoxy-N-[[4-[[[[4-(2-hydroxyethyl)phenyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-90-0P, cis-2-Methoxy-N-[[4-[[[[4-(1-hydroxyethyl)phenyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-91-1P, cis-2-Methoxy-N-[[4-[[[(3-hydroxymethylphenyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-92-2P, cis-2-Methoxy-N-[[4-[[[(2-hydroxyindan-1-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577033-93-3P, cis-N-[[4-(N'-Ethylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-97-7P, cis-N-[[4-(N',N'-Dimethylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-98-8P, cis-N-[[4-(N'-Benzylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577033-99-9P, cis-N-[[4-(N'-Methylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-00-5P, cis-N-[[4-(N'-Allylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-01-6P, cis-2,4-Dimethoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-08-3P, cis-2,4,5-Trimethoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-10-7P, cis-2-Phenoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-11-8P, cis-N-[[4-(N'-Methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]-2,4-Dimethoxypyridin-3-carboxamide 577034-13-0P, cis-2,6-Diethoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-14-1P, cis-2-Methoxy-4-methylthio-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-15-2P, cis-2-Methoxy-3-methyl-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-16-3P, cis-2-Isopropoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-17-4P, cis-2,6-Dimethoxy-3-chloro-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-18-5P, 2-Methoxynaphthalene-1-carboxylic acid N-[[cis-4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]amide 577034-19-6P, cis-2,3,4-Trimethoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-20-9P, cis-N-[[4-(N'-Methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]-2-Methoxypyridin-3-carboxamide 577034-21-0P, cis-N-[[4-(N'-Methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]-2-trifluoromethoxybenzamide 577034-22-1P, 2-Ethoxynaphthalene-1-carboxylic acid N-[[cis-4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]amide 577034-23-2P, cis-2-Benzyloxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]benzamide 577034-24-3P, 2-Methoxy-N-[[4-[N'-ethyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-26-5P, 2-Methoxy-N-[[4-[N'-propyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-27-6P, 2-Methoxy-N-[[4-[N'-tert-butyl-N''-

(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-28-7P, 2-Methoxy-N-[[4-[N'-hexyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-29-8P, 2-Methoxy-N-[[4-[N',N'-dipropyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-30-1P, 2-Methoxy-N-[[4-[N'-benzyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-31-2P, 2-Methoxy-N-[[4-[N'-methyl-N'-benzyl-N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-32-3P, 2-Methoxy-N-[[4-[N''-(ethoxycarbonyl)guanidino]-1-phenylcyclohexyl]methyl]benzamide 577034-33-4P, cis-N-[[4-(2,5-Dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-34-5P, cis-N-[[4-((S)-2,5-Dioxo-4-isopropylimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-35-6P, trans-N-[[4-(2,5-Dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-36-7P
, trans-N-[[4-((S)-2,5-Dioxo-4-isopropylimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-37-8P 577034-39-0P, Cis-N-[[4-((S)-4-Benzyl-2,5-dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-40-3P, Cis-N-[[4-((S)-4-Isobutyl-2,5-dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-41-4P, Cis-N-[[4-((S)-4-Ethyl-2,5-dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-42-5P, Cis-N-[[4-[(S)-4-(Hydroxymethyl)-2,5-dioxoimidazolidin-1-yl]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-43-6P, Cis-N-[[4-[(S)-4-[(Imidazol-4-yl)methyl]-2,5-dioxoimidazolidin-1-yl]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-44-7P 577034-45-8P 577034-46-9P, Cis-N-[[4-(3-Benzyl-2,5-dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-47-0P, Cis-N-[[4-(3-Methyl-2,5-dioxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-48-1P, cis-N-[(2,4-Dioxo-8-phenyl-1,3-diazaspiro[4.5]dec-8-yl)methyl]-2-methoxybenzamide 577034-49-2P, trans-N-[(2,4-Dioxo-1-phenyl-1,3-diazaspiro[4.5]dec-8-yl)methyl]-2-methoxybenzamide 577034-50-5P, cis-2-Methoxy-N-[[4-(2-oxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]benzamide 577034-54-9P, trans-2-Methoxy-N-[[4-(2-oxoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]benzamide 577034-56-1P, cis-N-[[4-(2-Cyanoiminoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-57-2P, trans-N-[[4-(2-Cyanoiminoimidazolidin-1-yl)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577034-58-3P, 1-Phenylcyclohexanecarboxylic acid benzylamide 577034-60-7P, 1-Phenylcyclohexanecarboxylic acid N-(3,4-difluorobenzyl)amide 577034-61-8P, 1-Phenylcyclohexanecarboxylic acid N-(4-chlorobenzyl)amide 577034-62-9P, 1-Phenylcyclohexanecarboxylic acid N-[2-(4-methoxyphenyl)ethyl]amide 577034-63-0P, 1-Phenylcyclohexanecarboxylic acid N-(2,4-dimethoxybenzyl)amide 577034-64-1P, 1-Phenylcyclohexanecarboxylic acid N-(1-phenylethyl)amide 577034-65-2P, 1-Phenylcyclohexanecarboxylic acid N-(3-phenylpropyl)amide 577034-66-3P, 1-Phenylcyclohexanecarboxylic acid N-(2-methoxybenzyl)amide 577034-67-4P, 1-Phenylcyclohexanecarboxylic acid N-(2-chlorobenzyl)amide 577034-68-5P, (1-Phenylcyclohexyl)(4-phenylpiperazin-1-yl)methanone 577034-69-6P, 1-Phenylcyclohexanecarboxylic acid N-(biphenyl-3-ylmethyl)amide 577034-70-9P, 1-Phenylcyclohexanecarboxylic acid N-(3-fluoro-5-trifluoromethylbenzyl)amide 577034-71-0P, 1-Phenylcyclohexanecarboxylic acid N-((S)-1-phenylethyl)amide 577034-72-1P, 1-Phenylcyclohexanecarboxylic acid N-((R)-1-phenylethyl)amide 577034-73-2P, 1-Phenylcyclohexanecarboxylic acid N-(3,3-diphenylpropyl)amide 577034-74-3P, 1-Phenylcyclohexanecarboxylic acid N-(4-trifluoromethylbenzyl)amide 577034-75-4P, [4-[(Benzo[1,3]dioxol-5-yl)methyl]piperazin-1-yl](1-

phenylcyclohexyl)methanone 577034-76-5P, 1-Phenylcyclohexanecarboxylic acid N-(3-methylbenzyl)amide 577034-77-6P, 1-Phenylcyclohexanecarboxylic acid N-(3,4-dichlorobenzyl)amide 577034-78-7P, 1-Phenylcyclohexanecarboxylic acid N-(4-methylbenzyl)amide 577034-79-8P, 1-Phenylcyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide 577034-80-1P, 1-Phenylcyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577034-81-2P, 1-Phenylcyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577034-82-3P, 1-Phenylcyclohexanecarboxylic acid N-[2-(3-trifluoromethylphenyl)ethyl]amide 577034-83-4P, 1-Phenylcyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577034-84-5P, 1-Phenylcyclohexanecarboxylic acid N-(3-trifluoromethylbenzyl)amide 577034-85-6P, 1-Phenylcyclohexanecarboxylic acid N-(4-fluorobenzyl)amide 577034-86-7P, 1-Phenylcyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577034-87-8P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577034-88-9P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577034-89-0P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-[2-(3-trifluoromethylphenyl)ethyl]amide 577034-90-3P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577034-91-4P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(4-chlorobenzyl)amide 577034-92-5P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(3-trifluoromethylbenzyl)amide 577034-93-6P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(4-fluorobenzyl)amide 577034-94-7P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide 577034-95-8P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(4-trifluoromethylbenzyl)amide 577034-96-9P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577034-97-0P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577034-98-1P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577034-99-2P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(3-trifluoromethylphenyl)ethyl]amide 577035-00-8P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577035-01-9P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(4-chlorobenzyl)amide 577035-02-0P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(3-trifluoromethylbenzyl)amide 577035-03-1P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(4-fluorobenzyl)amide 577035-04-2P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577035-05-3P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(4-trifluoromethylbenzyl)amide 577035-06-4P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577035-07-5P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577035-08-6P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577035-09-7P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(3-trifluoromethylphenyl)ethyl]amide 577035-10-0P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577035-11-1P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(4-chlorobenzyl)amide 577035-12-2P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(3-trifluoromethylbenzyl)amide 577035-13-3P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(4-fluorobenzyl)amide

577035-14-4P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide 577035-15-5P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(4-trifluoromethylbenzyl)amide 577035-16-6P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577035-17-7P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577035-18-8P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577035-19-9P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(3-trifluoromethylphenyl)ethyl]amide 577035-20-2P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577035-21-3P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(4-chlorobenzyl)amide 577035-22-4P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(3-trifluoromethylbenzyl)amide 577035-23-5P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(4-fluorobenzyl)amide 577035-24-6P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide 577035-25-7P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(4-trifluoromethylbenzyl)amide 577035-26-8P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577035-27-9P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(3,4-dimethylphenyl)ethyl]amide 577035-28-0P, 1-p-Tolylcyclohexanecarboxylic acid N-(2-m-tolylethyl)amide 577035-29-1P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(4-bromophenyl)ethyl]amide 577035-30-4P, 1-p-Tolylcyclohexanecarboxylic acid N-(2-p-tolylethyl)amide 577035-31-5P, 1-p-Tolylcyclohexanecarboxylic acid N-(3-phenylpropyl)amide 577035-32-6P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(2-chlorophenyl)ethyl]amide 577035-33-7P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]amide 577035-34-8P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(2,4-dichlorophenyl)ethyl]amide 577035-35-9P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(3-chlorophenyl)ethyl]amide 577035-36-0P, 1-p-Tolylcyclohexanecarboxylic acid N-(4-fluorobenzyl)amide 577035-37-1P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(3,4-dichlorophenyl)ethyl]amide 577035-38-2P, 1-p-Tolylcyclohexanecarboxylic acid N-(3-methylbenzyl)amide 577035-39-3P, 1-p-Tolylcyclohexanecarboxylic acid N-(4-phenylbutyl)amide 577035-40-6P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(2-methoxyphenyl)ethyl]amide 577035-41-7P, 1-p-Tolylcyclohexanecarboxylic acid N-(2-phenoxyethyl)amide 577035-42-8P, 1-p-Tolylcyclohexanecarboxylic acid N-(biphenyl-2-ylmethyl)amide 577035-43-9P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(thiophen-2-yl)ethyl]amide 577035-44-0P, 1-p-Tolylcyclohexanecarboxylic acid N-(4-methoxybenzyl)amide 577035-45-1P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(4-ethylphenyl)ethyl]amide 577035-46-2P, 1-p-Tolylcyclohexanecarboxylic acid N-[2-(2-fluorophenyl)ethyl]amide 577035-47-3P, 1-p-Tolylcyclohexanecarboxylic acid N-(4-methylbenzyl)amide 577035-48-4P, 1-p-Tolylcyclohexanecarboxylic acid N-(3-methoxybenzyl)amide 577035-49-5P, 1-p-Tolylcyclohexanecarboxylic acid N-(2-methoxybenzyl)amide 577035-50-8P, 1-p-Tolylcyclohexanecarboxylic acid N-(1-phenylethyl)amide 577035-51-9P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid [2-(4-chlorophenyl)ethyl][(1-methyl-1H-imidazol-2-yl)methyl]amide 577035-53-1P, 1-(4-Chlorophenyl)cyclohexanecarboxylic acid N-[2-(4-chlorophenyl)ethyl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]amide 577035-54-2P, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid N-(benzyl)-N-[(1-methyl-1H-imidazol-2-yl)methyl]amide 577035-55-3P, Ethylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-60-0P, 4-Phenyl-4-(5-phenyl-[1,2,4]oxadiazol-3-yl)cyclohexanone 577035-61-1P, 4-[5-(2-Methoxyphenyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexanone 577035-62-2P, Ethylcarbamic acid 4-phenyl-4-(5-phenyl-[1,2,4]oxadiazol-3-yl)cyclohexyl ester

577035-63-3P, Ethylcarbamic acid 4-[5-(2-methoxyphenyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-64-4P, Ethylcarbamic acid 4-[5-(3-chlorophenyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-65-5P, Ethylcarbamic acid 4-[5-(4-chlorophenyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-66-6P, Ethylcarbamic acid 4-phenyl-4-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)cyclohexyl ester 577035-67-7P, [2-(1-Methylpyrrolidin-2-yl)ethyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-68-8P, (Thiophen-2-ylmethyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-69-9P, (4-Phenylbutyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-70-2P, (Cyclopropylmethyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-71-3P, [2-(Pyridin-4-yl)ethyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-72-4P, [(Tetrahydrofuran-2-yl)methyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-73-5P, [2-(Thiophen-2-yl)ethyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-74-6P, [2-(Pyridin-2-yl)ethyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-75-7P, Isobutylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-76-8P, Phenethylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-77-9P, Butylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-78-0P, Allylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-79-1P, Cyclohexylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-80-4P, (Pyridin-4-ylmethyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-81-5P, Propylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-82-6P, Cyclopentylcarbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-83-7P, (2-Methoxyethyl)(methyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-84-8P, (Cyclohexylmethyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-85-9P, [2-(Pyridin-3-yl)ethyl]carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-86-0P, (2,4-Dichlorobenzyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-87-1P, (Benzyl)(methyl)carbamic acid 4-[5-(3-methoxybenzyl)-[1,2,4]oxadiazol-3-yl]-4-phenylcyclohexyl ester 577035-88-2P, Ethylcarbamic acid trans-4-[(isoquinolin-1-ylamino)methyl]-4-phenylcyclohexyl ester 577035-93-9P, Ethylcarbamic acid cis-4-[(isoquinolin-1-ylamino)methyl]-4-phenylcyclohexyl ester 577035-94-0P, (Isoquinolin-1-yl)[(1-phenylcyclohexyl)methyl]amine 577035-96-2P, 1-Phenylcyclohexanecarboxylic acid [1,7]naphthyridin-8-ylamide 577035-97-3P, ([1,7]Naphthyridin-8-yl)[(1-phenylcyclohexyl)methyl]amine 577035-98-4P, 1-Phenylcyclopropanecarboxylic acid N-(isoquinolin-1-yl)amide 577035-99-5P, (Isoquinolin-1-yl)[(1-phenylcyclopropyl)methyl]amine 577036-00-1P, [(1-Phenylcyclohexyl)methyl](quinazolin-4-yl)amine 577036-02-3P, N-Ethyl-N'-[(1-phenylcyclohexyl)methyl]quinazoline-2,4-diamine 577036-03-4P, cis-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(2-fluorophenyl)cyclohexyl]methyl]benzamide 577036-04-5P, cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(2-fluorophenyl)cyclohexyl]methyl]benzamide 577036-05-6P 577036-06-7P, cis-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-08-9P,

trans-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-09-0P, trans-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-10-3P, cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-11-4P, cis-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-12-5P, trans-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-13-6P, cis-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(3-fluorophenyl)cyclohexyl]methyl]benzamide 577036-14-7P, cis-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-15-8P, trans-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-16-9P, trans-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-17-0P, cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-18-1P, trans-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-19-2P, cis-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-20-5P, cis-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-(4-fluorophenyl)cyclohexyl]methyl]benzamide 577036-21-6P, cis-2-Methoxy-N-[[4-[[[[(pyridin-4-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-22-7P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[(pyridin-4-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-23-8P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[(pyridin-3-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-24-9P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[(pyridin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-25-0P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[(1-methylbenzimidazol-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-26-1P, cis-2-Methoxy-N-[[4-[[[[(pyridin-3-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-27-2P, cis-2-Methoxy-N-[[4-[[[[(benzimidazol-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-28-3P, cis-2-Methoxy-N-[[4-[[[[(5-methylpyrazin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-29-4P, cis-2-Methoxy-N-[[4-[[[[(S)-1-(methoxymethyl)-2-phenylethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-30-7P, cis-2-Methoxy-N-[[4-[[[(pyrazin-2-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-31-8P, cis-2-Methoxy-N-[[4-[[[(ethyl)[(pyridin-4-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-32-9P, cis-2-Methoxy-N-[[4-[[[(methyl)[2-(pyridin-4-yl)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-33-0P, cis-2-Methoxy-N-[[4-[[[(1H-1,2,4-triazol-3-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-34-1P, cis-2-Methoxy-N-[[4-[[[[2-(pyridin-4-yl)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-35-2P, cis-2-Methoxy-N-[[4-[[[[3-(imidazol-2-yl)propyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-36-3P, cis-2-Methoxy-N-[[4-[[[[2-(piperidino)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-37-4P, cis-2-Methoxy-N-[[4-[[[[2-(phenylamino)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-38-5P, cis-2-Methoxy-N-[[4-[[[(pyridin-4-yl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide

577036-39-6P, cis-2-Methoxy-N-[[4-[[[[(1-ethylpyrrolidin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-40-9P, cis-2-Methoxy-N-[[4-[[[[2-(pyrrolidino)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-41-0P, cis-2-Methoxy-N-[[4-[[[[(4-amino-2-methylpyrimidin-5-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-42-1P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[1-(pyridin-4-yl)propyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-43-2P, cis-2-Methoxy-N-[[4-[[[[2-(morpholino)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-44-3P, cis-2-Methoxy-N-[[4-[[[(2-methoxyethyl)[1-(pyridin-4-yl)ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-45-4P, cis-2-Methoxy-N-[[4-[[[[(2-aminophenyl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-46-5P, cis-2-Methoxy-N-[[4-[[[[(4-aminophenyl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-47-6P, cis-2-Methoxy-N-[[4-[(aminosulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577036-48-7P, cis-2-Methoxy-N-[[4-[[[[2-[(pyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-49-8P, cis-2-Methoxy-N-[[4-[[[[2-[(5-ethylpyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-50-1P, cis-2-Methoxy-N-[[4-[[[[2-[(pyridin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-51-2P, cis-2-Methoxy-N-[[4-[[[[2-[[4-chloro-6-(methoxycarbonyl)pyrimidin-2-yl]amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-52-3P, cis-2-Methoxy-N-[[4-[[[[2-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-53-4P, cis-2-Methoxy-N-[[4-[[[[2-[[4-chloro-6-(diethylamino)-1,3,5-triazin-2-yl]amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-54-5P, cis-2-Methoxy-N-[[4-[[[[2-[(4,6-dimethoxy-1,3,5-triazin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-55-6P, cis-2-Methoxy-N-[[4-[[[[2-[(6-butoxy-4-chloro-1,3,5-triazin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-56-7P, cis-2-Methoxy-N-[[4-[[[[2-[(4-chloro-5-methylpyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-57-8P, cis-2-Methoxy-N-[[4-[[[[2-[(4-chloro-6-methylpyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-58-9P, cis-2-Methoxy-N-[[4-[[[[2-[(2-chloro-6-methylpyrimidin-4-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-59-0P, cis-2-Methoxy-N-[[4-[[[[2-[(4,6-dichloropyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-60-3P, cis-2-Methoxy-N-[[4-[[[[2-[(2,6-dichloropyrimidin-4-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-61-4P, cis-2-Methoxy-N-[[4-[[[[2-[(4-chloropyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-62-5P, cis-2-Methoxy-N-[[4-[[[[2-[(2-chloropyrimidin-4-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-63-6P, cis-2-Methoxy-N-[[4-[[[[2-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-64-7P, cis-2-Methoxy-N-[[4-[[[[2-[(5-bromo-4-chloropyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-65-8P, cis-2-Methoxy-N-[[4-[[[[2-[(5-bromopyrimidin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-66-9P, cis-2-Methoxy-N-[[4-[[[[2-[[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-67-0P, cis-2-Methoxy-N-[[4-[[[[2-[(4-amino-6-chloro-1,3,5-triazin-2-yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-68-1P, cis-2-Methoxy-N-[[4-[[[[2-[(4-amino-5-cyanopyrimidin-2-

yl)amino]ethyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]benzamide 577036-69-2P 577036-70-5P, trans-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-71-6P, cis-2-Methoxy-N-[[4-(N'-allyl-N''-cyanoguanidino)-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-72-7P, trans-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-73-8P, cis-2-Methoxy-N-[[4-[N'-(cyclopropylmethyl)-N''-cyanoguanidino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-74-9P, cis-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-75-0P, trans-2-Methoxy-N-[[4-(N'-methyl-N''-cyanoguanidino)-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-76-1P, trans-2-Methoxy-N-[[4-(N'-ethyl-N''-cyanoguanidino)-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-77-2P, cis-2-Methoxy-N-[[4-[[[[(pyridin-2-yl)methyl]amino]sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-78-3P 577036-79-4P, trans-2-Methoxy-N-[[4-[[[[(S)-1-(methoxymethyl)-2-phenylethyl]amino]sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-80-7P, cis-2-Methoxy-N-[[4-[[(benzylamino)sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-81-8P, trans-2-Methoxy-N-[[4-[[(benzylamino)sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-82-9P, trans-2-Methoxy-N-[[4-[[[[(pyridin-2-yl)methyl]amino]sulfonyl]amino]-1-(2-methoxyphenyl)cyclohexyl]methyl]benzamide 577036-83-0P, (Isoquinolin-1-yl)[[cis-4-(N'-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]amine 577036-84-1P, (Isoquinolin-1-yl)[[trans-4-(N-methyl-N''-cyanoguanidino)-1-phenylcyclohexyl]methyl]amine 577038-25-6P, trans-N-[[4-[[(Cyanoimino)(amino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-26-7P, cis-N-[[4-[[(Cyanoimino)(amino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-27-8P, trans-N-[[4-[[(Cyanoimino)(ethylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-28-9P, cis-N-[[4-[[(Cyanoimino)(ethylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-29-0P, trans-N-[[4-[[(Cyanoimino)[(cyclopropylmethyl)amino]methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-30-3P
, cis-N-[[4-[[(Cyanoimino)[(cyclopropylmethyl)amino]methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-31-4P, trans-N-[[4-[[(Cyanoimino)(allylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-32-5P, cis-N-[[4-[[(Cyanoimino)(allylamino)methyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-33-6P, cis-N-[[4-[[[[(Pyridin-4-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-34-7P, trans-N-[[4-[[[[(Pyridin-4-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-36-9P, trans-N-[[4-[[[[(Pyridin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-37-0P, cis-N-[[4-[[[[(Pyridin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-38-1P, trans-N-[[4-[[[[(5-Methylpyrazin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-39-2P, cis-N-[[4-[[[[(5-Methylpyrazin-2-yl)methyl]amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-40-5P, trans-N-[[4-[[[(2-Methoxyethyl)(methyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-41-6P, cis-N-[[4-[[[(2-Methoxyethyl)(methyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-42-7P,

cis-N-[[4-[[[(Phenylsulfonyl)amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-44-9P, cis-N-[[4-[[[[[5-(Acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-45-0P, cis-N-[[4-[[[[[5-(Dimethylamino)naphthalen-1-yl]sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-46-1P, cis-N-[[4-[[[(Methylsulfonyl)amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-47-2P, cis-N-[[4-[[[(Hydroxysulfonyl)amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-48-3P, cis-N-[[4-[[[[[3-(4,5-Dihydro-3-methyl-5-oxopyrazol-1-yl)phenyl]sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-49-4P, cis-N-[[4-[[[[(5-Chlorothien-2-yl)sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-50-7P 577038-51-8P, cis-N-[[4-[[[[(Trifluoromethyl)sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-52-9P, cis-N-[[4-[[[[[5-(Acetylimino)-4-methyl-4,5-dihydro-1,3,4-thiadiazol-2-yl]sulfonyl]amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-53-0P, cis-N-[[4-[[[(Aminosulfonyl)amino]carbonyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-54-1P, cis-N-[[4-[[(Cyanoimino)[[(4-chlorophenyl)sulfonyl]amino]methyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-56-3P, cis-N-[[4-[[(Cyanoimino)[(phenylsulfonyl)amino]methyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-57-4P, cis-N-[[4-[[(Cyanoimino)[(methylsulfonyl)amino]methyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-58-5P, N-[[3-[[(Cyanoimino)(methylamino)methyl]amino]-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-64-3P, N-[[3-[[(Cyanoimino)(dimethylamino)methyl]amino]-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-65-4P, N-[[3-[[(Cyanoimino)(ethylamino)methyl]amino]-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-66-5P, N-[[3-[[(Cyanoimino)(amino)methyl]amino]-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-67-6P, N-[[3-[[(Cyanoimino)(allylamino)methyl]amino]-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-68-7P, cis-N-[[4-[N''-Cyano-N'-ethyl-N-(2-methoxyethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-71-2P, Cis-N-[[4-(N''-Cyano-N'-ethyl-N-methylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-72-3P, Cis-N-[[4-(N-Benzyl-N''-cyano-N'-ethylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-73-4P, Cis-N-[[4-[N''-Cyano-N'-ethyl-N-(pyridin-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-74-5P, Cis-N-[[4-[N''-Cyano-N'-ethyl-N-(pyridin-3-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-75-6P, Cis-N-[[4-[N''-Cyano-N'-ethyl-N-(furan-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-76-7P, trans-N-[[4-[N''-Cyano-N'-ethyl-N-(2-methoxyethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-77-8P, Trans-N-[[4-(N''-Cyano-N'-ethyl-N-methylguanidino)-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-78-9P, Trans-N-[[4-[N''-Cyano-N'-ethyl-N-(pyridin-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-79-0P, Trans-N-[[4-[N''-Cyano-N'-ethyl-N-(pyridin-3-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-80-3P, Trans-N-[[4-[N''-Cyano-N'-ethyl-N-(furan-2-ylmethyl)guanidino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-81-4P,

cis-2-Methoxy-N-[[4-[(2-methoxyethyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-82-5P, Cis-2-Methoxy-N-[[4-[methyl(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-83-6P, Cis-N-[[4-[(Benzyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-84-7P, Cis-2-Methoxy-N-[[4-[(morpholin-4-ylsulfonyl)(pyridin-2-ylmethyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-85-8P, Cis-2-Methoxy-N-[[4-[(morpholin-4-ylsulfonyl)(pyridin-3-ylmethyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-86-9P, Cis-N-[[4-[(Furan-2-ylmethyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-87-0P, trans-2-Methoxy-N-[[4-[(2-methoxyethyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-88-1P, Trans-2-Methoxy-N-[[4-[methyl(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-89-2P, Trans-N-[[4-[(Benzyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-90-5P, Trans-2-Methoxy-N-[[4-[(morpholin-4-ylsulfonyl)(pyridin-2-ylmethyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-91-6P, Trans-2-Methoxy-N-[[4-[(morpholin-4-ylsulfonyl)(pyridin-3-ylmethyl)amino]-1-phenylcyclohexyl]methyl]benzamide 577038-92-7P, Trans-N-[[4-[(Furan-2-ylmethyl)(morpholin-4-ylsulfonyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-93-8P, N-[(1-Benzylcyclohexyl)methyl]-2-methoxybenzamide 577038-95-0P, N-[(1-Benzylcyclohexyl)methyl]-2-(trifluoromethyl)benzamide 577038-96-1P, N-[(1-Benzylcyclohexyl)methyl]-3-methoxybenzamide 577038-97-2P, N-[(1-Benzylcyclohexyl)methyl]-3-cyanobenzamide 577038-98-3P, N-[(1-Benzylcyclohexyl)methyl]-2-fluoro-6-(trifluoromethyl)benzamide 577038-99-4P, N-[(1-Benzylcyclohexyl)methyl]-4-fluoro-2-(trifluoromethyl)benzamide 577039-00-0P, N-[(1-Benzylcyclohexyl)methyl]-2,4-difluorobenzenesulfonamide 577039-01-1P, N-[(1-Benzylcyclohexyl)methyl]-2,5-dimethoxybenzenesulfonamide 577039-02-2P, N-[(1-Benzylcyclohexyl)methyl]-2,3-difluorobenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577039-03-3P, N-[(1-Benzylcyclohexyl)methyl]-4-methylbenzamide 577039-04-4P, N-[(1-Benzylcyclohexyl)methyl]-2,4-difluorobenzamide 577039-05-5P, N-[(1-Benzylcyclohexyl)methyl]-2,6-difluorobenzamide 577039-06-6P, N-[(1-Benzylcyclohexyl)methyl]-2-chloropyridine-3-carboxamide 577039-07-7P, N-[(1-Benzylcyclohexyl)methyl]-2-methoxyacetamide 577039-08-8P, N-[(1-Benzylcyclohexyl)methyl]-3,4-difluorobenzamide 577039-09-9P, N-[(1-Benzylcyclohexyl)methyl]-2,4,5-trifluorobenzamide 577039-10-2P, N-[(1-Benzylcyclohexyl)methyl]-5-fluoro-2-methylbenzamide 577039-11-3P, N-[(1-Benzylcyclohexyl)methyl]-3-chlorobenzamide 577039-12-4P, N-[(1-Benzylcyclohexyl)methyl]benzamide 577039-13-5P, N-[(1-Benzylcyclohexyl)methyl]-3,5-dimethoxybenzamide 577039-14-6P, N-[(1-Benzylcyclohexyl)methyl]-2-trifluoromethoxybenzenesulfonamide 577039-15-7P, N-[(1-Benzylcyclohexyl)methyl]benzeneacetamide 577039-16-8P, N-[(1-Benzylcyclohexyl)methyl]-4-fluorobenzeneacetamide 577039-17-9P, N-[(1-Benzylcyclohexyl)methyl]-4-methoxybenzeneacetamide 577039-18-0P, N-[(1-Benzylcyclohexyl)methyl]-2-phenylcyclopropanecarboxamide 577039-19-1P, N-[(1-Benzylcyclohexyl)methyl]-3-phenylpropanamide 577039-20-4P, 2-Methoxy-N-[(1-phenylcyclohexyl)methyl]nicotinamide 577039-21-5P, N-Ethyl-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-23-7P, N-Benzyl-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-24-8P, N-[(2,3-Dimethoxyphenyl)methyl]-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-25-9P,

N-Cyclopentyl-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-26-0P, N-(Cyclopropylmethyl)-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-27-1P, N-[(Pyridin-4-yl)methyl]-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-28-2P, N-[(Pyridin-3-yl)methyl]-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-29-3P, N-[(2-Methoxyphenyl)methyl]-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-30-6P, N-(2-Phenylethyl)-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-31-7P, 4-[[((1-Phenylcyclohexyl)methyl)amino](cyanoimino)methyl]morpholine 577039-32-8P, N-(Indan-1-yl)-N'-[(1-phenylcyclohexyl)methyl]-N''-cyanoguanidine 577039-33-9P, 1-[[((1-Phenylcyclohexyl)methyl)amino](cyanoimino)methyl]pyrrolidine 577039-34-0P, 5-Benzyl-3-[(1-phenylcyclohexyl)methyl]imidazolidine-2,4-dione 577039-36-2P, 1-Isopropenylcyclohexanecarboxylic acid N-(3,3-diphenylpropyl)amide 577039-37-3P, 1-Isopropenylcyclohexanecarboxylic acid N-(biphenyl-3-ylmethyl)amide 577039-38-4P, 1-Isopropenylcyclohexanecarboxylic acid N-(isoquinolin-1-yl)amide 577039-39-5P, 1-Isopropylcyclohexanecarboxylic acid N-(3-phenylpropyl)amide 577039-40-8P, 1-Isopropylcyclohexanecarboxylic acid N-(3,3-diphenylpropyl)amide 577039-41-9P, 1-Isopropylcyclohexanecarboxylic acid N-(biphenyl-3-ylmethyl)amide 577039-44-2P, N-Bicyclohexyl-1'-en-1-ylmethyl-2-methoxybenzamide 577039-45-3P, N-[(1-Isopropylcyclohexyl)methyl]-2-methoxybenzamide 577039-46-4P, 2-Methyl-3-[(1-phenylcyclohexyl)methyl]-3H-imidazo[4,5-b]pyridine 577039-49-7P, 3-[(1-Phenylcyclohexyl)methyl]-1,3-dihydroimidazo[4,5-b]pyridin-2-one 577039-50-0P, [2-[[(1-Phenylcyclohexyl)methyl]amino]pyridin-3-yl]methanol 577039-52-2P, N-(4-Methylpyridin-2-yl)-3-phenyl-N-[(1-phenylcyclohexyl)methyl]propionamide 577039-55-5P, N-(4-Methylpyridin-2-yl)-3-phenyl-N-[(1-phenylcyclohexyl)methyl]acrylamide 577039-56-6P, 2-Methoxy-N-(4-methylpyridin-2-yl)-N-[(1-phenylcyclohexyl)methyl]benzamide 577039-57-7P, N-(4-Methylpyridin-2-yl)-2-phenyl-N-[(1-phenylcyclohexyl)methyl]acetamide 577039-58-8P, N-(4-Methylpyridin-2-yl)-N-[(1-phenylcyclohexyl)methyl]benzamide 577039-59-9P, N-(4-Methylpyridin-2-yl)-N-[(1-phenylcyclohexyl)methyl]acetamide 577039-60-2P, 3-Phenyl-N-[(1-phenylcyclohexyl)methyl]-N-pyrimidin-2-ylpropionamide 577039-62-4P, 2-Methoxy-N-[2-(1-phenylcyclohexyl)ethyl]benzamide 577039-65-7P, 2-Hydroxy-6-methoxy-N-[2-(1-phenylcyclohexyl)ethyl]benzamide 577039-66-8P, N-(2-Methoxyphenyl)-2-(1-phenylcyclohexyl)acetamide 577039-67-9P, 2-[(1-Phenylcyclohexyl)methyl]-1H-benzimidazole 577039-69-1P, 1-Methyl-2-[(1-phenylcyclohexyl)methyl]-1H-benzimidazole 577039-70-4P, 7-Methoxy-2-[(1-phenylcyclohexyl)methyl]-1H-benzimidazole 577039-71-5P, 2-[(1-Phenylcyclohexyl)methyl]-3H-quinazolin-4-one 577039-73-7P, 1-[(1-Phenylcyclohexyl)methoxy]isoquinoline 577039-74-8P, [(1-Isopropenylcyclohexyl)methyl](isoquinolin-1-yl)amine 577039-75-9P, 1-(3-Fluorophenyl)cyclohexanecarboxylic acid N-(isoquinolin-1-yl)amide 577039-76-0P, 1-(2-Fluorophenyl)cyclohexanecarboxylic acid N-(isoquinolin-1-yl)amide 577039-77-1P, [[1-(3-Fluorophenyl)cyclohexyl]methyl](isoquinolin-1-yl)amine 577039-78-2P, [[1-(2-Fluorophenyl)cyclohexyl]methyl](isoquinolin-1-yl)amine 577039-87-3P, trans-N-[[4-Hydroxy-1-(thiophen-3-yl)cyclohexyl]methyl]-2-methoxybenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577036-87-4P, (Isoquinolin-1-yl)[[cis-4-[[(ethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine 577036-88-5P, (Isoquinolin-1-yl)[[trans-4-

[[[(cyclopropylmethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine 577036-89-6P, (Isoquinolin-1-yl)[[cis-4-[[[(cyclopropylmethyl)amino]sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine 577036-90-9P, (Isoquinolin-1-yl)[[trans-4-[[(allylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine 577036-91-0P, (Isoquinolin-1-yl)[[cis-4-[[(allylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(drug candidate; preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 9002-04-4, Thrombin 9002-05-5, Factor Xa 9015-82-1, Angiotensin-converting enzyme 9028-35-7, HMG-CoA reductase 65312-43-8, Factor VIIa
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combined with cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 2251-65-2, 3-(Trifluoromethyl)benzoyl chloride 76429-73-7, 2,3-Dihydrobenzo[b]furan-5-carboxylic acid
RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)
(preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 577034-07-2P, cis-N-[(Cyanoimino)(methylamino)methyl]-4-(aminomethyl)-4-phenylcyclohexanamine
RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 67-64-1, Acetone, reactions 88-68-6, Anthranilamide 90-04-0, o-Anisidine 91-52-1, 2,4-Dimethoxybenzoic acid 95-54-5, 1,2-Phenylenediamine, reactions 96-33-3, Methyl acrylate 98-10-2, Benzenesulfonamide 98-64-6, 4-Chlorobenzenesulfonamide 100-39-0, Benzyl bromide 100-46-9, Benzylamine, reactions 104-94-9, p-Anisidine 109-85-3, 2-Methoxyethylamine 109-90-0, Ethyl isocyanate 156-41-2, 2-(4-Chlorophenyl)ethylamine 326-62-5, 2-Fluorophenylacetonitrile 459-22-3, 4-Fluorophenylacetonitrile 501-00-8, 3-Fluorophenylacetonitrile 607-68-1, 2,4-Dichloroquinazoline 645-45-4, Hydrocinnamoyl chloride 695-34-1, 4-Methylpyridin-2-ylamine 766-05-2, Cyclohexanecarbonitrile 1001-53-2, N-Acetylethylenediamine 1135-67-7, 1-Phenylcyclohexanecarboxylic acid 1452-94-4, Ethyl 2-chloronicotinate 1532-84-9, 1-Aminoisoquinoline 1828-66-6, Morpholine-4-sulfonyl chloride 2038-57-5, 3-Phenylpropylamine 2133-40-6, L-Proline methyl ester monohydrochloride 2201-23-2, 1-Phenylcyclohexanecarbonitrile 2949-22-6, Ethyl isocyanatoacetate 3132-64-7, Oxiranylmethyl bromide 3147-64-6, 6-Methoxysalicylic acid 3731-53-1, 4-(Aminomethyl)pyridine 6834-42-0, 3-Methoxyphenylacetyl chloride 7035-03-2, 2-Methoxyphenylacetonitrile 7693-46-1, 4-Nitrophenyl chloroformate 10191-60-3, Dimethyl N-cyanodithioiminocarbonate 13750-81-7, 1-Methyl-1H-imidazole-2-carboxaldehyde 16182-04-0, Ethyl isothiocyanatoformate 16498-81-0, 2-Methoxynicotinic acid 19493-44-8, 1-Chloroisoquinoline 19755-53-4, 2-Bromo-3-nitropyridine 20893-30-5, 2-Thiopheneacetonitrile 21615-34-9, o-Anisoyl chloride 25115-74-6, 4-Phenyl-4-cyanocyclohexan-1-one 30293-86-8, Methyl (S)-(-)-2-isocyanato-3-methylbutyrate 79463-77-7, Diphenyl N-cyanocarbonimidate 87543-80-4, Ethyl 2-isocyanato-3-phenylpropionate 214263-00-0, 1-(4-Fluorophenyl)cyclohexanecarboxylic acid

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

IT 17380-54-0P, [(1-Phenylcyclohexyl)methyl]amine 20494-36-4P, Phenyl N-ethyl-N'-cyanocarbamimidate 22612-69-7P, 1-Phenylcyclohexanecarboxaldehyde 32231-02-0P, 2-(1-Phenylcyclohexyl)ethylamine 32231-03-1P, (1-Phenylcyclohexyl)acetic acid 32294-72-7P, (1-Phenylcyclohexyl)acetonitrile 50654-50-7P, 1-(1-Hydroxy-1-methylethyl)cyclohexanecarbonitrile 51509-98-9P 56326-98-8P, 4-Cyano-4-(4-fluorophenyl)cyclohexan-1-one 58379-06-9P, 4-Cyano-4-(2-methoxyphenyl)cyclohexan-1-one 63089-66-7P, 1-Isopropenylcyclohexanecarbonitrile 65619-56-9P, Dimethyl 4-cyano-4-(thien-2-yl)heptanedioate 65619-57-0P, Methyl 5-cyano-5-(thien-2-yl)-2-oxocyclohexanecarboxylate 65619-58-1P, 4-Cyano-4-(thien-2-yl)cyclohexan-1-one 65619-59-2P 68692-77-3P, (1-Phenylcyclohexyl)methanol 72349-96-3P, 1-Isopropenylcyclohexanecarboxylic acid 104367-54-6P, 1-Benzylcyclohexanecarbonitrile 179064-47-2P, Dimethyl 4-cyano-4-(2-fluorophenyl)heptanedioate 179064-48-3P, Methyl 5-cyano-5-(2-fluorophenyl)-2-oxocyclohexanecarboxylate 179064-61-0P, 4-Cyano-4-(2-fluorophenyl)cyclohexan-1-one 265656-18-6P, 4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexan-1-one 267403-38-3P, cis-4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 267403-49-6P, trans-4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 443687-93-2P 577032-41-8P 577032-42-9P 577032-43-0P, 4-[[(2-Methoxybenzoyl)amino]methyl]-4-(thien-2-yl)cyclohexan-1-one 577032-54-3P 577032-73-6P, 4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577032-74-7P, N-[(Cyanoimino)(phenoxy)methyl]-cis-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577032-97-4P, N-[(Cyanoimino)(phenoxy)methyl]-trans-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577033-08-0P, N-Ethyl-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577033-10-4P 577033-94-4P, 1-[cis-4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl]thiourea 577033-95-5P, N-[cis-4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl]-S-methylisothiourea 577033-96-6P, N-Acetyl-N'-[cis-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl]-S-methylisothiourea 577034-02-7P 577034-03-8P, 4-[[(Trifluoroacetyl)amino]methyl]-4-phenylcyclohexan-1-one 577034-04-9P, 4-[[(Trifluoroacetyl)amino]methyl]-4-phenylcyclohexanamine 577034-06-1P, trans-N-[(Cyanoimino)(methylamino)methyl]-4-[[(trifluoroacetyl)amino]methyl]-4-phenylcyclohexanamine 577034-25-4P, 2-Methoxy-N-[[4-[3-(ethoxycarbonyl)thioureido]-1-phenylcyclohexyl]methyl]benzamide 577034-38-9P, 4-[[(2-Methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl isocyanate 577034-51-6P, cis-N-(tert-Butoxycarbonyl)-N-[2-(acetylamino)ethyl]-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577034-52-7P, trans-N-(tert-Butoxycarbonyl)-N-[2-(acetylamino)ethyl]-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577034-53-8P, cis-N-[2-Aminoethyl]-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577034-55-0P, trans-N-[2-Aminoethyl]-4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577034-59-4P, 1-Phenylcyclohexanecarbonyl fluoride 577035-52-0P, [2-(4-Chlorophenyl)ethyl][(1-methyl-1H-imidazol-2-yl)methyl]amine dihydrochloride 577035-56-4P 577035-57-5P 577035-58-6P, 4-[5-(3-Methoxybenzyl)-1,2,4-oxadiazol-3-yl]-4-phenylcyclohexan-1-one 577035-59-7P, 4-[5-(3-Methoxybenzyl)-1,2,4-oxadiazol-3-yl]-4-phenylcyclohexanol 577035-89-3P 577035-90-6P, 4-[(Isoquinolin-1-ylamino)methyl]-4-phenylcyclohexan-1-one 577035-91-7P, trans-4-[(Isoquinolin-1-ylamino)methyl]-4-phenylcyclohexanol

577035-92-8P, cis-4-[(Isoquinolin-1-ylamino)methyl]-4-phenylcyclohexanol 577035-95-1P, N-(Isoquinolin-1-yl)-1-phenylcyclohexanecarboxamide 577036-01-2P, (2-Chloroquinazolin-4-yl)[(1-phenylcyclohexyl)methyl]amine 577036-07-8P, 4-Cyano-4-(3-fluorophenyl)cyclohexan-1-one 577036-85-2P, 4-[(Isoquinolin-1-ylamino)methyl]-4-phenylcyclohexanamine 577036-86-3P, (Isoquinolin-1-yl)[[trans-4-[[(ethylamino)sulfonyl]amino]-1-phenylcyclohexyl]methyl]amine 577038-20-1P 577038-21-2P, 4-[[(2-Hydroxy-6-methoxybenzoyl)amino]methyl]-4-phenylcyclohexan-1-one 577038-22-3P, trans-4-[[(2-Hydroxy-6-methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl mesylate 577038-23-4P, cis-4-[[(2-Hydroxy-6-methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl azide 577038-24-5P, cis-4-[[(2-Hydroxy-6-methoxybenzoyl)amino]methyl]-4-phenylcyclohexanamine 577038-35-8P, N-[[4-[[(2-Oxooxazolidin-3-yl)sulfonyl]amino]-1-phenylcyclohexyl]methyl]-2-hydroxy-6-methoxybenzamide 577038-43-8P, cis-N-[[4-Isocyanato-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-55-2P, cis-N-[[4-[[(Cyanoimino)(methylthio)methyl]amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-59-6P, cis-3-Cyano-3-(3-fluorophenyl)cyclobutanol 577038-60-9P, 3-(Aminomethyl)-3-(3-fluorophenyl)cyclobutanol 577038-61-0P, N-[[3-Hydroxy-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-62-1P, N-[[3-Mesyloxy-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-63-2P, N-[[3-Amino-1-(3-fluorophenyl)cyclobutyl]methyl]-2-methoxybenzamide 577038-69-8P, cis-N-[[4-[(2-Methoxyethyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-70-1P, trans-N-[[4-[(2-Methoxyethyl)amino]-1-phenylcyclohexyl]methyl]-2-methoxybenzamide 577038-94-9P, 1-Benzylcyclohexanemethanamine 577039-22-6P 577039-43-1P, [(1-Isopropenylcyclohexyl)methyl]amine 577039-47-5P, (3-Nitropyridin-2-yl)[(1-phenylcyclohexyl)methyl]amine 577039-48-6P, N-[(1-Phenylcyclohexyl)methyl]pyridine-2,3-diamine 577039-51-1P, Ethyl 2-[[(1-phenylcyclohexyl)methyl]amino]pyridine-3-carboxylate 577039-53-3P, N-(4-Methylpyridin-2-yl)-1-phenylcyclohexanecarboxamide 577039-54-4P, (4-Methylpyridin-2-yl)[(1-phenylcyclohexyl)methyl]amine 577039-61-3P, (Pyrimidin-2-yl)[(1-phenylcyclohexyl)methyl]amine 577039-63-5P, Hydroxy(1-phenylcyclohexyl)acetonitrile 577039-64-6P, Imidazole-1-carbothioic acid O-[cyano(1-phenylcyclohexyl)methyl] ester 577039-68-0P, N-(2-Aminophenyl)-2-(1-phenylcyclohexyl)acetamide 577039-72-6P, 2-[2-(1-Phenylcyclohexyl)acetylamino]benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cycloalkyl inhibitors of potassium channel function for preventing/treating arrhythmia and IKur-associated conditions)

L68 ANSWER 9 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:376835 HCAPLUS
DN 138:385420
ED Entered STN: 16 May 2003
TI Preparation of oxazole-heterocyclic glycine derivatives useful as **antidiabetic** and **antiobesity** agents
IN **Devasthale, Pratik; Jeon, Yoon T.**
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D263-56
ICS A61K031-421
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040114	A1	20030515	WO 2002-US35704	20021106
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003130306	A1	20030710	US 2002-289053	20021106
	US 6673815	B2	20040106		
PRAI	US 2001-333022P	P	20011106		
OS	MARPAT 138:385420				
GI					



I



II

AB Compds., e.g. of formula I [R1 = H, alkyl; R2, R4 = H, alkyl, alkoxy, halo, (substituted) amino; R3 = aryloxycarbonyl, alkyloxycarbonyl, cycloalkylaryloxycarbonyl, alkoxy, alkylsulfonyl, arylsulfonyl etc.; X = CH, N; A = (CH2)x; x = 1-5; E = O, S, N, CH; M = N, CH; G = O, S, NH, CH2, etc.; m = 0-2; n = 0-2], are prepared which are useful as **antidiabetic**, hypolipidemic, and **antiobesity** agents (no data). Thus, II is prepared from 2-(5-methyl-2-phenyl-4-oxazolyl)ethanol, 3-amino-4-hydroxybenzoic acid Me ester hydrochloride, glycine tert-Bu ester hydrochloride and 4-methoxyphenyl chloroformate.

ST oxazole heterocyclic glycine deriv prepn **antidiabetic antiobesity**

IT Intestine, disease
(Crohn's; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT Intestine, disease
(irritable bowel syndrome; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT Adipose tissue, neoplasm
(liposarcoma; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT **Antidiabetic** agents
Antiobesity agents
Atherosclerosis
Diabetes mellitus
Human
Hyperglycemia
Hypertriglyceridemia
Inflammation
Lung, neoplasm
Mammary gland, neoplasm
Obesity
Osteoporosis
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
(preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT Disease, animal
(syndrome X; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT Stomach, disease
(ulcer; preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT 524959-38-4P 524959-39-5P 524959-40-8P 524959-41-9P 524959-42-0P
524959-43-1P 524959-44-2P 524959-45-3P 524959-46-4P 524959-47-5P
524959-48-6P 524959-49-7P 524959-50-0P 524959-51-1P 524959-52-2P
524959-53-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT 106-41-2, 4-Bromophenol 453-71-4, 4-Fluoro-3-nitrobenzoic acid
616-34-2, Glycine methyl ester 937-62-2, 4-Methylphenyl chloroformate
5680-79-5, Glycine methyl ester hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 27532-96-3, Glycine tert-butyl ester hydrochloride
39830-66-5, Methyl indole-4-carboxylate 60032-63-5, 3-Iodo-4-hydroxybenzaldehyde 65885-07-6 103788-61-0 103788-65-4 107367-98-6
140130-10-5 227029-27-8 258346-53-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
IT 99-42-3P 42564-42-1P 132646-34-5P 258346-54-2P 258346-55-3P
396652-42-9P 524959-54-4P 524959-55-5P 524959-56-6P 524959-57-7P
524959-58-8P 524959-60-2P 524959-62-4P 524959-64-6P 524959-65-7P
524959-66-8P 524959-67-9P 524959-68-0P 524959-69-1P 524959-70-4P

524959-71-5P 524959-72-6P 524959-73-7P 524959-74-8P 524959-75-9P
524959-76-0P 524959-77-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazole-heterocyclic glycine derivs. as **antidiabetic** and **antiobesity** agents)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aotsuka; US 6136831 A 2000 HCAPLUS

L68 ANSWER 10 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:238978 HCAPLUS
DN 139:83136
ED Entered STN: 28 Mar 2003
TI The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state
AU Tamakoshi, K.; Yatsuya, H.; Kondo, T.; Hori, Y.; Ishikawa, M.; **Zhang, H.**; Murata, C.; Otsuka, R.; Zhu, S.; Toyoshima, H.
CS Dep. Public Health/Health Information Dynamics, Nagoya Univ. Grad. Sch. Med., Nagoya, 466-8550, Japan
SO International Journal of Obesity (2003), 27(4), 443-449
CODEN: IJOBDP; ISSN: 0307-0565
PB Nature Publishing Group
DT Journal
LA English
CC 14-5 (Mammalian Pathological Biochemistry)
AB OBJECTIVE:: To elucidate the underlying mechanisms between C-reactive protein (CRP) and cardiovascular disease, we examined the association of circulating CRP in healthy reference range (.ltoreq.1.0 mg/dL) measured by high-sensitive CRP assay with the metabolic syndrome (MS). DESIGN:: Cross-sectional study of circulating CRP in adult men. SUBJECTS:: A total of 3692 Japanese men aged 34-69 yr. MEASUREMENTS:: Serum CRP, total cholesterol, triglycerides, LDL-cholesterol, fasting glucose, fasting insulin, uric acid, systolic blood pressure, diastolic blood pressure, and body mass index (BMI). RESULTS:: There was a statistically significant pos. correlation between CRP and BMI (r=0.25), total cholesterol (r=0.096), triglycerides (r=0.22), LDL-cholesterol (r=0.12), fasting glucose (r=0.088), fasting insulin (r=0.17), uric acid (r=0.13), systolic blood pressure (r=0.12), and diastolic blood pressure (r=0.11), and a significant neg. correlation of CRP with HDL-cholesterol (r=0.24). After adjusting for age, smoking, and all other components of MS, **obesity**, hypertriglyceridemia, hyper-LDL-cholesterolemia, **diabetes**, hyperinsulinemia, and hyperuricemia were significantly associated with both mildly (.gtoreq.0.06 mg/dL) and moderately (.gtoreq.0.11 mg/dL) elevated CRP. Compared with men who had no such components of the MS, those who had one, two, three, four, and five or more components were, resp., 1.48, 1.84, 1.92, 3.42, and 4.17 times more likely to have mildly elevated CRP levels (trend P<0.001). As for moderately elevated CRP, the same association was observed CONCLUSIONS:: These results indicate that a variety of components of the MS are associated with elevated CRP levels in a systemic low-grade inflammatory state.
ST CRP hyperinsulinemia hypertriglyceridemia hypercholesterolemia hyperuricemia hypertension metabolic syndrome inflammation
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C-reactive; elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT Hypercholesterolemia
(LDL; elevated CRP in association with metabolic syndrome, inflammation and

cardiovascular disease)
IT Body weight
Cardiovascular system, disease
Diabetes mellitus
Human
Human groups
Hypertension
Hypertriglyceridemia
Obesity
(elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(low-d.; elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT Disease, animal
(syndrome X; elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT 50-99-7, Glucose, biological studies 57-88-5, Cholesterol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperinsulinemia; elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
IT 69-93-2, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperuricemia; elevated CRP in association with metabolic syndrome, inflammation and cardiovascular disease)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Baumann, H; Immunol Today 1994, V15, P74 HCAPLUS
(2) Baumann, H; Mol Biol Med 1990, V7, P147 HCAPLUS
(3) Chambers, J; Circulation 2001, V104, P145 HCAPLUS
(4) Danesh, J; BMJ 2000, V321, P199 MEDLINE
(5) Danesh, J; JAMA 1998, V279, P1477 MEDLINE
(6) Fernandez-Real, J; J Clin Endocrinol Metab 2001, V86, P1154 HCAPLUS
(7) Ferrannini, E; Diabetologia 1991, V34, P416 MEDLINE
(8) Festa, A; Int J Obes Relat Metab Disord 2001, V25, P1407 MEDLINE
(9) Folsom, A; Am J Cardiol 2001, V88, P112 HCAPLUS
(10) Fourcade, O; Cell 1995, V80, P919 HCAPLUS
(11) Frohlich, M; Diabetes Care 2000, V23, P1835 HCAPLUS
(12) Gauldie, J; Ann NY Acad Sci 1989, V557, P46 HCAPLUS
(13) Gray, R; Am J Epidemiol 1998, V148, P869 MEDLINE
(14) Hack, C; Immunol Today 1997, V18, P111 HCAPLUS
(15) Hansson, G; Br Heart J 1993, V69, P38
(16) Hashimoto, H; Circulation 2001, V104, P63 HCAPLUS
(17) Heinrich, J; Thromb Haemost 1995, V73, P374 HCAPLUS
(18) Heinrich, P; Biochem J 1990, V265, P621 HCAPLUS
(19) Hotamisligil, G; J Clin Invest 1995, V95, P2409 HCAPLUS
(20) Hotamisligil, G; Science 1993, V259, P87 HCAPLUS
(21) Howard, B; Am J Epidemiol 1995, V142, P254 MEDLINE
(22) Juhan-Vague, I; Arterioscler Thromb 1993, V13, P1865 MEDLINE
(23) Kern, P; J Clin Invest 1995, V95, P2111 HCAPLUS

(24) Koenig, W; Circulation 1999, V99, P237 MEDLINE
(25) Kuller, L; Am J Epidemiol 1996, V144, P537 MEDLINE
(26) Lagrand, W; Circulation 1999, V100, P96 MEDLINE
(27) Mendall, M; BMJ 1996, V312, P1061 MEDLINE
(28) Mohamed-Ali, V; J Clin Endocrinol Metab 1997, V82, P4196 HCAPLUS
(29) Pannacciulli, N; Int J Obes Relat Metab Disord 2001, V25, P1416 HCAPLUS
(30) Pepys, M; Lancet 1981, V1, P653 HCAPLUS
(31) Ridker, P; Circulation 1998, V97, P425 MEDLINE
(32) Ridker, P; N Engl J Med 1997, V336, P973 HCAPLUS
(33) Rifai, N; Clin Chem 2001, V47, P403 HCAPLUS
(34) SPSS Incorporation; SPSS Base 10.0J user's guide 1999
(35) Strandberg, T; Arterioscler Thromb Vasc Biol 2000, V20, P1057 HCAPLUS
(36) Tracy, R; Arterioscler Thromb Vasc Biol 1997, V17, P1121 HCAPLUS
(37) Vgontzas, A; J Clin Endocrinol Metab 1997, V82, P1313 HCAPLUS
(38) Wolbink, G; J Immunol 1996, V157, P473 HCAPLUS
(39) Yamada, S; Am J Epidemiol 2001, V153, P1183 MEDLINE

L68 ANSWER 11 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:213477 HCAPLUS
DN 138:367304
ED Entered STN: 19 Mar 2003
TI Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity
AU Zhu, Z.; Hattori, K.; **Zhang, H.**; Jimenez, X.; Ludwig, D. L.; Dias, S.; Kussie, P.; Koo, H.; Kim, H. J.; Lu, D.; Liu, M.; Tejada, R.; Friedrich, M.; Bohlen, P.; Witte, L.; Rafii, S.
CS Department of Antibody Technology, ImClone Systems Incorporated, New York, NY, USA
SO Leukemia (2003), 17(3), 604-611
CODEN: LEUKED; ISSN: 0887-6924
PB Nature Publishing Group
DT Journal
LA English
CC 15-3 (Immunochemistry)
Section cross-reference(s): 2
AB Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We recently showed that certain 'liquid' tumors such as leukemia not only produce VEGF, but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. A chimeric anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-1C11, was shown to be able to inhibit VEGF-induced proliferation of human leukemia cells in vitro, and to prolong survival of **nonobese diabetic**-severe combined immune deficient (NOD-SCID) mice inoculated with human leukemia cells. Here we produced two fully human anti-KDR antibodies (IgG1), IMC-2C6 and IMC-1121, from Fab fragments originally isolated from a large antibody phage display library. These antibodies bind specifically to KDR with high affinities: 50 and 200 pM for IMC-1121 and IMC-2C6, resp., as compared to 270 pM for IMC-1C11. Like IMC-1C11, both human antibodies block VEGF/KDR interaction with an IC50 of approx. 1 nM, but IMC-1121 is a more potent inhibitor to VEGF-stimulated proliferation of human endothelial cells. These anti-KDR antibodies strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. It is noteworthy that the mice treated with antibody of the highest affinity, IMC-1121, survived the longest period of time, followed by mice treated with IMC-2C6 and IMC-1C11. Taken together, our data suggest that anti-KDR antibodies may

have broad applications in the treatment of both solid tumors and leukemia. It further underscores the efforts to identify antibodies of high affinity for enhanced antiangiogenic and antitumor activities.

ST leukemia antibody vascular endothelial growth factor receptor 2

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); BIOL (Biological study); PREP (Preparation)
(IgG1, IMC-1121; inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

IT Antibodies and Immunoglobulins
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); BIOL (Biological study); PREP (Preparation)
(IgG1, IMC-2C6; inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

IT Angiogenesis
Angiogenesis inhibitors
Antitumor agents
Human
Leukemia
(inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

IT Cell migration
(inhibition of human leukemia migration in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

IT Cell proliferation
(inhibition of human leukemia proliferation in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

IT Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type VEGFR-2; inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2)

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aguayo, A; Blood 1999, V94, P3717 HCAPLUS
(2) Aguayo, A; Blood 2000, V96, P2240 HCAPLUS
(3) Aguayo, A; Blood 2000, V96, P768 HCAPLUS
(4) Bellamy, W; Blood 2001, V97, P1427 HCAPLUS
(5) Bellamy, W; Cancer Res 1999, V59, P728 HCAPLUS
(6) Bellamy, W; Semin Oncol 2001, V28, P551 HCAPLUS
(7) Boocock, C; J Natl Cancer Inst 1995, V87, P506 HCAPLUS
(8) De Haard, H; J Biol Chem 1999, V274, P18218 HCAPLUS
(9) Dias, S; J Clin Invest 2000, V106, P511 HCAPLUS
(10) Dias, S; Proc Natl Acad Sci USA 2001, V98, P10857 HCAPLUS
(11) Ferrajoli, A; Clin Cancer Res 2001, V7, P795 HCAPLUS
(12) Ferrara, N; J Mol Med 1999, V77, P527 HCAPLUS
(13) Fiedler, W; Blood 1997, V89, P1870 HCAPLUS
(14) Fiedler, W; Cancer J Supl 2001, V3, PS129
(15) Fong, T; Cancer Res 1999, V59, P99 HCAPLUS
(16) Fusetti, L; Cancer Res 2000, V60, P2527 HCAPLUS
(17) Gerber, H; Nature 2002, V417, P954 HCAPLUS
(18) Glennie, M; Immunol Today 2000, V21, P403 HCAPLUS
(19) Hattori, K; Nat Med 2002, V8, P841 HCAPLUS
(20) Hiratsuka, S; Cancer Res 2001, V61, P1207 HCAPLUS
(21) Hoogenboom, H; Immunol Today 2000, V21, P371 HCAPLUS
(22) Hussong, J; Blood 2000, V95, P309 HCAPLUS

(23) Itakura, J; Int J Cancer 2000, V85, P27 HCAPLUS
(24) Kanai, T; Int J Cancer 1998, V77, P933 HCAPLUS
(25) Kanno, S; Oncogene 2000, V19, P2138 HCAPLUS
(26) Kim, K; Nature 1993, V362, P841 HCAPLUS
(27) Klagsbrum, M; Cytokine Growth Factor Rev 1996, V7, P259
(28) Lacal, P; J Invest Dermatol 2000, V115, P1000 HCAPLUS
(29) List, A; The Oncologist 2001, V6, P24 HCAPLUS
(30) Little, M; Immunol Today 2000, V21, P364 HCAPLUS
(31) Lu, D; Cancer Res 2001, V61, P7002 HCAPLUS
(32) Lu, D; Int J Cancer 2002, V97, P393 HCAPLUS
(33) Lu, D; J Biol Chem 2000, V275, P14321 HCAPLUS
(34) Luttun, A; Nat Med 2002, V8, P831 HCAPLUS
(35) Margolin, K; Curr Oncol Rep 2002, V4, P20
(36) Masood, R; Blood 2001, V98, P1904 HCAPLUS
(37) Mesters, R; Blood 2001, V98, P241 HCAPLUS
(38) Neufeld, G; FASEB J 1999, V13, P9 HCAPLUS
(39) Padro, T; Blood 2000, V95, P2637 HCAPLUS
(40) Pavco, P; Clin Cancer Res 2000, V6, P2094 HCAPLUS
(41) Perez-Atayde, A; Am J Pathol 1997, V150, P815 MEDLINE
(42) Prewett, M; Cancer Res 1999, V59, P5209 HCAPLUS
(43) Price, D; Cell Growth Differ 2001, V12, P129 HCAPLUS
(44) Pruneri, G; Br J Cancer 1999, V81, P1398 MEDLINE
(45) Smolich, B; Blood 2001, V97, P1413 HCAPLUS
(46) Soker, S; Am J Pathol 2001, V159, P651 HCAPLUS
(47) Vacca, A; Br J Haematol 1994, V87, P503 MEDLINE
(48) Witte, L; Cancer Metastasis Rev 1998, V17, P155 HCAPLUS
(49) Wood, J; Cancer Res 2000, V60, P2178 HCAPLUS
(50) Zhu, Z; Cancer Lett 1999, V136, P203 HCAPLUS
(51) Zhu, Z; Cancer Res 1998, V58, P3209 HCAPLUS
(52) Zhu, Z; Curr Cancer Drug Targets 2002, V2, P135 HCAPLUS
(53) Zhu, Z; Recent Research Developments in Cancer 2001, V3, P369
(54) Ziegler, B; Science 1999, V285, P1553 HCAPLUS
(55) Zogakis, T; Exp Opin Biol Ther 2001, V1, P253 HCAPLUS

L68 ANSWER 12 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927185 HCAPLUS
DN 138:24716
ED Entered STN: 06 Dec 2002
TI Preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents
IN **Cheng, Peter T.**; **Zhang, Hao**; Hariharan, Narayanan
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096358	A2	20021205	WO 2002-US16633	20020523
	WO 2002096358	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1390363 A2 20040225 EP 2002-729306 20020523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2001-294380P P 20010530
WO 2002-US16633 W 20020523
OS MARPAT 138:24716
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; .gtoreq.1 of x2, x3 .noteq. 0; X1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, alkyl(halo)aryloxycarbonyl, alkoxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, aryloxyarylalkyl, alkynyloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, arylsulfinylarylcarbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with provisos], were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-.gamma. (PPAR.gamma.) and stimulators of peroxisome proliferator activated receptor-.alpha. (PPAR.alpha.). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to

human PPAR.alpha. and to PPAR.gamma. ligand binding domains with IC50 = 69 nM.

ST azolecarboxylate prepn **antidiabetic antiobesity** agent; PPAR agonist antagonist azolecarboxylate prepn

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AP-2 (activator protein 2), inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(Crohn's, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, upregulators, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Liver
(abnormality treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Angiotensin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiotensin II, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Ion channel blockers
(calcium, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Antihypertensives
(coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopamine-transporting, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adipose tissue, neoplasm
(liposarcoma, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT **Antidiabetic** agents
Antiobesity agents
Cardiovascular agents
Human
Platelet aggregation inhibitors
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter, inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Cardiovascular system, disease
Diabetes mellitus
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Obesity
Osteoporosis
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
(treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Stomach, disease
(ulcer, treatment; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., stimulators; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptor antagonists
(.beta.-, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptor agonists
(.beta.3-, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., inhibitors; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477773-71-0P 477773-72-1P 477773-73-2P 477773-74-3P 477773-75-4P
477773-76-5P 477773-77-6P 477773-78-7P 477773-79-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477773-70-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 54870-28-9, Meglitinide 89750-14-1, Glucagon-like peptide I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 58-32-2,

Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 4205-91-8, Clonidine hydrochloride 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 143443-90-7, Ifetroban 144288-97-1, Ts-962 145599-86-6, Cerivastatin 152755-31-2, Ly295427 159183-92-3, l750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, Cgs 30440 170861-63-9, Jtt-501 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4 199113-98-9, Nn-2344 199914-96-0, Ym-440 213252-19-8, Krp297 244081-42-3, Aj9677 251572-86-8, p32/98 287714-41-4 335149-08-1, l895645 335149-14-9, r-119702 335149-15-0, Kad1129 335149-17-2, Arho39242 335149-19-4, Gw-409544 335149-23-0, Nvp-dpp-728a 335149-24-1, Atl-962 335149-25-2, Cp331648 416839-88-8, Axokine 430433-17-3, Glipyride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 943-45-3, Fibric acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(derivs., coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 9001-62-1, Lipase 9015-82-1 9027-63-8, ACAT 9028-35-7, HMG-CoA reductase 9029-60-1, Lipoxygenase 9033-06-1, Glucosidase 9077-14-9, Squalene synthetase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, coadministration; preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 57-71-6 62-53-3, Benzenamine, reactions 98-80-6 100-39-0 100-46-9, Benzenemethanamine, reactions 100-63-0 105-34-0 123-08-0 501-94-0 536-89-0 539-44-6 621-37-4 622-37-7 674-82-8, Ketene dimer 824-94-2 1003-09-4 2033-24-1 3034-53-5 4693-91-8 6834-42-0 10564-55-3 13254-27-8 14199-15-6 20570-96-1 103788-65-4 244152-94-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 27492-46-2P 36397-19-0P 36963-39-0P 42058-59-3P 75140-48-6P 103788-59-6P 103788-61-0P 179248-84-1P 192213-57-3P 226956-10-1P 227029-27-8P 244149-78-8P 244151-17-5P 477773-80-1P 477773-81-2P 477773-82-3P 477773-83-4P 477773-84-5P 477773-85-6P 477773-86-7P 477773-87-8P 477773-88-9P 477773-89-0P 477773-90-3P 477773-91-4P 477773-92-5P 477773-93-6P 477773-94-7P 477773-95-8P 477773-96-9P 477773-97-0P 477773-98-1P 477773-99-2P 477774-00-8P 477774-01-9P 477774-02-0P 477774-03-1P 477774-04-2P 477774-05-3P 477774-06-4P 477774-07-5P 477774-08-6P 477774-09-7P 477774-10-0P 477774-11-1P

477774-12-2P 477774-13-3P 477774-14-4P 477774-15-5P 477774-16-6P
477774-17-7P 477774-18-8P 477774-19-9P 477774-20-2P 477774-21-3P
477774-22-4P 477774-23-5P 477774-24-6P 477774-25-7P 477774-26-8P
477774-27-9P 477774-28-0P 477774-29-1P 477774-30-4P 477774-31-5P
477774-32-6P 477774-33-7P 477774-34-8P 477774-35-9P 477774-36-0P
477774-37-1P 477774-38-2P 477774-39-3P 477774-40-6P 477774-41-7P
477774-42-8P 477774-43-9P 477774-44-0P 477774-45-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477774-47-3P 477774-48-4P 477774-49-5P 477774-50-8P 477774-51-9P
477774-52-0P 477774-53-1P 477774-54-2P 477774-55-3P 477774-56-4P
477774-57-5P 477774-58-6P 477774-59-7P 477774-60-0P 477774-61-1P
477774-62-2P 477774-63-3P 477774-64-4P 477774-65-5P 477774-66-6P
477774-67-7P 477774-68-8P 477774-69-9P 477774-70-2P 477774-71-3P
477774-72-4P 477774-73-5P 477774-74-6P 477774-75-7P 477774-76-8P
477774-77-9P 477774-78-0P 477774-79-1P 477774-80-4P 477774-81-5P
477774-82-6P 477774-83-7P 477774-84-8P 477774-85-9P 477774-86-0P
477774-87-1P 477774-88-2P 477774-89-3P 477774-90-6P 477774-91-7P
477774-92-8P 477774-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 100-83-4, 3-Hydroxybenzaldehyde 142933-69-5 477774-96-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

IT 477774-93-9P 477774-94-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolecarboxylic acids useful as **antidiabetic** and **antiobesity** agents)

L68 ANSWER 13 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927184 HCAPLUS
DN 138:14048
ED Entered STN: 06 Dec 2002
TI Preparation of oxazolylethoxyphenylprolines and related compounds as **antidiabetic** and **antiobesity** agents.
IN **Cheng, Peter T.**; **Jeon, Yoon**; Wang, Wei
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096357	A2	20021205	WO 2002-US16628	20020523
WO 2002096357	A3	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003092697	A1	20030515	US 2002-153342	20020522	
EP 1401433	A2	20040331	EP 2002-737192	20020523	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2001-294505P P 20010530
WO 2002-US16628 W 20020523
OS MARPAT 138:14048
GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = (CH2)x, (CH2)x1, with an alkenyl or alkynyl bond in the chain, (CH2)x2O(CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; provided that .gtoreq.1 of x2 and x3 .noteq. 0; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that .gtoreq.1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroarylheteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxyarylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = (CH2)x4, (CH2)x5, (CH2)x6O(CH2)x7; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepared as **antidiabetic** and **antiobesity** agents (no data). Thus, title compound (II) was prepared in 6 steps.

ST oxazolylethoxyphenylproline prepn **antidiabetic** **antiobesity** agent; proline oxazolylethoxyphenyl prepn **antidiabetic antiobesity** agent

IT Proteins

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(ALBP (adipocyte lipid-binding protein), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(AP-2 (activator protein 2), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(Crohn's, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Lipoprotein receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(LDL, upregulators, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Proteins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(MTP (microsomal triglyceride-exchanging protein), inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Thyroid hormone receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(agonists, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Angiotensin receptor antagonists
(angiotensin II, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Osteoporosis
(antiosteoporotics, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Ion channel blockers
(calcium, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Appetite depressants
Platelet aggregation inhibitors
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Intestine, neoplasm
(colon, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT **Diabetes** mellitus
(complication treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(dopamine-transporting, inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Neoplasm
(epithelial, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Adipose tissue, neoplasm
(liposarcoma, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Anti-inflammatory agents
Antihypertensives
Antiobesity agents
Antitumor agents
Human
Hypolipemic agents
(preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(serotonin transporter, inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Disease, animal
(syndrome X, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Atherosclerosis
Hyperglycemia
Hypertriglyceridemia
Inflammation
Lung, neoplasm
Mammary gland, neoplasm
Neoplasm
Obesity
Ovary, neoplasm
Prostate gland, neoplasm
Psoriasis
Stomach, neoplasm
(treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Stomach, disease
(ulcer, treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., agonists, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptor antagonists

(.beta.-, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Adrenoceptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.3, agonist coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.gamma., agonists, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 477719-09-8P 477719-10-1P 477719-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 89750-14-1, Glucagon-like peptide I
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 50-78-2, Aspirin 51-64-9, Dexamphetamine 52-53-9, Verapamil 58-32-2, Dipyridamole 59-67-6, Niacin, biological studies 94-20-2, Chlorpropamide 122-09-8, Phentermine 525-66-6, Propranolol 637-07-0, Clofibrate 657-24-9, Metformin 4205-91-8, Clonidine hydrochloride 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 14838-15-4, Phenylpropanolamine 19237-84-4, Prazosin hydrochloride 21187-98-4, Gliclazide 21829-25-4, Nifedipine 22232-71-9, Mazindol 25812-30-0, Gemfibrozil 29094-61-9, Glipizide 42200-33-9, Nadolol 49562-28-9, Fenofibrate 54870-28-9, Meglitinide 55142-85-3, Ticlopidine 56180-94-0, Acarbose 62571-86-2, Captopril 72432-03-2, Miglitol 72956-09-3, Carvedilol 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 79902-63-9, Simvastatin 80830-42-8, Fentiapril 81093-37-0, Pravastatin 85441-61-8, Quinapril 86541-75-5, Benazepril 87333-19-5, Ramipril 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 96829-58-2, Orlistat 97240-79-4, Topiramate 97322-87-7, Troglitazone 98048-97-6, Fosinopril 103775-10-6, Moexipril 105816-04-4, Nateglinide 106650-56-0, Sibutramine 111025-46-8, Pioglitazone 111470-99-6, Amlodipine besylate 113665-84-2, Clopidogrel 114798-26-4, Losartan 122320-73-4, Rosiglitazone 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4, Valsartan 138402-11-6, Irbesartan 141758-74-9, AC 2993 143443-90-7, Ifetroban 144288-97-1, TS-962 145599-86-6, Cerivastatin 147511-69-1 152755-31-2, LY295427 159183-92-3, L750355 160135-92-2, Gemopatrilat 161600-01-7, Isaglitazone 166518-60-1, Avasimibe 167305-00-2, Omapatrilat 169319-62-4, CGS 30440 170861-63-9, JTT-501 176435-10-2, LY315902 178759-95-0, MD 700 182815-44-7, Cholestagel 196808-45-4, GI 262570 199113-98-9, NN-2344 199914-96-0, YM-440 213252-19-8, KRP297 244081-42-3, AJ9677 251565-85-2, AR-H 039242 251572-86-8, P32/98 287714-41-4 335149-08-1, L895645 335149-14-9, R-119702 335149-15-0, KAD1129 335149-19-4, GW-409544 335149-23-0, NVP-DPP-728A 335149-24-1, ATL-962 335149-25-2, CP331648 416839-88-8, Axokine 430433-17-3, Glipyride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 943-45-3, Fibric acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivs., coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 107-66-4, DP 4 9001-62-1, Lipase 9015-82-1 9028-35-7, HMG-CoA reductase 9033-06-1, Glucosidase 9077-14-9, Squalene synthetase 82707-54-8, Neutral endopeptidase 335197-46-1, SGLT2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 9027-63-8, ACAT 9029-60-1, Lipoxygenase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, coadministration; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 50-99-7, Glucose, biological studies
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(intolerance treatment; preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 477719-12-3P 477719-13-4P 477719-14-5P 477719-15-6P 477719-16-7P 477719-17-8P 477719-18-9P 477719-19-0P 477719-20-3P 477719-21-4P 477719-22-5P 477719-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 67-36-7, 4-Phenoxybenzaldehyde 106-41-2, 4-Bromophenol 501-53-1, Benzyl chloroformate 591-20-8, 3-Bromophenol 1068-90-2, Diethyl acetamidomalonate 1137-42-4, 4'-Hydroxybenzophenone 7685-44-1, Allylglycine 7693-41-6, 4-Methoxyphenyl chloroformate 24277-39-2 72086-72-7 73872-71-6 103788-65-4 227029-27-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 2847-87-2P 4006-70-6P 67963-68-2P 70837-19-3P 81323-62-8P 103788-59-6P 147698-05-3P 197159-25-4P 208520-00-7P 477719-24-7P 477719-25-8P 477719-26-9P 477719-27-0P 477719-28-1P 477719-29-2P 477719-30-5P 477719-31-6P 477719-32-7P 477719-33-8P 477719-34-9P 477719-35-0P 477719-36-1P 477719-37-2P 477719-38-3P 477719-39-4P 477719-40-7P 477719-41-8P 477719-42-9P 477719-43-0P 477719-44-1P 477719-45-2P 477719-46-3P 477719-47-4P 477719-48-5P 477719-49-6P 477719-50-9P 477719-51-0P 477719-52-1P 477719-53-2P 477719-54-3P 477719-55-4P 477719-56-5P 477719-57-6P 477719-58-7P 477719-59-8P 477719-60-1P 477719-61-2P 477719-62-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolylethoxyphenylprolines and related compds. as **antidiabetic** and **antiobesity** agents)

L68 ANSWER 14 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:600638 HCAPLUS
DN 138:280883
ED Entered STN: 13 Aug 2002
TI Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.
AU Mukherjee, Ranjan; Sun, Shaoxian; Santomenna, Linda; Miao, Bowman; Walton, Harry; Liao, Boshan; Locke, Kenneth; Zhang, Ji-Hu; Nguyen, Sonny H.;

Zhang, Li Tao; Murphy, Kathleen; Ross, Harold O.; Xia, M. X.; Teleha, Christopher; **Chen, S.-Y.**; Selling, Bernard; Wynn, Richard; Burn, Timothy; Young, Peter R.
CS Cardiovascular Diseases Research, Experimental Station, **Bristol-Myers Squibb** Company, Wilmington, DE, 19880, USA
SO Journal of Steroid Biochemistry and Molecular Biology (2002), 81(3), 217-225
CODEN: JSBBEZ; ISSN: 0960-0760
PB Elsevier Science Ltd.
DT Journal
LA English
CC 1-8 (Pharmacology)
AB The mechanism by which ligands of nuclear receptors show differential effects on gene transcription is not fully understood, but is believed to result in part from the preferential recruitment and/or displacement of coactivators and corepressors. We have explored the interaction of several known ligands and the nuclear receptor (peroxisome proliferator activated receptor .alpha., PPAR.alpha.) using scintillation proximity assay (SPA) and the interaction of LXXLL containing peptides derived from three coactivators (SRC-1, CBP and PGC-1) with PPAR.alpha. in the presence of PPAR.alpha. agonist ligands using fluorescence resonance energy transfer (FRET). The EC50s of the individual ligands for recruitment showed the same rank order regardless of the coactivator peptide used, with GW2331 <WY14643 = ciprofibrate <L165041 <gemfibrozil. Similarly, for all ligands tested, the rank order of EC50 for peptide recruitment was CBP <PGC-1 <SRC-1. These data suggest that for these LXXLL coactivator peptides, the ligands do not substantially differ in their preferences. Partial agonism was observed with ciprofibrate and PGC-1 and gemfibrozil and CBP giving a lower FRET at saturation than with the other ligands. This suggests that ciprofibrate and gemfibrozil induce a different conformation to the receptor-PGC-1 and receptor-CBP complex, resp. In cotransfection assays, unexpected differences in potencies and efficacies were observed and the rank order of EC50s for activation differed from that predicted by FRET assays. In most cases, the presence of a coactivator peptide led to decrease in the EC50s seen in FRET assays compared to the Kis observed in binding to receptor only, consistent with the lower EC50s obtained in the transfection assays. Our data demonstrate that ligand induced coactivator preferences of PPAR.alpha. contribute to transcription potency and efficacy.
ST peroxisome proliferator activated receptor ligand coactivator binding mechanism
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CBP (CREB-binding protein); ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PPAR gamma coactivator-1; ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.)
IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(SRC-1 (steroid receptor coactivator-1); ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.)
IT Hypolipemic agents
(ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.; ligand and coactivator recruitment preferences of peroxisome

proliferator activated receptor .alpha.)
IT 25812-30-0, Gemfibrozil 50892-23-4, WY14643 52214-84-3, Ciprofibrate
79558-09-1, L165041 190844-95-2, GW2331
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor .alpha.)
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amri, E; J Biol Chem 1995, V270, P2367 HCAPLUS
(2) Berger, J; J Biol Chem 1999, V274, P6718 HCAPLUS
(3) Camp, H; Diabetes 2000, V49, P539 HCAPLUS
(4) Chakravarti, D; Nature 1996, V383, P99 HCAPLUS
(5) Cheng, Y; Biochem Pharmacol 1973, V22, P3099 HCAPLUS
(6) Dowell, P; J Biol Chem 1999, V274, P15901 HCAPLUS
(7) Dreyer, C; Cell 1992, V68, P879 HCAPLUS
(8) Freedman, L; Cell 1999, V97, P5 HCAPLUS
(9) Gervois, P; Mol Endocrinol 1999, V13, P1535 HCAPLUS
(10) Greene, M; Gene Exp 1995, V4, P281 HCAPLUS
(11) Hillman, M; Protein Expr Purif 2001, V23, P359 HCAPLUS
(12) Isseman, I; Nature 1990, V347, P645
(13) Kamei, Y; Cell 1996, V85, P403 HCAPLUS
(14) Kliewer, S; Proc Natl Acad Sci 1994, V91, P7355 HCAPLUS
(15) Kliewer, S; Proc Natl Acad Sci 1997, V94, P4318 HCAPLUS
(16) Krey, G; Mol Endocrinol 1997, V11, P779 HCAPLUS
(17) Lazennec, G; Mol Endocrinol 2000, V14, P1962 HCAPLUS
(18) Lehmann, J; J Biol Chem 1995, V270, P12953 HCAPLUS
(19) Leibowitz, M; FEBS Lett 2000, V473, P333 HCAPLUS
(20) Mukherjee, R; J Biol Chem 1997, V272, P8071 HCAPLUS
(21) Mukherjee, R; J Steroid Biochem Mol Biol 1994, V51, P157 HCAPLUS
(22) Oliver, W; Proc Natl Acad Sci 2001, V98, P5306 HCAPLUS
(23) Onate, S; Science 1995, V270, P1354 HCAPLUS
(24) Parks, D; Science 1999, V284, P1365 HCAPLUS
(25) Rachez, C; Nature 1999, V398, P824 HCAPLUS
(26) Schmidt, A; Mol Endocrinol 1992, V6, P1634 HCAPLUS
(27) Shao, D; Nature 1998, V396, P377 HCAPLUS
(28) Sher, T; Biochemistry 1993, V32, P5598 HCAPLUS
(29) Tontonoz, P; Cell 1994, V79, P1147 MEDLINE
(30) Tontonoz, P; published erratum appears in Cell 1995, V80(6), P957
(31) Zhou, G; Mol Endocrinol 1998, V12, P1594 HCAPLUS
(32) Zhu, Y; J Biol Chem 1997, V272, P25500 HCAPLUS

L68 ANSWER 15 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:502825 HCAPLUS
DN 137:63237
ED Entered STN: 04 Jul 2002
TI Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as **antidiabetic** and **antiobesity** agents
IN **Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen, Sean; Zhang, Hao**
PA **Bristol-Myers Squibb** Company, USA
SO U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-42
ICS A61K031-425; C07D277-30; C07D413-04
NCL 514374000
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 34

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6414002	B1	20020702	US 2001-812960	20010320
	US 2003069275	A1	20030410	US 2002-80965	20020222
	US 2003087935	A1	20030508	US 2002-81075	20020222
	US 6727271	B2	20040427		
	US 2003096846	A1	20030522	US 2002-80981	20020222
	US 6653314	B2	20031125		
PRAI	US 1999-155400P	P	19990922		
	US 2000-664598	A2	20000918		
	US 2001-812960	A3	20010320		

OS MARPAT 137:63237

GI



I



II

AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0.degree.-room temperature to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addition of N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane afforded the benzylamine derivative (55%), which was stirred with aqueous NaOH in MeOH for 14 h to give the title compound II (71%). I are useful for the treatment of **diabetes**, especially Type II **diabetes**, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, **obesity**, atherosclerosis, and related diseases (no data).

ST oxazolylalkoxybenzylglycine thiazolylalkoxybenzylglycine prepn **antidiabetic antiobesity** antiatherosclerosis agent

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperlipidemia; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT **Diabetes** mellitus
(non-insulin-dependent; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT **Antidiabetic** agents
Antiobesity agents
Atherosclerosis
Human
Hyperglycemia
Hypolipemic agents
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hyperinsulinemia; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331746-96-4P, Oxazole, 5-methyl-2-phenyl-4-(2-propenyl)-
RL: BYP (Byproduct); PREP (Preparation)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331739-69-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331739-67-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-68-5P, Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-70-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl- 331739-71-0P, Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-72-1P, Glycine, N-2-benzoxazolyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-73-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331739-74-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331739-75-4P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-76-5P, Glycine, N-[[5-(4-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-77-6P, Glycine, N-[[4-(3-fluorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-78-7P, Glycine, N-[[4-(3-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-79-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-pyridinyl)phenyl]methyl]- 331739-80-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- 331739-81-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenylethyl)- 331739-82-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenylpropyl)- 331739-83-4P, Glycine, N-[[3-(3,4-dichlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-

phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-84-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331739-85-6P, Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-86-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-87-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- 331739-88-9P, Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-89-0P, Glycine, N-[[3-(4-methoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-90-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- 331739-91-4P, Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-92-5P, Glycine, N-[(2E)-3,7-dimethyl-2,6-octadienyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-93-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- 331739-94-7P, Glycine, N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-95-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxy-2-thienyl)methyl]- 331739-96-9P, Glycine, N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-97-0P, Glycine, N-[(4-fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-98-1P, Glycine, N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331739-99-2P, Glycine, N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-00-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylmethyl)- 331740-01-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- 331740-02-4P, Glycine, N-(1H-indol-2-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-03-5P, Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-04-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-05-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(3-nitrophenyl)-2-furanyl]methyl]- 331740-06-8P, Glycine, N-[[5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-07-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-08-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-nitrophenyl)-2-furanyl]methyl]- 331740-09-1P, 1H-Pyrrole-2-carboxylic acid, 5-[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-, 2-(phenylmethyl) ester 331740-10-4P, Glycine, N-[[5-(4-bromophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-11-5P, Glycine, N-[[5-(3-chlorophenyl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-12-6P, Glycine, N-[[5-(1,3-dioxolan-2-yl)-2-furanyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-13-7P, Glycine, N-[[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-14-8P, Glycine, N-[[5-(2,4-dichlorophenyl)-2-furanyl]methyl]-N-[[3-

[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-15-9P, Glycine, N-[[4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-16-0P, Glycine, N-[(4-benzoyl-1-methyl-1H-pyrrol-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-17-1P, Glycine, N-([2,2'-bithiophen]-5-ylmethyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-18-2P, Glycine, N-[(5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-19-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(phenylethynyl)-2-thienyl]methyl]- 331740-20-6P, Glycine, N-[[4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-21-7P, Glycine, N-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-22-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylethynyl)-2-thienyl]methyl]- 331740-23-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-24-0P, Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-25-1P, Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-26-2P, Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-27-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-28-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-29-5P, Glycine, N-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-30-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- 331740-31-9P, Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-32-0P, Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-33-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-34-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- 331740-35-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- 331740-36-4P, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-37-5P, Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-38-6P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-39-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-40-0P, Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-41-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331740-42-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-43-3P, Glycine, N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-44-4P, Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-45-5P, Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331740-46-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- 331740-47-7P, Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-48-8P, Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-49-9P, Glycine, N-[[3-[4-(1,1-dimethylethyl)phenoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-50-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- 331740-51-3P, Glycine, N-[[4-[4-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-52-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)methyl]- 331740-53-5P, Glycine, N-[[4-(3-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-54-6P, Glycine, N-[[4-(4-bromophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-55-7P, Glycine, N-[[4-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-56-8P, Glycine, N-[[4-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-57-9P, Glycine, N-[[4-(4-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-58-0P, Glycine, N-[[4-(2-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-59-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(trifluoromethyl)phenoxy]phenyl]methyl]- 331740-60-4P, Glycine, N-[[4-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-61-5P, Glycine, N-[[4-(4-fluorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-62-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- 331740-63-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[4-(methylthio)phenoxy]phenyl]methyl]- 331740-64-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxy-2-thienyl)methyl]- 331740-65-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[3-(trifluoromethyl)phenoxy]phenyl]methyl]- 331740-66-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-nitrophenoxy)phenyl]methyl]- 331740-67-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylamino)phenyl]methyl]- 331740-68-2P, Glycine, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-69-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- 331740-70-6P, Glycine, N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-71-7P, Glycine, N-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-72-8P, Glycine, N-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-73-9P, Glycine, N-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-74-0P, Glycine, N-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-75-1P, Glycine, N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-76-2P, Glycine,

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- 331740-77-3P, Glycine, N-[(3-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-78-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- 331740-79-5P, Glycine, N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-80-8P, Glycine, N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-81-9P, Glycine, N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-82-0P, Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-83-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- 331740-84-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- 331740-85-3P, Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-86-4P, Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-87-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- 331740-88-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- 331740-89-7P, Glycine, N-(1H-indol-2-ylmethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-90-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1R)-1-phenylethyl]- 331740-91-1P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-92-2P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-93-3P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-94-4P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-95-5P, L-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-96-6P, D-Valine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-97-7P, Acetic acid, (2,2-dimethylpropoxy)[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]-, (2R)- 331740-98-8P, D-Serine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331740-99-9P , Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-00-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331741-01-6P, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-02-7P, Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-03-8P, Glycine, N-[[(3-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-04-9P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-05-0P, Glycine, N-[[4-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-06-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]- 331741-07-2P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-08-3P, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- 331741-09-4P, Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-10-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(3-phenoxyphenyl)methoxy]carbonyl]- 331741-11-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-propynyloxy)carbonyl]- 331741-12-9P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-13-0P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-14-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitrophenoxy)carbonyl]- 331741-15-2P, Glycine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-16-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(4-nitrophenyl)methoxy]carbonyl]- 331741-17-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenoxy)carbonyl]- 331741-18-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenoxy)carbonyl]- 331741-19-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(2-phenoxyphenyl)methoxy]carbonyl]- 331741-20-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(4-phenoxyphenyl)methoxy]carbonyl]- 331741-21-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenoxy)carbonyl]- 331741-22-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenoxy)carbonyl]- 331741-23-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyethoxy)carbonyl]- 331741-24-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-25-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(3-phenyl-2-propynyl)oxy]carbonyl]- 331741-26-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenylethoxy)carbonyl]- 331741-27-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenylpropoxy)carbonyl]- 331741-28-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-29-8P, Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-30-1P, Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-31-2P, Glycine, N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-32-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethoxyphenoxy)carbonyl]- 331741-33-4P, Glycine, N-[[(3-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-34-5P, Glycine, N-[[(4-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-35-6P, Glycine, N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-36-7P, Glycine, N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-37-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331741-38-9P, Glycine, N-[[(4-methoxy-1-naphthalenyl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331741-39-0P, Glycine, N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-40-3P, Benzoic acid, 4-[[[(carboxymethyl)[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester 331741-41-4P, Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-42-5P, Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-43-6P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-44-7P, Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-45-8P, Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-46-9P, Glycine, N-[(4-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-47-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331741-48-1P, Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-49-2P, Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-50-5P, Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-51-6P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-52-7P, Glycine, N-[(4-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-53-8P, Glycine, N-[(3-acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-54-9P, Glycine, N-[[(2,3-dihydro-3-oxo-6-benzofuranyl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-55-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331741-56-1P, Glycine, N-[(3-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-57-2P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-58-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331741-59-4P, Glycine, N-[(4-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-60-7P, Glycine, N-[(3-ethoxy-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-61-8P, Glycine, N-[(4-cyclopentylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-63-0P, Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-64-1P, Glycine, N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-65-2P, Glycine, N-[(4-butylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-66-3P, Glycine, N-[(4-hexylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-67-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- 331741-68-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331741-69-6P, Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331741-70-9P, Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-71-0P, Glycine, N-[(3,4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-72-1P, Glycine, N-[(3,5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-73-2P, Glycine, N-[(3-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-74-3P, Glycine, N-[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-75-4P, Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-76-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331741-77-6P, Glycine, N-[(4-ethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-78-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-propylphenoxy)carbonyl]- 331741-79-8P, Glycine, N-[[(2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-80-1P, Glycine, N-[(3-ethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-81-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-pentylphenoxy)carbonyl]- 331741-82-3P, Glycine, N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-83-4P, Glycine, N-[[(3-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-84-5P, Glycine, N-[[(3-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-85-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331741-86-7P, Glycine, N-[[(4-fluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331741-87-8P, Glycine, N-[[(4-chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-88-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331741-89-0P, Glycine, N-[[(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-90-3P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-91-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(3-phenoxyphenyl)methoxy]carbonyl]- 331741-92-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-propynyloxy)carbonyl]- 331741-93-6P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-94-7P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-95-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-nitrophenoxy)carbonyl]- 331741-96-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- 331741-97-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]-N-[[(4-nitrophenyl)methoxy]carbonyl]-
331741-98-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenoxy)carbonyl]-
331741-99-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenoxy)carbonyl]-
331742-00-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[(2-phenoxyphenyl)methoxy]carbonyl]-
331742-01-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[(4-phenoxyphenyl)methoxy]carbonyl]-
331742-02-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenoxy)carbonyl]-
331742-03-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenoxy)carbonyl]-
331742-04-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyethoxy)carbonyl]-
331742-05-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]-
331742-06-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[(3-phenyl-2-propynyl)oxy]carbonyl]-
331742-07-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenylethoxy)carbonyl]-
331742-08-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenylpropoxy)carbonyl]-
331742-09-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]-
331742-10-0P, Glycine, N-[(2-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-
methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-11-1P, Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-12-2P, Glycine,
N-[(3,4-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-13-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-
trimethoxyphenoxy)carbonyl]- 331742-14-4P, Glycine, N-[(3-
acetylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-15-5P, Glycine,
N-[[(4-methoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-16-6P, Glycine,
N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-17-7P, Glycine,
N-[(1,3-benzodioxol-5-yloxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-18-8P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-
(trifluoromethoxy)phenoxy]carbonyl]- 331742-19-9P, Glycine,
N-[[(4-methoxy-1-naphthalenyl)oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-20-2P, Glycine,
N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-21-3P, Benzoic acid,
4-[[[(carboxymethyl)[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester
331742-22-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-
331742-23-5P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-
phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-24-6P, Glycine,
N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-25-7P, Glycine,
N-[(4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-26-8P, Glycine,
N-[(4-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331742-27-9P, Glycine,
N-[(4-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331742-28-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331742-29-1P, Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-30-4P, Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-31-5P, Glycine, N-[(3-bromophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-32-6P, Glycine, N-[(3,5-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-33-7P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-34-8P, Glycine, N-[(3-chloro-4-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-35-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3,4,5-trimethylphenoxy)carbonyl]- 331742-36-0P, Glycine, N-[(4-chloro-3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-37-1P, Glycine, N-[(3,4-difluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-38-2P, Glycine, N-[(4-ethenylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-39-3P, Glycine, N-[(4-fluoro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-40-6P, Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-41-7P, Glycine, N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-42-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1H-pyrrol-1-yl)phenoxy]carbonyl]- 331742-43-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331742-44-0P, Glycine, N-[([1,1'-biphenyl]-3-yloxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-45-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethyl)phenoxy]carbonyl]- 331742-46-2P, Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-47-3P, Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-48-4P, Glycine, N-[(3,4-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-49-5P, Glycine, N-[(3,5-dimethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-50-8P, Glycine, N-[(3-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-51-9P, Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-52-0P, Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-53-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- 331742-54-2P, Glycine, N-[(4-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-55-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-propylphenoxy)carbonyl]- 331742-56-4P, Glycine, N-[[(2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-57-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-

naphthalenyloxy)carbonyl]- 331742-58-6P, Glycine, N-[(3-ethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-59-7P, Glycine, N-[(3,5-dichlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-60-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331742-61-1P, Glycine, N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-62-2P, Glycine, N-[(3-methoxy-5-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-63-3P, Glycine, N-[[(3-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-64-4P, Glycine, N-[[(3-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-65-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-66-6P, Glycine, N-[[(4-fluorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-67-7P, Glycine, N-[[(4-chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-68-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- 331742-69-9P, Glycine, N-[[(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-70-2P, Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-71-3P, Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-72-4P, Glycine, N-[(3-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-73-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- 331742-74-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- 331742-75-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- 331742-76-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)- 331742-77-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-thienylcarbonyl)- 331742-78-0P, Glycine, N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-79-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylcarbonyl)- 331742-80-4P, Glycine, N-(3,4-difluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-81-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- 331742-82-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- 331742-83-7P, Glycine, N-(3,5-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-84-8P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-85-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-methyl-2-thienyl)carbonyl]- 331742-86-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(5-nitro-2-thienyl)carbonyl]- 331742-87-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methyl-2-thienyl)carbonyl]- 331742-88-2P, Glycine, N-(4-butoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-89-3P, Glycine, N-(4-methoxy-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-90-6P, Glycine,

N-(3-chloro-4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-91-7P, Glycine, N-(3,4-dimethylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-92-8P, Glycine, N-(4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-93-9P, Glycine, N-(3-fluoro-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-94-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(methylthio)benzoyl]- 331742-95-1P, Glycine, N-[4-(1-methylethyl)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-96-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331742-97-3P, Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-98-4P, Glycine, N-(3-methoxy-4-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331742-99-5P, Glycine, N-(1,3-benzodioxol-5-ylcarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-00-1P, Glycine, N-[4-(1-methylethoxy)benzoyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-02-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-thienylcarbonyl)- 331743-04-5P, Glycine, N-benzoyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-05-6P, Glycine, N-(3-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-06-7P, Glycine, N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-07-8P, Glycine, N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-08-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- 331743-09-0P, Glycine, N-(4-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-10-3P, Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-11-4P, Glycine, N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-12-5P, Glycine, N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-13-6P, Glycine, N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-14-7P, Glycine, N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-15-8P, Glycine, N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-16-9P, Glycine, N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-17-0P, Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-18-1P, Glycine, N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-19-2P, Glycine, N-[(5-chloro-2-thienyl)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-20-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- 331743-21-6P, Glycine, N-[(4-methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-22-7P, Glycine, N-[(3-fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-23-8P, Glycine, N-[(3,5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331743-24-9P, Glycine, N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-25-0P, Glycine, N-[(4-ethoxyphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-26-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-nitrophenyl)acetyl]- 331743-27-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-nitrophenyl)acetyl]- 331743-28-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-oxo-3-phenylpropyl)- 331743-29-4P, Glycine, N-([1,1'-biphenyl]-2-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-30-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- 331743-31-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylmethyl)benzoyl]- 331743-32-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[3-(phenylsulfinyl)benzoyl]- 331743-33-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-[(4-methylphenyl)thio]benzoyl]- 331743-34-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylsulfinyl)benzoyl]- 331743-35-2P, Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-36-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-phenoxybenzoyl)- 331743-37-4P, Glycine, N-([1,1'-biphenyl]-4-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-38-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- 331743-39-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)acetyl]- 331743-40-9P, Glycine, N-([1,1'-biphenyl]-4-ylacetyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-41-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(phenylmethyl)benzoyl]- 331743-42-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- 331743-43-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)acetyl]- 331743-44-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)acetyl]- 331743-45-4P, Glycine, N-([2,2'-bithiophen]-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-46-5P, Glycine, N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-47-6P, Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-48-7P, Glycine, N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-49-8P, Glycine, N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-50-1P, Glycine, N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-51-2P, Glycine, N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-52-3P, Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-53-4P, Glycine, N-[4-(1-methylethyl)benzoyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-54-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-(2-methylpropyl)benzoyl]- 331743-55-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)-

331743-56-7P, Glycine, N-(4-butylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-57-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- 331743-58-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(phenylmethyl)amino]carbonyl]- 331743-59-0P, Glycine, N-[[(4-methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-60-3P, Glycine, N-[[(4-methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-61-4P, Glycine, N-[([1,1'-biphenyl]-4-ylamino)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-62-5P, Glycine, N-[[(3,5-dimethoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-63-6P, Glycine, N-[[(3,5-dichlorophenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-64-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]- 331743-65-8P, Glycine, N-[[(2,4-difluorophenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-66-9P, Glycine, N-[[(2,4-dimethoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-67-0P, Glycine, N-[[(2-methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-68-1P, Glycine, N-[([1,1'-biphenyl]-4-ylamino)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-69-2P, Glycine, N-[[(3,5-dimethoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-70-5P, Glycine, N-[[(3,5-dichlorophenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-71-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]- 331743-72-7P, Glycine, N-[[(2,4-difluorophenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-73-8P, Glycine, N-[[(2,4-dimethoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-74-9P, Glycine, N-[[(4-methoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-75-0P, Glycine, N-[[(2-methoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-76-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)- 331743-77-2P, Glycine, N-[[(4-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-78-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- 331743-79-4P, Glycine, N-[(2,5-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-80-7P, Glycine, N-[(4-fluorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-81-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)sulfonyl]- 331743-82-9P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(1E)-2-phenylethenyl]sulfonyl]- 331743-83-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2,2,2-trifluoroethyl)sulfonyl]- 331743-84-1P, Glycine, N-[(2,5-dimethylphenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-85-2P, Glycine, N-[(3,4-dichlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-86-3P, Glycine, N-[(2,5-dichloro-3-thienyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331743-87-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-pyridinylsulfonyl)-2-thienyl]sulfonyl]- 331743-88-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 331743-89-6P, Glycine, N-[[(3-methylphenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-90-9P, Glycine, N-[[(2-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-91-0P, Glycine, N-[(4-chlorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-92-1P, Glycine, N-[[(3,4-dichlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-93-2P, Glycine, N-[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-94-3P, Glycine, N-[[(4-chlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-95-4P, Glycine, N-[[(2-chlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-96-5P, Glycine, N-[[(2,4-dichlorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-97-6P, Glycine, N-[[(2-methylphenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-98-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- 331743-99-8P, Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-00-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-propylphenyl)sulfonyl]- 331744-01-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylsulfonyl)- 331744-02-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- 331744-03-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2,4,6-trimethylphenyl)sulfonyl]- 331744-04-8P, Glycine, N-[(4-chlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-05-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethyl)sulfonyl]- 331744-06-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(1E)-2-phenylethenyl]sulfonyl]- 331744-07-1P, Glycine, N-[(2,5-dimethylphenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-08-2P, Glycine, N-[(3,4-dichlorophenyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-09-3P, Glycine, N-[[4-(2-chloro-6-nitrophenoxy)phenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-10-6P, Glycine, N-(2-dibenzofuranylsulfonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-11-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 331744-12-8P, Glycine, N-[[(3-methylphenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331744-13-9P, Glycine, N-[[(2-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-14-0P, Glycine, N-[[(4-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-15-1P, Glycine,

N-[[(3,4-dichlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-16-2P, Glycine, N-[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-17-3P, Glycine, N-[[(4-chlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-18-4P, Glycine, N-[[(2-chlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-19-5P, Glycine, N-[[(2,4-dichlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-20-8P, Glycine, N-[[(2-methylphenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-21-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- 331744-22-0P, Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-23-1P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331744-24-2P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331744-25-3P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[(4-phenoxyphenyl)methyl]- 331744-26-4P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-27-5P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[(phenylmethoxy)carbonyl]- 331744-28-6P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-(phenylmethyl)- 331744-29-7P, Carbamic acid, [[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl](1H-tetrazol-5-ylmethyl)-, 4-methoxyphenyl ester 331744-30-0P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-31-1P, .beta.-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-32-2P, .beta.-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-33-3P, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- 331744-34-4P, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331744-35-5P, .beta.-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-36-6P, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- 331744-37-7P, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331744-38-8P, .beta.-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-39-9P, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-40-2P, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-41-3P, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-42-4P, Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-43-5P, Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-44-6P, Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-45-7P, Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-46-8P, Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]methyl]- 331744-47-9P, Glycine,
N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-48-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-
propylphenoxy)carbonyl]- 331744-49-1P, Glycine, N-[(4-
cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-50-4P, Glycine,
N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-51-5P, Glycine,
N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-52-6P, Glycine,
N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-53-7P, Glycine,
N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-54-8P, Glycine,
N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-55-9P, Glycine,
N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-56-0P, Glycine,
N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-57-1P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-
propylphenoxy)carbonyl]- 331744-58-2P, Glycine, N-[(3-
cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-59-3P, Glycine,
N-[(4-cyclopropylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-60-6P, Glycine,
N-[[4-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- 331744-61-7P, Benzoic acid,
2-(carboxymethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]hydrazide 331744-62-8P, Benzoic acid,
2-(carboxymethyl)-2-[[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]hydrazide 331744-63-9P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]ethyl]- 331744-64-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]ethyl]- 331744-65-1P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]ethyl]- 331744-66-2P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]pentyl]- 331744-67-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]-3-butenyl]- 331744-68-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]butyl]- 331744-69-5P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-
thiazolyl)ethoxy]phenyl]ethyl]- 331744-70-8P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-
thiazolyl)ethoxy]phenyl]ethyl]- 331744-71-9P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]cyclopropyl]- 331744-72-0P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]ethyl]- 331744-73-1P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]ethyl]- 331744-74-2P, Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]pentyl]- 331744-75-3P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]propyl]- 331744-76-4P, Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-

oxazolyl)ethoxy]phenyl]butyl]- 331744-77-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331744-78-6P, Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-79-7P, Glycine, N-[(3-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-80-0P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-81-1P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-82-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-83-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331744-84-4P, Alanine, N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-85-5P, Cyclopropanecarboxylic acid, 1-[[(4-methoxyphenoxy)carbonyl][[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-86-6P, Cyclopropanecarboxylic acid, 1-[[(4-methylphenoxy)carbonyl][[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-87-7P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-88-8P, L-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-89-9P, D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-90-2P, D-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-91-3P, D-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-92-4P, Cyclopropanecarboxylic acid, 1-[[(4-methoxyphenoxy)carbonyl][[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-93-5P, Cyclopropanecarboxylic acid, 1-[[(4-methylphenoxy)carbonyl][[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- 331744-94-6P, Alanine, N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-95-7P, D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-96-8P, D-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-97-9P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331744-98-0P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-99-1P, L-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-00-7P, L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331745-01-8P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331745-02-9P, D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331745-03-0P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331745-04-1P, D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- 331745-05-2P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-06-3P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl]methyl]- 331745-07-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- 331745-08-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-09-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[(2Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]- 331745-10-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-11-0P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-12-1P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-13-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- 331745-14-3P, Glycine, N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-15-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-16-5P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-17-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- 331745-18-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- 331745-19-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- 331745-20-1P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- 331745-21-2P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]- 331745-22-3P, Glycine, N-(5-methyl-2-benzoxazolyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-23-4P, Glycine, N-(5-methyl-2-benzoxazolyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-24-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- 331745-25-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-26-7P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]- 331745-27-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl]methyl]- 331745-28-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]- 331745-29-0P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl]methyl]- 331745-30-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]- 331745-31-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]cyclopropyl]phenyl]methyl]-, rel- 331745-32-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]- 331745-33-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- 331745-34-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331745-35-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl]methyl]- 331745-36-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1,2-propadienyl]phenyl]methyl]- 331745-37-0P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-

oxazolyl)propyl]phenyl]methyl]- 331745-38-1P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl]methyl]- 331745-39-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]- 331745-40-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]- 331745-41-6P, Glycine, N-[[4-[2-[2-(4-chlorophenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- 331745-42-7P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-thiazolyl]ethoxy]phenyl]methyl]- 331745-43-8P, Glycine, N-[[3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-44-9P, Glycine, N-[[3-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methylphenoxy)carbonyl]- 331745-45-0P, Glycine, N-[[4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- 331745-46-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(oxophenylacetyl)- 331745-47-2P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(oxophenylacetyl)- 331745-48-3P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(3-phenoxyphenyl)methyl]- 331745-49-4P, Glycine, N-[[(4-methoxyphenyl)thio]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-60-9P, Glycine, N-[(3-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- 331745-69-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1S)-1-phenylethyl]- 331745-80-3P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, mono(trifluoroacetate) 331745-86-9P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, mono(trifluoroacetate) 331746-91-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]- 331746-92-0P, Glycine, N-[[(4-methoxyphenyl)thio]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331746-93-1P, L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- 331746-95-3P, Glycine, N-(6-methyl-2-benzoxazolyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 439276-48-9P 439276-49-0P 439276-50-3P 439276-51-4P 439276-54-7P 439276-55-8P 439276-57-0P 439276-58-1P 439276-59-2P 439276-61-6P 439276-62-7P 439579-19-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 65-85-0, Benzoic acid, reactions 66-99-9, 2-Naphthaldehyde 67-36-7, 4-Phenoxybenzaldehyde 85-46-1, 1-Naphthalenesulfonyl chloride 90-05-1, 2-Methoxyphenol 93-09-4, 2-Naphthalenecarboxylic acid 94-53-1, Piperonylic acid 96-32-2, Methyl bromoacetate 98-88-4, Benzoyl chloride 100-83-4, 3-Hydroxybenzaldehyde 102-29-4, Resorcinol monoacetate 103-16-2, 4-Benzyloxyphenol 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 121-71-1, Ethanone, 1-(3-hydroxyphenyl)- 123-08-0, 4-Hydroxybenzaldehyde 151-18-8, 2-Cyanoethylamine 455-91-4, 3'-Fluoro-4'-methoxyacetophenone 501-53-1, Benzyl chloroformate 527-72-0, 2-Thiophenecarboxylic acid 591-35-5, 3,5-Dichlorophenol 615-18-9, 2-Chlorobenzoxazole 621-84-1, Benzyl carbamate 623-33-6, Glycine ethyl ester hydrochloride 626-02-8, 3-Iodophenol 626-55-1, 3-Bromopyridine 766-85-8, 3-Iodoanisole

768-35-4, 3-Fluorophenylboronic acid 815-60-1, 2,4-Dibromo-3-pentanone 937-62-2, 4-Methylphenyl chloroformate 1005-56-7, Phenyl chlorothionoformate 1066-54-2, Trimethylsilylacetylene 1132-21-4, 3,5-Dimethoxybenzoic acid 1700-37-4, 3-Benzyloxybenzaldehyde 2215-77-2, p-Phenoxybenzoic acid 2589-71-1, 1-Pentanone, 1-(4-hydroxyphenyl)- 2627-86-3, (S)-.alpha.-Methylbenzylamine 2835-98-5, Phenol, 2-amino-5-methyl- 3173-56-6, Benzyl isocyanate 3403-25-6 3424-93-9, 4-Methoxybenzamide 3886-69-9, Benzenemethanamine, .alpha.-methyl-, (.alpha.R)- 4949-44-4, Ethyl propionylacetate 5292-43-3, tert-Butyl bromoacetate 5345-54-0, 3-Chloro-4-methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate 5680-79-5, Glycine methyl ester hydrochloride 5961-59-1, N-Methyl-p-anisidine 6436-90-4, N-Benzylglycine ethyl ester 6945-92-2, Ethyl hydrazinoacetate hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 7699-00-5, Propanoic acid, 2-hydroxy-, ethyl ester, (2R)- 7745-91-7, 3-Bromo-4-methylaniline 15028-41-8, Methyl .alpha.-aminoisobutyrate hydrochloride 15894-04-9, 4-Fluorobenzyl mercaptan 16728-01-1, Cyclopropanecarboxylic acid, 1-(4-methoxyphenyl)- 19621-92-2, 2-Hydroxypyridine-6-carboxylic acid 22038-86-4, (R)-1-(4-Methoxyphenyl)ethylamine 27492-46-2, Oxazole, 4,5-dimethyl-2-phenyl-, 3-oxide 27532-96-3, Glycine tert-butyl ester hydrochloride 30414-53-0, Methyl propionylacetate 34035-03-5, 2-Furancarboxaldehyde, 5-(4-chlorophenyl)- 41851-59-6, (S)-1-(4-Methoxyphenyl)ethylamine 50428-03-0, 4-Pentynoic acid, 2-amino- 50868-72-9, Benzenamine, 5-methoxy-2-methyl- 59531-86-1 64318-28-1, Carbamic acid, [2-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester 66171-50-4, Methyl 2-hydroxypyridine-5-carboxylate 81228-89-9, Carbonochloridic acid, (3-methoxyphenyl)methyl ester 87199-17-5, 4-Formylphenylboronic acid 103788-65-4, 4-Oxazoleethanol, 5-methyl-2-phenyl- 107367-98-6, 2-Phenyl-5-methyloxazole-4-acetic acid 164660-78-0, Phenol, 3-[(trimethylsilyl)ethynyl]-, acetate 175136-30-8, 4-Thiazoleethanol, 5-methyl-2-phenyl- 182913-11-7, Glycine, N-[(2-hydroxyphenyl)methyl]-, methyl ester 331746-63-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-64-6, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-65-7, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-66-8, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, mono(trifluoroacetate) 331746-68-0, Glycine, N-[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-69-1, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)-, 1,1-dimethylethyl ester 331746-70-4, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)-, 1,1-dimethylethyl ester 331746-71-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)-, 1,1-dimethylethyl ester 331746-72-6, 3-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331746-73-7, Benzenesulfonamide, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-2,4-dinitro- 331746-74-8, .beta.-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-75-9, Glycine, N-(chlorocarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-76-0, Glycine, N-[[3-(cyclopropyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-78-2, Glycine, N-[(1S)-1-(4-methoxyphenyl)ethyl]-, methyl ester 331746-80-6, Glycine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, ethyl ester 331746-81-7, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, ethyl ester 331746-82-8, Glycine,

N-[(4-hydroxyphenyl)methyl]-, methyl ester 331746-83-9, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-84-0, Glycine, N-[(4-iodophenyl)methyl]-, methyl ester 331746-85-1, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-86-2, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1R,2R)-2-[(5-methyl-2-phenyl-4-oxazolyl)methyl]cyclopropyl]phenyl]methyl]-, methyl ester, rel- 331746-87-3, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-88-4, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]-, 1,1-dimethylethyl ester 331746-89-5, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester 331746-90-8, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 405-06-1P, Benzene, 2-fluoro-4-methoxy-1-methyl- 452-78-8P, Phenol, 3-fluoro-4-methyl- 621-27-2P, 3-Propylphenol 768-70-7P, Benzene, 1-ethynyl-3-methoxy- 2293-75-6P, 2-Methoxyphenyl chloroformate 2454-30-0P, Phenol, 3-ethenyl-, acetate 3621-83-8P, Benzoxazole, 2-chloro-6-methyl- 4847-94-3P, Piperonylamide 10401-12-4P, Phenol, 3-ethynyl-, acetate 18093-12-4P, 3-Chloro-4-methoxyphenol 23417-29-0P, 2(3H)-Benzoxazolethione, 6-methyl- 28857-88-7P, Phenol, 3-cyclopropyl- 30062-34-1P, 2-Pyridinecarboxylic acid, 1,6-dihydro-6-oxo-, methyl ester 36187-69-6P, Ethyl 4-bromo-3-oxopentanoate 42861-71-2P, Phenol, 3-iodo-, acetate 52177-62-5P, 3-Methoxyphenyl chloroformate 52177-75-0P, Carbonochloridic acid, 4-(phenylmethoxy)phenyl ester 60710-39-6P, 3-Bromo-4-methylphenol 62103-69-9P, Benzene, 1-methoxy-3-propyl- 68331-44-2P, Propanoic acid, 2-[(methylsulfonyl)oxy]-, ethyl ester, (2R)- 70170-23-9P, 4-Oxazolecarboxaldehyde, 5-methyl-2-phenyl- 72934-40-8P, Cyclopropanamine, 1-(4-methoxyphenyl)- 74067-76-8P, 1-Penten-3-one, 4-bromo- 103360-04-9P, 4-Fluorobenzylsulfonyl chloride 103788-59-6P, Benzaldehyde, 4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 103788-61-0P, Oxazole, 4-(chloromethyl)-5-methyl-2-phenyl- 103788-64-3P, 4-Oxazoleacetic acid, 5-methyl-2-phenyl-, methyl ester 105983-77-5P, Pentanoic acid, 4-bromo-3-oxo-, methyl ester 136058-69-0P, 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl- 137208-84-5P, Ethanol, 2-[3-(phenylmethoxy)phenoxy]- 140130-09-2P, Benzamide, N-(1-acetyl-3-butynyl)- 140130-10-5P, Oxazole, 5-methyl-2-phenyl-4-(2-propynyl)- 157169-61-4P, 3-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 174258-60-7P, Ethanone, 1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 196810-26-1P, 4-Oxazoleacetic acid, 2-(4-methoxyphenyl)-5-methyl-, methyl ester 223562-18-3P, Benzene, 1-methoxy-3-(1-propynyl)- 227029-27-8P, 4-Oxazoleethanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 244152-94-1P, Benzaldehyde, 3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 258346-53-1P, 4-Oxazolepropanol, 5-methyl-2-phenyl- 258346-54-2P, 4-Oxazolepropanenitrile, 5-methyl-2-phenyl- 331745-61-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)-, ethyl ester 331745-62-1P, Glycine, N,N-bis[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester 331745-63-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester 331745-64-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-65-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester 331745-66-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331745-67-6P, Glycine,

N-[(4-hydroxyphenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-68-7P, Glycine, N-[(4-boronophenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1-(1,1-dimethylethyl) ester 331745-70-1P, Benzenemethanamine, .alpha.-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, (.alpha.S)- 331745-71-2P, Glycine, N-(chlorocarbonyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-72-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-, 1,1-dimethylethyl ester 331745-73-4P, Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-74-5P, Carbonochloridic acid, 3-(acetyloxy)phenyl ester 331745-75-6P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331745-76-7P, Glycine, N-[[(4-methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-77-8P, Glycine, N-[[(4-methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-78-9P, 3-Pyridinecarboxylic acid, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester 331745-79-0P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-3-pyridinyl]methyl]-, methyl ester 331745-81-4P, 2-Pyridinecarboxylic acid, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-, methyl ester 331745-82-5P, 2-Pyridinemethanol, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331745-83-6P, 2-Pyridinecarboxaldehyde, 6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- 331745-84-7P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-, methyl ester 331745-85-8P, Glycine, N-[[6-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-2-pyridinyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, methyl ester 331745-87-0P, Carbamic acid, [2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-88-1P, Glycine, N-[(2,4-dinitrophenyl)sulfonyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-89-2P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-90-5P, Carbamic acid, [2-[(2-cyanoethyl)amino]-2-oxoethyl][[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 4-methoxyphenyl ester 331745-91-6P, Carbamic acid, [[1-(2-cyanoethyl)-1H-tetrazol-5-yl]methyl][[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 4-methoxyphenyl ester 331745-92-7P, Glycine, N-[(2-hydroxyphenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331745-93-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-94-9P, Phenol, 3-cyclopropyl-, acetate 331745-95-0P, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331745-96-1P, Acetic acid, [3-(phenylmethoxy)phenoxy]-, ethyl ester 331745-97-2P, Benzene, 1-(2-bromoethoxy)-3-(phenylmethoxy)- 331745-98-3P, Benzene, 1-(ethenyloxy)-3-(phenylmethoxy)- 331745-99-4P, Benzene, 1-(cyclopropyloxy)-3-(phenylmethoxy)- 331746-00-0P, Phenol, 3-(cyclopropyloxy)- 331746-01-1P, Carbonochloridic acid, 3-fluoro-4-methylphenyl ester 331746-02-2P, Carbonochloridic acid, 3-bromo-4-methylphenyl ester 331746-03-3P, Benzoic acid, 2-(carboxymethyl)hydrazide 331746-04-4P, Benzoic acid, 2-(2-ethoxy-2-oxoethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide 331746-05-5P, Oxazole, 4-[2-[3-(bromomethyl)phenoxy]ethyl]-5-methyl-2-phenyl- 331746-06-6P, Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-07-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-

[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-08-8P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-, methyl ester 331746-09-9P, Glycine, N-[(1S)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-10-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-11-3P, 1-Pentanone, 1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]- 331746-12-4P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]-, methyl ester 331746-13-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester 331746-14-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]-, methyl ester 331746-15-7P, 4-Thiazoleethanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 331746-16-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-thiazolyl)ethoxy]phenyl]ethyl]-, ethyl ester 331746-17-9P, Glycine, N-[1-(4-methoxyphenyl)cyclopropyl]-, methyl ester 331746-18-0P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-, methyl ester 331746-19-1P, Glycine, N-[1-(4-hydroxyphenyl)cyclopropyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-20-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]cyclopropyl]-, methyl ester 331746-21-5P, Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-22-6P, Alanine, 2-methyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331746-23-7P, L-Alanine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-, methyl ester 331746-24-8P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-, methyl ester 331746-25-9P, L-Alanine, N-[(1R)-1-(4-hydroxyphenyl)ethyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-26-0P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester 331746-27-1P, 4-Oxazolepropanoic acid, 5-methyl-2-phenyl-, ethyl ester 331746-28-2P, 4-Oxazolepropanol, 5-methyl-2-phenyl-, methanesulfonate (ester) 331746-29-3P, Benzaldehyde, 4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]- 331746-30-6P, Glycine, N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-31-7P, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-methylphenoxy)carbonyl]-, methyl ester 331746-32-8P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, methyl ester 331746-33-9P, Oxazole, 4-(2,2-dibromoethenyl)-5-methyl-2-phenyl- 331746-34-0P, 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)- 331746-35-1P, 2-Propyn-1-ol, 3-(5-methyl-2-phenyl-4-oxazolyl)-, methanesulfonate (ester) 331746-36-2P, Benzaldehyde, 4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]- 331746-37-3P, Glycine, N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-38-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-39-5P, 4-Oxazoleacetic acid, .alpha.,5-dimethyl-2-phenyl-, methyl ester 331746-40-8P, 4-Oxazoleacetic acid, .alpha.,.alpha.,5-trimethyl-2-phenyl-, methyl ester 331746-41-9P, 4-Oxazoleethanol, .beta.,.beta.,5-trimethyl-2-phenyl- 331746-42-0P, Benzaldehyde, 4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]- 331746-43-1P, Glycine, N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-44-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester 331746-45-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[[(2Z)-3-(5-methyl-2-phenyl-4-oxazolyl)-2-propenyl]oxy]phenyl]methyl]-, 1,1-dimethylethyl ester 331746-46-4P, Benzaldehyde, 3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]- 331746-47-5P, Glycine, N-[[3-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-48-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[[3-(5-methyl-2-phenyl-4-

oxazolyl)-2-propynyl]oxy]phenyl]methyl]-, methyl ester 331746-50-0P, 4-Oxazoleethanol, 2-(4-methoxyphenyl)-5-methyl-, methanesulfonate (ester) 331746-51-1P, Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-52-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-53-3P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester 331746-54-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-2-propynyl]oxy]phenyl]ethyl]-, ethyl ester 331746-55-5P, Glycine, N-[(4-iodophenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-56-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propynyl]phenyl]methyl]-, methyl ester 331746-57-7P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]-, methyl ester 331746-58-8P, Oxazole, 4-(3-bromo-2-propynyl)-5-methyl-2-phenyl- 331746-59-9P, Oxazole, 5-methyl-2-phenyl-4-[3-(tributylstannyl)-2-propenyl]- 331746-60-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[(1E)-3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, methyl ester 331746-61-3P, Glycine, N-[[4-[(4-bromo-3-oxopentyl)oxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, methyl ester 331746-62-4P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-(4-pyridinyl)-4-thiazolyl]ethoxy]phenyl]methyl]-, methyl ester 331746-67-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester 331746-77-1P, Carbonochloridic acid, 3-chloro-4-methylphenyl ester 331746-79-3P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester 331746-94-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[(phenylmethyl)amino]carbonyl]-, ethyl ester 439276-63-8P 439573-59-8P 439573-60-1P 439573-63-4P 439573-65-6P 439573-66-7P 439573-67-8P 439573-68-9P 439573-69-0P 439573-70-3P 439573-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 439573-86-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 9222533 1992 HCAPLUS
(2) Anon; EP 0520723 B1 1994 HCAPLUS
(3) Anon; WO 9638415 1996 HCAPLUS
(4) Anon; WO 9727847 1997 HCAPLUS
(5) Anon; WO 9727857 1997 HCAPLUS
(6) Anon; WO 9728137 1997 HCAPLUS
(7) Anon; WO 9728149 1997 HCAPLUS
(8) Anon; WO 9731907 1997 HCAPLUS
(9) Anon; WO 9800137 1998 HCAPLUS
(10) Anon; WO 9800403 1998 HCAPLUS
(11) Anon; WO 9827974 1998 HCAPLUS
(12) Anon; WO 9907357 1999 HCAPLUS
(13) Anon; WO 9908501 1999 HCAPLUS
(14) Anon; WO 9911255 1999 HCAPLUS
(15) Anon; WO 9915520 1999 HCAPLUS
(16) Anon; WO 9916758 1999 HCAPLUS
(17) Anon; WO 9920275 1999 HCAPLUS

(18) Anon; WO 9946232 1999 HCAPLUS
(19) Anon; WO 0008002 2000 HCAPLUS
(20) Anon; WO 0064876 2000 HCAPLUS
(21) Anon; WO 0064888 2000 HCAPLUS
(22) Cobb; J Med Chem 1998, V41, P5055 HCAPLUS
(23) Collins; J Med Chem 1998, V41, P5037 HCAPLUS
(24) Henke; J Med Chem 1998, V41, P5020 HCAPLUS

L68 ANSWER 16 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:97548 HCAPLUS
DN 137:93700
ED Entered STN: 06 Feb 2002
TI A general synthesis of dioxolenone prodrug moieties
AU Sun, Chong-Qing; **Cheng, Peter T. W.**; Stevenson, Jay; Dejneka, Tamara; Brown, Baerbel; Wang, Tammy C.; Robl, Jeffrey A.; Poss, Michael A.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
SO Tetrahedron Letters (2002), 43(7), 1161-1164
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
CC 28-5 (Heterocyclic Compounds (More Than One Hetero Atom))
OS CASREACT 137:93700
AB A general method for the synthesis of dioxolenone prodrug moieties from appropriately substituted .beta.-ketoesters is described. This novel and versatile sequence allows for the synthesis of alkyl- or aryl-substituted dioxolenone alcs. or bromides. Coupling of the bromides to prepare bis-dioxolenone phosphonate prodrug esters is also presented.
ST dioxolenone prodrug moiety prepn; bisdioxolenone phosphonate prodrug ester prepn
IT Drug delivery systems
(prodrugs; general synthesis of dioxolenone prodrug moieties)
IT 4949-45-5 5006-35-9 66696-91-1 77902-92-2 94250-56-3 157126-18-6 188526-07-0 441742-49-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(general synthesis of dioxolenone prodrug moieties)
IT 173604-86-9P 188525-85-1P 188525-89-5P 188525-93-1P 188525-96-4P 188525-99-7P 188526-00-3P 188526-01-4P 188526-04-7P 188526-20-7P 188526-21-8P 188526-22-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(general synthesis of dioxolenone prodrug moieties)
IT 86005-12-1P 173604-83-6P 188525-86-2P 188525-90-8P 188525-97-5P 188526-05-8P 441742-48-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(general synthesis of dioxolenone prodrug moieties)
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Alexander, J; J Med Chem 1996, V39, P480 HCAPLUS
(2) Alpegiani, M; Synth Commun 1992, V22, P1277 HCAPLUS
(3) Bundgaard, H; A Textbook of Drug Design and Development 1991, P113
(4) Bundgaard, H; Adv Drug Deliv Rev 1989, V3, P39 HCAPLUS
(5) Cheng, P; US 5610314 1997 HCAPLUS
(6) Clay, R; Synthesis 1993, P290 HCAPLUS
(7) Freeman, S; Progress in Medicinal Chemistry 1997, V34, P111 HCAPLUS
(8) Krapcho, J; J Med Chem 1988, V31, P1148 HCAPLUS
(9) Krise, J; Adv Drug Deliv Rev 1996, V19, P287 HCAPLUS
(10) Lawrence, M; J Am Chem Soc 1996, V118, P11668 HCAPLUS
(11) Miyauchi, M; Chem Pharm Bull 1990, V38, P1077 HCAPLUS

(12) Ryono, D; Bioorg Med Chem Lett 1994, V4, P201 HCAPLUS
(13) Saari, W; J Med Chem 1984, V27, P713 HCAPLUS
(14) Sakamoto, F; Chem Pharm Bull 1984, V32, P2241 HCAPLUS
(15) Sakamoto, F; Chem Pharm Bull 1987, V35, P642 HCAPLUS
(16) Taber, D; J Org Chem 1985, V50, P3618 HCAPLUS

L68 ANSWER 17 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:872198 HCAPLUS
DN 136:177334
ED Entered STN: 04 Dec 2001
TI .beta.3 agonists. Part 1: Evolution from inception to BMS-194449
AU Washburn, W. N.; Sher, P. M.; Poss, K. M.; Girotra, R. N.; McCann, P. J.; Gavai, A. V.; Mikkilineni, A. B.; Mathur, A.; **Cheng, P.**; Dejneka, T. C.; Sun, C. Q.; Wang, T. C.; Harper, T. W.; Russell, A. D.; Slusarchyk, D. A.; Skwish, S.; Allen, G. T.; Hillyer, D. E.; Frohlich, B. H.; Abboa-Offei, B. E.; Cap, M.; Waldron, T. L.; George, R. J.; Tesfamariam, B.; Ciosek, C. P.; Ryono, D.; Young, D. A.; Dickinson, K. E.; Seymour, A. A.; Arbeeny, C. M.; Gregg, R. E.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(23), 3035-3039
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review. Screening of the BMS collection identified 4-hydroxy-3-methylsulfonanilidoethanolamines as full .beta.3 agonists. Substitution of the ethanolamine N with a benzyl group bearing a para-H-bond acceptor promoted .beta.3 selectivity. Structure-activity studies established that highly selective .beta.3 agonists were generated upon substitution of C.alpha. with either benzyl to form (R)-1,2-diarylethylamines or with aryl to generate 1,1-diarylmethylamines. This latter subset yielded a clin. candidate, BMS-194449.
ST review beta 3 receptor agonist structure drug design antidiabetic; BMS 194449 beta 3 receptor agonist structure design review
IT Drug design
(development of .beta.3-receptor agonists)
IT Antidiabetic agents
(development of .beta.3-receptor agonists as)
IT Structure-activity relationship
(.beta.3-receptor agonist; development of .beta.3-receptor agonists in relation to)
IT 74-89-5DP, Methylamine, diaryl derivs. 75-04-7DP, Ethylamine, diaryl derivs. 141-43-5DP, Ethanolamine, hydroxymethylsulfonannilido derivs. 170686-12-1P, BMS 194449
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(development of .beta.3-receptor agonists, including)
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Amos, A; Diabetic Med 1997, V14, PS7
(2) Arbeeny, C; Am J Physiol 1995, V268, PE678 HCAPLUS
(3) Bloom, J; Drugs Future 1994, V19, P23
(4) Bray, G; Nature 2000, V404, P672 HCAPLUS
(5) Cantello, B; Drugs Future 1991, V16, P797
(6) Emorine, L; Science 1989, V245, P1118 HCAPLUS
(7) Friedman, J; Nature 2000, V404, P632 HCAPLUS
(8) Gavai, A; Bioorg Med Chem Lett 2001, V11, P3041 HCAPLUS

(9) Himms-Hagen, J; Handbook of Obesity 1998, P415
(10) Kordik, C; J Med Chem 1999, V42, P181 HCAPLUS
(11) Larsen, A; J Med Chem 1967, V10, P462 HCAPLUS
(12) Lipworth, B; Eur J Clin Pharmacol 1989, V37, P297 HCAPLUS
(13) Lowell, B; Nature 2000, V404, P652 HCAPLUS
(14) Sher, P; J Med Chem Res 1997, V7, P109 HCAPLUS
(15) Slugg, P; Unpublished work
(16) Tesfamariam, B; Br J Pharmacol 1994, V112, P55 HCAPLUS
(17) Washburn, W; US 5776983 1998 HCAPLUS
(18) Washburn, W; 216th National ACS Meeting 1998
(19) Weber, A; Annu Rep Med Chem 1998, V33, P193 HCAPLUS
(20) Weyer, C; Diabetes Metab 1999, V25, P11 HCAPLUS
(21) Weyer, C; Drug Dev Res 2000, V51, P80 HCAPLUS

L68 ANSWER 18 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:423696 HCAPLUS
DN 135:37181
ED Entered STN: 12 Jun 2001
TI Methods and temperature control apparatus for improved administration of pharmaceutically active compounds including hormones
IN Zhang, Jie; **Zhang, Hao**
PA Zars, Inc., USA
SO U.S., 37 pp., Cont.-in-part of U.S. 5,919,479.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61F013-02
NCL 424449000
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 2
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6245347	B1	20010612	US 1998-162890	19980929
	US 5658583	A	19970819	US 1995-508463	19950728
	CA 2345492	AA	20000406	CA 1999-2345492	19990929
	WO 2000018339	A1	20000406	WO 1999-US22698	19990929
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9964062	A1	20000417	AU 1999-64062	19990929
	EP 1117357	A1	20010725	EP 1999-951669	19990929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002525172	T2	20020813	JP 2000-571862	19990929
	US 6303142	B1	20011016	US 2000-545591	20000407
	US 6306431	B1	20011023	US 2000-545497	20000407
	US 6340472	B1	20020122	US 2000-545495	20000407
	US 6465006	B1	20021015	US 2000-545496	20000407
	US 6613350	B1	20030902	US 2000-544897	20000407
	US 2001037104	A1	20011101	US 2001-796250	20010228
	US 2002119186	A1	20020829	US 2001-878558	20010611
	US 6756053	B2	20040629		
	US 2002114827	A1	20020822	US 2001-954904	20010918

WO 2003024383 A2 20030327 WO 2002-US29533 20020917
WO 2003024383 A3 20031231
WO 2003024383 B1 20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003138464 A1 20030724 US 2002-307091 20021127
US 2003219470 A1 20031127 US 2002-310204 20021204
PRAI US 1995-508463 A3 19950728
US 1997-819880 A2 19970318
US 1998-162587 A2 19980929
US 1998-162890 A 19980929
US 1999-317313 A 19990524
US 1999-317372 A 19990524
WO 1999-US22698 W 19990929
US 2000-185913P P 20000229
US 2000-544897 A3 20000407
US 2000-545496 A1 20000407
US 2000-545591 A2 20000407
US 2001-954904 A 20010918

AB Methods and apparatus for improving dermal and mucosal administration of drugs through the use of controlled heat and other phys. means, i.e., ultrasound, microwave, elec. current, and vibrations, are described. The controlled heat and other phys. means are used to alter, mainly increase, the drug release rate from dermal drug delivery systems (DDDSs), conventional com. DDDSs, or drugs delivered into a sub-skin depot site via injection and other methods. For example, with heating by the temperature control apparatus, it was found that fentanyl entered the systemic circulation of human volunteers earlier and at faster rate from a com. available dermal patch, Duragesic 50 (designed to deliver an average of 50 g fentanyl/h), compared to the unheated patch. At 240 min, the end of the heating and fentanyl patch application, the average serum concns. of fentanyl was about 5 times that of the unheated patch. These results demonstrates that controlled heat can significantly increase the speed of dermal fentanyl absorption and shorten the onset time. It is believed that the increased temperature increases the skin permeability resulting in the drug entering the patient's systemic circulation faster.

ST transdermal mucosal drug absorption heating device; temp control app transdermal mucosal drug absorption; sustained drug release temp control app; ultrasound transdermal mucosal drug absorption; microwave transdermal mucosal drug absorption; electricity transdermal mucosal drug absorption; vibration transdermal mucosal drug absorption

IT Polymers, biological studies
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Tobacco smoke
(cessation; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Rhythm, biological
(circadian, mimicking of; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT 5-HT agonists
Allergy inhibitors
Analgesics
Anti-infective agents
Antiasthmatics
Antibiotics
Antidepressants
Antidiabetic agents
Antiemetics
Antihypertensives
Antimigraine agents
Antiobesity agents
Antitumor agents
Cardiovascular agents
Contraceptives
Electric current
Electroporation
Iontophoresis
Sound and Ultrasound
Vibration
(controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Androgens
Estrogens
Steroids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Brain
(controlled heat and other phys. means for improved dermal and mucosal drug delivery targeting brain)

IT Circulation
(controlled heat and other phys. means for improved dermal and mucosal drug delivery targeting systemic circulation)

IT Drug targeting
(controlled heat and other phys. means for improved dermal and mucosal drug delivery targeting systemic circulation and brain)

IT Temperature effects, biological
(heat; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(implants; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(injections, i.m.; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(injections, sustained release; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Anesthetics
(local; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Anti-inflammatory agents
(nonsteroidal; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Exothermic reaction
(oxygen-activated; temperature control device for improved dermal and mucosal drug delivery)

IT Skin

(permeability, increase of; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Biological transport
(permeation, increase of skin; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Membrane, biological
Sawdust
(temperature control device for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(topical, mucosal; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(transdermal, controlled-release; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(transdermal, sustained-release; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Drug delivery systems
(transdermal; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Biological transport
(uptake; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wintergreen; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT 990-73-8, Duragesic
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(Duragesic; controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT 7440-44-0, Carbon, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activated; temperature control device for improved dermal and mucosal drug delivery)

IT 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26680-10-4, Poly(DL-lactide) 70524-20-8, Caprolactone-DL-lactide copolymer
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-81-7, vitamin C, biological studies 51-55-8, Atropine, biological studies 54-11-5, Nicotine 55-63-0, Nitroglycerin 57-27-2, Morphine, biological studies 57-42-1, Meperidine 57-83-0, Progesterone, biological studies 58-20-8, Testosterone cypionate 58-22-0, Androderm 94-24-6, Tetracaine 113-15-5, Ergotamine 137-58-6, Lidocaine 315-37-7, Testosterone enanthate 511-12-6, Dihydroergotamine 721-50-6, Prilocaine 1406-18-4, vitamin E 4205-90-7, Clonidine 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 11103-57-4, Vitamin A 26780-50-7, Medisorb 8515DL 34346-01-5, Atrigel 38396-39-3, Bupivacaine 56030-54-7, Sufentanil 71195-58-9, Alfentanil 103628-46-2, Sumatriptan 131723-69-8, Smart Hydrogel 132875-61-7, Remifentanil 139264-17-8, Zolmitriptan 144034-80-0, Rizatriptan
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled heat and other phys. means for improved dermal and mucosal drug delivery)

IT 7782-44-7, Oxygen, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(exothermic reaction activated by; temperature control device for improved dermal and mucosal drug delivery)
IT 7439-89-6, Iron, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(powder; temperature control device for improved dermal and mucosal drug delivery)
IT 7647-14-5, Sodium chloride, biological studies 9002-88-4, Polyethylene
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(temperature control device for improved dermal and mucosal drug delivery)
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; GB 2163956 1988 HCAPLUS
(2) Anon; WO 8809169 1988 HCAPLUS
(3) Argaud; US 4963360 1990
(4) Arky; Physicians' Desk Reference 1997, P1336
(5) Astra Usa Inc; EMLA Cream Product Information Form For American Hospital Formulary Service 1993, P1
(6) Chandrasekaran; US 4286592 1981
(7) Colley; US 5217718 1993
(8) Dittman; US 5364350 1994
(9) Dvoretzky; US 5534021 1996
(10) Ennis; US 4693706 1987
(11) Haber; US 5114411 1992
(12) Haber; US 5329976 1994
(13) Hardwick; US 3929131 1975
(14) Harwood; US 4230105 1980 HCAPLUS
(15) Heiber; US 4911707 1990
(16) Jackson; US 5279594 1994
(17) King; US 5276032 1994 HCAPLUS
(18) Knutson; Journal of Controlled Release 1990, V11, P93 HCAPLUS
(19) Konno; US 4685911 1987
(20) Kuratomi; US 4747841 1988
(21) Latzke; US 4898592 1990
(22) Latzke; US 4994049 1991
(23) Little; US 5108710 1992
(24) Lycka; J Dermotol Surg Oncol 1992, V18, P859 MEDLINE
(25) Mack Publishing Company; Pharmaceutical Sciences 1985, P1481
(26) McCafferty; Br J Anaesth 1988, V60, P64 MEDLINE
(27) McCafferty; Br J Anaesth 1989, V62, P18
(28) McCafferty; Br J Anaesth 1993, V71, P370 MEDLINE
(29) Muller; US 5128137 1992
(30) Someah; US 5213129 1993
(31) Stewart; US 4830855 1989 HCAPLUS
(32) Strack; US 4913957 1990
(33) Sundstrom; US 5147339 1992
(34) Sundstrom; US 5662624 1997
(35) Woolfson; Br J Anaesth 1988, V61, P590
(36) Woolfson; Percutaneous Local Anaesthesia 1993, P166
(37) Wright; US 5229133 1993
(38) Zook; US 5330452 1994

L68 ANSWER 19 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:319681 HCAPLUS
DN 134:331629
ED Entered STN: 04 May 2001

TI Oral transmucosal drug dosage using solid solution
IN **Zhang, Hao**; Croft, Jed
PA Anesta Corp., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61F013-02
ICS A61K009-20; A61K009-68
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030288	A1	20010503	WO 2000-US28113	20001012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6264981	B1	20010724	US 1999-428071	19991027
	EP 1242013	A1	20020925	EP 2000-972083	20001012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003512402	T2	20030402	JP 2001-532709	20001012
PRAI	US 1999-428071	A	19991027		
	WO 2000-US28113	W	20001012		

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid solution with a dissoln. agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent. Oral transmucosal formulation containing piroxicam 2, mannitol 10, Emdex 86.7, sodium hydroxide 0.24, and magnesium stearate 1% was prepared Th Cmax and AUC of the drug was two fold of the wet granulation formulation and it was absorbed into the blood stream faster.

ST oral transmucosal drug solid soln piroxicam
IT Tobacco smoke
(agents for cessation of; oral transmucosal drug dosage using solid solution)
IT Polyoxyalkylenes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl ethers; oral transmucosal drug dosage using solid solution)
IT Heart, disease
(angina pectoris; oral transmucosal drug dosage using solid solution)
IT Solvents
(cosolvents; oral transmucosal drug dosage using solid solution)
IT Anesthetics
(local; oral transmucosal drug dosage using solid solution)
IT Drug delivery systems
(mucosal, trans-; oral transmucosal drug dosage using solid solution)
IT Anti-inflammatory agents
(nonsteroidal; oral transmucosal drug dosage using solid solution)
IT Absorbents
Acacia

Allergy inhibitors
Analgesics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antibiotics
Antidepressants
Antidiabetic agents
Antidiuretics
Antiemetics
Antihypertensives
Antimicrobial agents
Antimigraine agents
Antiobesity agents
Antioxidants
Antiparkinsonian agents
Antitumor agents
Binders
Bronchodilators
Buffers
Contraceptives
Dissolution rate
Diuretics
Drug bioavailability
Dyes
Emulsifying agents
Flavoring materials
Fungicides
Lubricants
Plasticizers
Solvents
Surfactants
Sweetening agents
Viscosity
(oral transmucosal drug dosage using solid solution)

IT Acrylic polymers, biological studies
Androgens
Antibodies
Antigens
Borates
Carbonates, biological studies
Enkephalins
Enzymes, biological studies
Estrogens
Gelatins, biological studies
Gonadotropins
Lecithins
Opioids
Peptides, biological studies
Phosphates, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Steroids, biological studies
Zeins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)

IT Acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(organic; oral transmucosal drug dosage using solid solution)

IT Phenols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted; oral transmucosal drug dosage using solid solution)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wintergreen; oral transmucosal drug dosage using solid solution)

IT 9015-82-1 329900-75-6, Cyclooxygenase 2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; oral transmucosal drug dosage using solid solution)

IT 9004-34-6, Cellulose, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microcryst.; oral transmucosal drug dosage using solid solution)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progestron, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol 3385-03-3, Flunisolide 3715-17-1, Tartrate, biological studies 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotropic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycolalginate 9005-38-3, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil

60617-12-1, .beta.-Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril 71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol 103628-46-2, Sumatriptan 106392-12-5, Poloxamer
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid solution)
IT 56-12-2, GABA, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stimulants; oral transmucosal drug dosage using solid solution)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Lovrecich; US 5449521 A 1995 HCAPLUS

L68 ANSWER 20 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:228872 HCAPLUS
DN 134:266299
ED Entered STN: 30 Mar 2001
TI Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as **antidiabetic** and **antiobesity** agents.
IN **Cheng, Peter T. W.**; **Devasthale, Pratik**; **Jeon, Yoon T.**; **Chen, Sean**; **Zhang, Hao**
PA **Bristol-Myers Squibb** Company, USA
SO PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D263-32
ICS C07D263-58; C07D277-24; C07D495-04; C07D417-04; C07D413-14; C07D413-12; C07D417-12; A61K031-421; A61K031-426; A61K031-4439; A61P003-10; A61P003-06
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001021602	A1	20010329	WO 2000-US25710	20000919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1218361	A1	20020703	EP 2000-965172	20000919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014189	A	20020820	BR 2000-14189	20000919
	TR 200200732	T2	20021021	TR 2002-20020073220000919	
	JP 2003509503	T2	20030311	JP 2001-524981	20000919
	ZA 2002000937	A	20030502	ZA 2002-937	20020201
	NO 2002001408	A	20020514	NO 2002-1408	20020321
PRAI	US 1999-155400P	P	19990922		
	WO 2000-US25710	W	20000919		

OS MARPAT 134:266299
GI



I



II

AB Title compds. [I; Q = C, N; A = O, S; B = (CH2)x; Z = O, bond; X = CH, N; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, amino; R3 = H, alkyl, aralkyl, aryloxycarbonyl, alkoxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R2a, R2b, R2c = H, alkyl, alkoxy, halo, amino; Y = CO2R4, 1-tetrazolyl, PO(OR4a)R5; R4 = H, alkyl, prodrug or ester; R4a = H, prodrug ester; R5 = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph3P, and DEAD were stirred in THF at 0.degree.-room temperature to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-benzylglycine Et ester and NaBH(OAc)3 in 1,2-dichloroethane to give 55% benzylamine derivative, which was stirred 14 h with aqueous NaOH in MeOH to give 71% title compound (II).

ST oxazolylalkoxybenzylglycine prepn **antidiabetic** **antiobesity** agent; anticancer oxazolylalkoxybenzylglycine thiazolylalkoxybenzylglycine prepn; thiazolylalkoxybenzylglycine prepn **antidiabetic antiobesity** agent; psoriasis treatment thiazolylalkoxybenzylglycine oxazolylalkoxybenzylglycine; antiosteoporotic thiazolylalkoxybenzylglycine oxazolylalkoxybenzylglycine; irritable bowel syndrome treatment thiazolylalkoxybenzylglycine oxazolylalkoxybenzylglycine

IT Intestine, disease
(Crohn's, treatment; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Intestine, disease
(irritable bowel syndrome, treatment; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT **Antidiabetic** agents
Antiobesity agents
Antitumor agents
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Osteoporosis
(therapeutic agents; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT Psoriasis
(treatment; preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity**

agents)

IT 331739-69-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331739-67-4P 331739-68-5P 331739-70-9P 331739-71-0P 331739-72-1P
331739-73-2P 331739-74-3P 331739-75-4P 331739-76-5P 331739-77-6P
331739-78-7P 331739-79-8P 331739-80-1P 331739-81-2P 331739-82-3P
331739-83-4P 331739-84-5P 331739-85-6P 331739-86-7P 331739-87-8P
331739-88-9P 331739-89-0P 331739-90-3P 331739-91-4P 331739-92-5P
331739-93-6P 331739-94-7P 331739-95-8P 331739-96-9P 331739-97-0P
331739-98-1P 331739-99-2P 331740-00-2P 331740-01-3P 331740-02-4P
331740-03-5P 331740-04-6P 331740-05-7P 331740-06-8P 331740-07-9P
331740-08-0P 331740-09-1P 331740-10-4P 331740-11-5P 331740-12-6P
331740-13-7P 331740-14-8P 331740-15-9P 331740-16-0P 331740-17-1P
331740-18-2P 331740-19-3P 331740-20-6P 331740-21-7P 331740-22-8P
331740-23-9P 331740-24-0P 331740-25-1P 331740-26-2P 331740-27-3P
331740-28-4P 331740-29-5P 331740-30-8P 331740-31-9P 331740-32-0P
331740-33-1P 331740-34-2P 331740-35-3P 331740-36-4P 331740-37-5P
331740-38-6P 331740-39-7P 331740-40-0P 331740-41-1P 331740-42-2P
331740-43-3P 331740-44-4P 331740-45-5P 331740-46-6P 331740-47-7P
331740-48-8P 331740-49-9P 331740-50-2P 331740-51-3P 331740-52-4P
331740-53-5P 331740-54-6P 331740-55-7P 331740-56-8P 331740-57-9P
331740-58-0P 331740-59-1P 331740-60-4P 331740-61-5P 331740-62-6P
331740-63-7P 331740-64-8P 331740-65-9P 331740-66-0P 331740-67-1P
331740-68-2P 331740-69-3P 331740-70-6P 331740-71-7P 331740-72-8P
331740-73-9P 331740-74-0P 331740-75-1P 331740-76-2P 331740-77-3P
331740-78-4P 331740-79-5P 331740-80-8P 331740-81-9P 331740-82-0P
331740-83-1P 331740-84-2P 331740-85-3P 331740-86-4P 331740-87-5P
331740-88-6P 331740-89-7P 331740-90-0P 331740-91-1P 331740-92-2P
331740-93-3P 331740-94-4P 331740-95-5P 331740-96-6P 331740-97-7P
331740-98-8P 331740-99-9P 331741-00-5P 331741-01-6P 331741-02-7P
331741-03-8P 331741-04-9P 331741-05-0P 331741-06-1P 331741-07-2P
331741-08-3P 331741-09-4P 331741-10-7P 331741-11-8P 331741-12-9P
331741-13-0P 331741-14-1P 331741-15-2P 331741-16-3P 331741-17-4P
331741-18-5P 331741-19-6P 331741-20-9P 331741-21-0P 331741-22-1P
331741-23-2P 331741-24-3P 331741-25-4P 331741-26-5P 331741-27-6P
331741-28-7P 331741-29-8P 331741-30-1P 331741-31-2P 331741-32-3P
331741-33-4P 331741-34-5P 331741-35-6P 331741-36-7P 331741-37-8P
331741-38-9P 331741-39-0P 331741-40-3P 331741-41-4P 331741-42-5P
331741-43-6P 331741-44-7P 331741-45-8P 331741-46-9P 331741-47-0P
331741-48-1P 331741-49-2P 331741-50-5P 331741-51-6P 331741-52-7P
331741-53-8P 331741-54-9P 331741-55-0P 331741-56-1P 331741-57-2P
331741-58-3P 331741-59-4P 331741-60-7P 331741-61-8P 331741-63-0P
331741-64-1P 331741-65-2P 331741-66-3P 331741-67-4P 331741-68-5P
331741-69-6P 331741-70-9P 331741-71-0P 331741-72-1P 331741-73-2P
331741-74-3P 331741-75-4P 331741-76-5P 331741-77-6P 331741-78-7P
331741-79-8P 331741-80-1P 331741-81-2P 331741-82-3P 331741-83-4P
331741-84-5P 331741-85-6P 331741-86-7P 331741-87-8P 331741-88-9P
331741-89-0P 331741-90-3P 331741-91-4P 331741-92-5P 331741-93-6P
331741-94-7P 331741-95-8P 331741-96-9P 331741-97-0P 331741-98-1P
331741-99-2P 331742-00-8P 331742-01-9P 331742-02-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331742-03-1P 331742-04-2P 331742-05-3P 331742-06-4P 331742-07-5P
331742-08-6P 331742-09-7P 331742-10-0P 331742-11-1P 331742-12-2P
331742-13-3P 331742-14-4P 331742-15-5P 331742-16-6P 331742-17-7P
331742-18-8P 331742-19-9P 331742-20-2P 331742-21-3P 331742-22-4P
331742-23-5P 331742-24-6P 331742-25-7P 331742-26-8P 331742-27-9P
331742-28-0P 331742-29-1P 331742-30-4P 331742-31-5P 331742-32-6P
331742-33-7P 331742-34-8P 331742-35-9P 331742-36-0P 331742-37-1P
331742-38-2P 331742-39-3P 331742-40-6P 331742-41-7P 331742-42-8P
331742-43-9P 331742-44-0P 331742-45-1P 331742-46-2P 331742-47-3P
331742-48-4P 331742-49-5P 331742-50-8P 331742-51-9P 331742-52-0P
331742-53-1P 331742-54-2P 331742-55-3P 331742-56-4P 331742-57-5P
331742-58-6P 331742-59-7P 331742-60-0P 331742-61-1P 331742-62-2P
331742-63-3P 331742-64-4P 331742-65-5P 331742-66-6P 331742-67-7P
331742-68-8P 331742-69-9P 331742-70-2P 331742-71-3P 331742-72-4P
331742-73-5P 331742-74-6P 331742-75-7P 331742-76-8P 331742-77-9P
331742-78-0P 331742-79-1P 331742-80-4P 331742-81-5P 331742-82-6P
331742-83-7P 331742-84-8P 331742-85-9P 331742-86-0P 331742-87-1P
331742-88-2P 331742-89-3P 331742-90-6P 331742-91-7P 331742-92-8P
331742-93-9P 331742-94-0P 331742-95-1P 331742-96-2P 331742-97-3P
331742-98-4P 331742-99-5P 331743-00-1P 331743-02-3P 331743-04-5P
331743-05-6P 331743-06-7P 331743-07-8P 331743-08-9P 331743-09-0P
331743-10-3P 331743-11-4P 331743-12-5P 331743-13-6P 331743-14-7P
331743-15-8P 331743-16-9P 331743-17-0P 331743-18-1P 331743-19-2P
331743-20-5P 331743-21-6P 331743-22-7P 331743-23-8P 331743-24-9P
331743-25-0P 331743-26-1P 331743-27-2P 331743-28-3P 331743-29-4P
331743-30-7P 331743-31-8P 331743-32-9P 331743-33-0P 331743-34-1P
331743-35-2P 331743-36-3P 331743-37-4P 331743-38-5P 331743-39-6P
331743-40-9P 331743-41-0P 331743-42-1P 331743-43-2P 331743-44-3P
331743-45-4P 331743-46-5P 331743-47-6P 331743-48-7P 331743-49-8P
331743-50-1P 331743-51-2P 331743-52-3P 331743-53-4P 331743-54-5P
331743-55-6P 331743-56-7P 331743-57-8P 331743-58-9P 331743-59-0P
331743-60-3P 331743-61-4P 331743-62-5P 331743-63-6P 331743-64-7P
331743-65-8P 331743-66-9P 331743-67-0P 331743-68-1P 331743-69-2P
331743-70-5P 331743-71-6P 331743-72-7P 331743-73-8P 331743-74-9P
331743-75-0P 331743-76-1P 331743-77-2P 331743-78-3P 331743-79-4P
331743-80-7P 331743-81-8P 331743-82-9P 331743-83-0P 331743-84-1P
331743-85-2P 331743-86-3P 331743-87-4P 331743-88-5P 331743-89-6P
331743-90-9P 331743-91-0P 331743-92-1P 331743-93-2P 331743-94-3P
331743-95-4P 331743-96-5P 331743-97-6P 331743-98-7P 331743-99-8P
331744-00-4P 331744-01-5P 331744-02-6P 331744-03-7P 331744-04-8P
331744-05-9P 331744-06-0P 331744-07-1P 331744-08-2P 331744-09-3P
331744-10-6P 331744-11-7P 331744-12-8P 331744-13-9P 331744-14-0P
331744-15-1P 331744-16-2P 331744-17-3P 331744-18-4P 331744-19-5P
331744-20-8P 331744-21-9P 331744-22-0P 331744-23-1P 331744-24-2P
331744-25-3P 331744-26-4P 331744-27-5P 331744-28-6P 331744-29-7P
331744-30-0P 331744-31-1P 331744-32-2P 331744-33-3P 331744-34-4P
331744-35-5P 331744-36-6P 331744-37-7P 331744-38-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331744-39-9P 331744-40-2P 331744-41-3P 331744-42-4P 331744-43-5P
331744-44-6P 331744-45-7P 331744-46-8P 331744-47-9P 331744-48-0P
331744-49-1P 331744-50-4P 331744-51-5P 331744-52-6P 331744-53-7P
331744-54-8P 331744-55-9P 331744-56-0P 331744-57-1P 331744-58-2P
331744-59-3P 331744-60-6P 331744-61-7P 331744-62-8P 331744-63-9P
331744-64-0P 331744-65-1P 331744-66-2P 331744-67-3P 331744-68-4P
331744-69-5P 331744-70-8P 331744-71-9P 331744-72-0P 331744-73-1P
331744-74-2P 331744-75-3P 331744-76-4P 331744-77-5P 331744-78-6P

331744-79-7P 331744-80-0P 331744-81-1P 331744-82-2P 331744-83-3P
331744-84-4P 331744-85-5P 331744-86-6P 331744-87-7P 331744-88-8P
331744-89-9P 331744-90-2P 331744-91-3P 331744-92-4P 331744-93-5P
331744-94-6P 331744-95-7P 331744-96-8P 331744-97-9P 331744-98-0P
331744-99-1P 331745-00-7P 331745-01-8P 331745-02-9P 331745-03-0P
331745-04-1P 331745-05-2P 331745-06-3P 331745-07-4P 331745-08-5P
331745-09-6P 331745-10-9P 331745-11-0P 331745-12-1P 331745-13-2P
331745-14-3P 331745-15-4P 331745-16-5P 331745-17-6P 331745-18-7P
331745-19-8P 331745-20-1P 331745-21-2P 331745-22-3P 331745-23-4P
331745-24-5P 331745-25-6P 331745-26-7P 331745-27-8P 331745-28-9P
331745-29-0P 331745-30-3P 331745-31-4P 331745-32-5P 331745-33-6P
331745-34-7P 331745-35-8P 331745-36-9P 331745-37-0P 331745-38-1P
331745-39-2P 331745-40-5P 331745-41-6P 331745-42-7P 331745-43-8P
331745-44-9P 331745-45-0P 331745-46-1P 331745-47-2P 331745-48-3P
331745-49-4P 331745-60-9P 331745-69-8P 331745-80-3P 331745-86-9P
331746-91-9P 331746-92-0P 331746-93-1P 331746-95-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 331746-96-4P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 65-85-0, Benzoic acid, reactions 66-99-9, 2-Naphthaldehyde 67-36-7, 4-Phenoxybenzaldehyde 85-46-1, 1-Naphthalenesulfonyl chloride 90-05-1, 2-Methoxyphenol 93-09-4, 2-Naphthalenecarboxylic acid 98-88-4, Benzoyl chloride 100-83-4, 3-Hydroxybenzaldehyde 102-29-4, Resorcinol monoacetate 103-16-2, 4-Benzyloxyphenol 105-36-2, Ethyl bromoacetate 106-95-6, Allyl bromide, reactions 106-96-7, Propargyl bromide 121-71-1 123-08-0, 4-Hydroxybenzaldehyde 151-18-8, 2-Cyanoethylamine 455-91-4, 3'-Fluoro-4'-methoxyacetophenone 501-53-1, Benzyl chloroformate 527-72-0, 2-Thiophenecarboxylic acid 591-35-5, 3,5-Dichlorophenol 615-18-9, 2-Chlorobenzoxazole 623-33-6, Glycine ethyl ester hydrochloride 626-02-8, 3-Iodophenol 626-55-1, 3-Bromopyridine 766-85-8, 3-Iodoanisole 768-35-4, 3-Fluorophenylboronic acid 815-60-1, 2,4-Dibromo-3-pentanone 937-62-2, 4-Methylphenyl chloroformate 1005-56-7, Phenyl chlorothionoformate 1066-54-2, Trimethylsilylacetylene 1132-21-4, 3,5-Dimethoxybenzoic acid 1700-37-4, 3-Benzyloxybenzaldehyde 2215-77-2, p-Phenoxybenzoic acid 2589-71-1 2627-86-3, (S)-.alpha.-Methylbenzylamine 2835-98-5 3173-56-6, Benzyl isocyanate 3403-25-6, D-Phenylalanine tert-butyl ester hydrochloride 3424-93-9, 4-Methoxybenzamide 3886-69-9 5292-43-3, tert-Butyl bromoacetate 5345-54-0, 3-Chloro-4-methoxyaniline 5416-93-3, 4-Methoxyphenyl isocyanate 5680-79-5, Glycine methyl ester hydrochloride 5961-59-1, N-Methyl-p-anisidine 6436-90-4, N-Benzylglycine ethyl ester 6945-92-2, Ethyl hydrazinoacetate hydrochloride 7693-41-6, 4-Methoxyphenyl chloroformate 7699-00-5 7745-91-7, 3-Bromo-4-methylaniline 15028-41-8, Methyl .alpha.-aminoisobutyrate hydrochloride 15894-04-9, 4-Fluorobenzyl mercaptan 16728-01-1 19621-92-2, 2-Hydroxypyridine-6-carboxylic acid 22038-86-4, (R)-1-(4-Methoxyphenyl)ethylamine 27492-46-2 27532-96-3, Glycine tert-butyl ester hydrochloride 30414-53-0, Methyl propionylacetate 34035-03-5 41851-59-6, (S)-1-(4-Methoxyphenyl)ethylamine 50428-03-0 50868-72-9 59531-86-1, D-Alanine tert-butyl ester hydrochloride 64318-28-1 66171-50-4, Methyl 2-hydroxypyridine-5-carboxylate 81228-89-9 87199-17-5, 4-Formylphenylboronic acid 103788-65-4 107367-98-6, 2-Phenyl-5-methyloxazole-4-acetic acid 164660-78-0 175136-30-8

182913-11-7 331746-63-5 331746-64-6 331746-65-7 331746-66-8
331746-68-0 331746-69-1 331746-70-4 331746-71-5 331746-72-6
331746-73-7 331746-74-8 331746-75-9 331746-76-0 331746-78-2
331746-80-6 331746-81-7 331746-82-8 331746-83-9 331746-84-0
331746-85-1 331746-86-2 331746-87-3 331746-88-4 331746-89-5
331746-90-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

IT 405-06-1P 452-78-8P 621-27-2P, 3-Propylphenol 768-70-7P
2293-75-6P, 2-Methoxyphenyl chloroformate 2454-30-0P 3621-83-8P
10401-12-4P 18093-12-4P, 3-Chloro-4-methoxyphenol 23417-29-0P
28857-88-7P 30062-34-1P 42861-71-2P 52177-62-5P, 3-Methoxyphenyl chloroformate 52177-75-0P 60710-39-6P, 3-Bromo-4-methylphenol
62103-69-9P 68331-44-2P 70170-23-9P 72934-40-8P 74067-76-8P
103360-04-9P, 4-Fluorobenzylsulfonyl chloride 103788-59-6P
103788-61-0P 103788-64-3P 105983-77-5P 136058-69-0P 137208-84-5P
140130-09-2P 140130-10-5P 157169-61-4P 174258-60-7P 196810-26-1P
223562-18-3P 227029-27-8P 244152-94-1P 258346-53-1P 258346-54-2P
331745-61-0P 331745-62-1P 331745-63-2P 331745-64-3P 331745-65-4P
331745-66-5P 331745-67-6P 331745-68-7P 331745-70-1P 331745-71-2P
331745-72-3P 331745-73-4P 331745-74-5P 331745-75-6P 331745-76-7P
331745-77-8P 331745-78-9P 331745-79-0P 331745-81-4P 331745-82-5P
331745-83-6P 331745-84-7P 331745-85-8P 331745-87-0P 331745-88-1P
331745-89-2P 331745-90-5P 331745-91-6P 331745-92-7P 331745-93-8P
331745-94-9P 331745-95-0P 331745-96-1P 331745-97-2P 331745-98-3P
331745-99-4P 331746-00-0P 331746-01-1P 331746-02-2P 331746-03-3P
331746-04-4P 331746-05-5P 331746-06-6P 331746-07-7P 331746-08-8P
331746-09-9P 331746-10-2P 331746-11-3P 331746-12-4P 331746-13-5P
331746-14-6P 331746-15-7P 331746-16-8P 331746-17-9P 331746-18-0P
331746-19-1P 331746-20-4P 331746-21-5P 331746-22-6P 331746-23-7P
331746-24-8P 331746-25-9P 331746-26-0P 331746-27-1P 331746-28-2P
331746-29-3P 331746-30-6P 331746-31-7P 331746-32-8P 331746-33-9P
331746-34-0P 331746-35-1P 331746-36-2P 331746-37-3P 331746-38-4P
331746-39-5P 331746-40-8P 331746-41-9P 331746-42-0P 331746-43-1P
331746-44-2P 331746-45-3P 331746-46-4P 331746-47-5P 331746-48-6P
331746-50-0P 331746-51-1P 331746-52-2P 331746-53-3P 331746-54-4P
331746-55-5P 331746-56-6P 331746-57-7P 331746-58-8P 331746-59-9P
331746-60-2P 331746-61-3P 331746-62-4P 331746-67-9P 331746-77-1P
331746-79-3P 331746-94-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as **antidiabetic** and **antiobesity** agents)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Cobb, J; JOURNAL OF MEDICINAL CHEMISTRY 1998, V41(25), P5055 HCAPLUS
(2) Glaxo Group Limited; WO 9731907 A 1997 HCAPLUS
(3) Ono Pharmaceutical Co Ltd; WO 9946232 A 1999 HCAPLUS

L68 ANSWER 21 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:529508 HCAPLUS
ED Entered STN: 21 Aug 1998
TI Beta 3 adrenoceptor agonists part I: Program evolution from inception to BMS-194449.
AU Washburn, W. N.; Girotra, R. N.; McCann, P. J.; Gavai, A. V.; Mikkilineni, A. B.; **Cheng, P.**; Dejneka, T. C.; Sher, P. M.; Sun, C. Q.; Wang, T. G.; Ryono, D.; Harper, T. W.; Russell, A. D.; Slusarchyk, D. A.; Skwish, S.; Allen, G. T.; Hillyer, D. E.; Frohlich, B. H.; Abboa-Offei, B. E.; Cap, M.; Waldron, T. L.; George, R. J.; Tesfamariam, B.; Ciosek, C.

P., Jr.; Young, D. A.; Dickinson, K. E.; Seymour, A. A.; Arbeeny, C. M.; Gregg, R. E.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Book of Abstracts, 216th ACS National Meeting, Boston, August 23-27 (1998), MEDI-022 Publisher: American Chemical Society, Washington, D. C. CODEN: 66KYA2
DT Conference; Meeting Abstract
LA English
AB Induction of thermogenesis in brown adipose tissue (BAT) to lower plasma glucose by beta 3 selective full agonists potentially represents an alternative therapy for non-insulin dependent **diabetes** mellitus (NIDDM) and **obesity.** A new paradigm for beta 3 selectivity that guided the SAR evolution to the clin. candidate BMS-194449 will be discussed in conjunction with the metabolic and pharmacokinetic issues that encumbered the progression of this program. The enantioselective synthesis and preclin. characterization of BMS-194449 will be presented.

L68 ANSWER 22 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:427778 HCAPLUS
DN 129:81960
ED Entered STN: 11 Jul 1998
TI Preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists
IN **Cheng, Peter T. W.**; Bisacchi, Gregory S.; Gavai, Ashvinikumar V.; Poss, Kathleen M.; Ryono, Denis E.; Sher, Philip M.; Sun, Chong-qing; Washburn, William N.
PA **Bristol-Myers Squibb** Co., USA
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-425
ICS A61K031-165; C07D277-28; C07C321-00
NCL 514365000
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5770615	A	19980623	US 1997-825309	19970328
PRAI	US 1997-825309		19970328		

OS MARPAT 129:81960
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Catecholamine surrogates I [R1 = alkyl, aryl, arylalkyl; R2 = H, OH, hydroxymethyl, halo; R3 = H, alkyl; R4, R14 = H, alkoxy, alkoxymethyl, OH, cyano, CONR6R16, CO2R6, NR6R16, NR6COR8, NR6SO2R1; R4, R14 together with the carbon atoms to which they are bonded form heterocycle; R5, R15, R25 = independently A or B; A = H, alkyl, cycloalkyl, halo, OH, aryl, alkoxy, cyano, SR7, S(O)R7, SO2R7, NR6R16, NR6COR8, OCH2CONR6R16, OCH2CO2R6, CONR6R16, CO2R6; B = (CH2)nNR6R16, (CH2)mPO(OR6)OR16, (CH2)nNR6COR8, O-aryl, OCH2CH2NR6R16, COR7, SO2NR6R16, NR6CO2R7, NR6CONR6R16, heterocycle; R5, R15 together with the carbon atoms to which they are bonded form heterocycle; provided that at least one of R5, R15, and R25 =

B; R6, R16 = H, alkyl; R7 = alkyl; R8 = H, alkyl, aryl, arylalkyl; m = 0-6; n = 1-6] and pharmaceutically acceptable salts thereof, are .beta.3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of **diabetes**, **obesity**, and gastrointestinal diseases. Thus, alkylation of .alpha.-Me amino ester II (preparation given) with iodide III (preparation given), followed by saponification, amidation with di-Et
4-aminobenzylphosphonate, and desilylation gave desired cataecholamine surrogate IV.

ST catecholamine surrogate prepn adrenergic receptor agonist; beta 3 receptor agonist catecholamine surrogate

IT Intestine, disease
(hypermotility; preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT **Antidiabetic** agents
Antiobesity agents
(preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT Adrenoceptor agonists
(.beta.3-; preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(.beta.3; preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT 197643-50-8P 197643-54-2P 197643-57-5P 197643-60-0P 197643-63-3P
197643-66-6P 197643-69-9P 197643-72-4P 197643-74-6P 197643-76-8P
197643-77-9P 197643-79-1P 197643-81-5P 197643-83-7P 197643-84-8P
197643-86-0P 197643-88-2P 197643-90-6P 197643-92-8P 197643-94-0P
197643-96-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT 22348-32-9
RL: CAT (Catalyst use); USES (Uses)
(preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT 96-72-0, 2-Chloro-5-nitrobenzenesulfonamide 99-03-6, 3-Acetylaniline
99-60-5, 2-Chloro-4-nitrobenzoic acid 99-93-4, p-Hydroxyacetophenone
100-06-1 100-28-7, 4-Nitrophenyl isocyanate 108-01-0 121-52-8,
3-Nitrobenzenesulfonamide 121-90-4, 3-Nitrobenzoyl chloride 122-04-3,
4-Nitrobenzoyl chloride 122-52-1, Triethyl phosphite 288-36-8,
1,2,3-Triazole 288-47-1, Thiazole 591-27-5, 3-Aminophenol 636-98-6,
4-Nitrophenyl iodide 645-00-1, 3-Nitrophenyl iodide 3320-87-4,
3-Nitrophenyl isocyanate 3586-12-7, 3-Phenoxyaniline 3958-57-4,
3-Nitrobenzyl bromide 7073-36-1, 2-Chloro-4-nitrobenzoyl chloride
20074-79-7, Diethyl 4-aminobenzylphosphonate 38818-50-7,
4-Chloro-3-nitrobenzoyl chloride 41252-96-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

IT 98-18-0P, 3-Aminosulfonylaniline 123-30-8P 2015-19-2P 6274-18-6P
6322-56-1P 14347-05-8P 14347-08-1P 14347-15-0P 14347-25-2P
22927-78-2P 27958-77-6P, 3-[(Dimethylamino)methyl]aniline 35582-08-2P
62345-76-0P, 4-[2-(Dimethylamino)ethoxy]aniline 62882-11-5P
104139-11-9P, Diethyl 3-aminobenzylphosphonate 170687-75-9P
170687-82-8P 170689-16-4P 181513-08-6P 184097-39-0P 193017-26-4P

197643-97-3P 197643-98-4P 197643-99-5P 197644-01-2P 197644-02-3P
197644-03-4P 197644-04-5P 197644-05-6P 197644-06-7P 197644-07-8P
197644-10-3P 197644-11-4P 197644-13-6P 197644-14-7P 197644-15-8P
209405-51-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of catecholamine surrogates as .beta.3 adrenergic receptor agonists)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ainsworth; US 4338333 1982 HCAPLUS
(2) Anon; GB 1005025 1965
(3) Anon; DE 2310142 1973 HCAPLUS
(4) Anon; GB 1367678 1974 HCAPLUS
(5) Anon; JP 51125291 1974 HCAPLUS
(6) Anon; DE 122967 1975
(7) Anon; JP 51143678 1975 HCAPLUS
(8) Anon; JP 51149282 1975 HCAPLUS
(9) Anon; JP 53002443 1976 HCAPLUS
(10) Anon; EP 0023385 1981 HCAPLUS
(11) Anon; CA 1204445 1983 HCAPLUS
(12) Anon; AU A19223183 1984
(13) Anon; EP 556880 1993 HCAPLUS
(14) Anon; ZA 837012 1993
(15) Bloom; US 5061727 1991 HCAPLUS
(16) Buu-Hoi; US 3954871 1976 HCAPLUS
(17) Cecchi; US 4707497 1987 HCAPLUS
(18) Ebnother; US 3804899 1974 HCAPLUS
(19) Francis; US 3906110 1975 HCAPLUS
(20) Gould; US 3574741 1971
(21) Holloway; US 4772631 1988 HCAPLUS
(22) Jack; US 3689524 1972 HCAPLUS
(23) Jack; US 3803230 1974 HCAPLUS
(24) Lambelin; US 4638070 1987 HCAPLUS
(25) Larsen; US 3341584 1967
(26) Larsen; US 3660487 1972 HCAPLUS
(27) Lunts; US 3705233 1972 HCAPLUS
(28) Lunts; US 3732300 1973
(29) Lunts; US 4012444 1977 HCAPLUS
(30) Lunts; US 4066755 1978
(31) Sugihara; US 4035512 1977
(32) Washburn; 1995

L68 ANSWER 23 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:376573 HCAPLUS
DN 129:95699
ED Entered STN: 19 Jun 1998
TI The enantioselective synthesis of anti-.beta.-hydroxy .alpha.-amino acids via the reaction of lithium enolates of glycine bearing an oxazolidine chiral auxiliary with aldehydes
AU Iwanowicz, Edwin J.; Blomgren, Peter; **Cheng, Peter T. W.**; Smith, Kennith; Lau, Wan F.; Pan, Yolanda Y.; Gu, Henry H.; Malley, Mary F.; Gougoutas, Jack Z.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Synlett (1998), (6), 664-666
CODEN: SYNLES; ISSN: 0936-5214
PB Georg Thieme Verlag
DT Journal
LA English

CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 22

GI



I

AB A new anti-selective aldol reaction utilizing oxazolidine-functionalized glycine ester I is described. The Li enolate of I, was demonstrated to undergo a highly anti-diastereoselective aldol reaction with a variety of aldehydes. Facile removal of the chiral auxiliary allows for the efficient preparation of chiral .beta.-hydroxy .alpha.-amino acids of erythro stereochem.

ST hydroxy amino acid stereoselective prepn; oxazolidine functionalized glycine enolate stereoselective aldol

IT Amino acids, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(hydroxy; preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

IT Conformation
(of oxazolidines)

IT Aldol condensation
(stereoselective; preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

IT 209793-14-6 209793-15-7
RL: PRP (Properties)
(conformation)

IT 209793-03-3P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystal structure, preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

IT 78-84-2 110-62-3, Pentanal 123-72-8, Butanal 630-19-3, Pivaldehyde 947-91-1, Diphenylacetaldehyde 2913-97-5 209792-98-3 209793-04-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

IT 209793-08-8P 209793-11-3P 209793-12-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

IT 209792-99-4P 209793-00-0P 209793-01-1P 209793-02-2P 209793-05-5P 209793-06-6P 209793-09-9P 209793-10-2P 209793-13-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxy .alpha.-amino acids by stereoselective aldol reaction of oxazolidine-modified glycine lithium enolates)

L68 ANSWER 24 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:684268 HCAPLUS
DN 127:318773
ED Entered STN: 29 Oct 1997

TI Preparation of catecholamine surrogates for use as .beta.3 adrenergic receptor agonists

IN **Cheng, Peter T. W.**; Bisacchi, Gregory S.; Gavai, Ashvinikumar V.; Poss, Kathleen M.; Ryono, Denis E.; Sher, Philip M.; Sun, Chong-qing; Washburn, William N.

PA **Bristol-Myers Squibb** Co., USA

SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-18
ICS A61K031-42; A61K031-425

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9737646	A1	19971016	WO 1997-US5324	19970401
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9726013	A1	19971029	AU 1997-26013	19970401

PRAI US 1996-14861P P 19960404
WO 1997-US5324 W 19970401

OS MARPAT 127:318773

GI



I



II

AB Amides I [R1 = alkyl, aryl, arylalkyl; R2 = H, OH, CH2OH, halogen; R3 = H,

alkyl; R4 = R4' = H, alkoxy, alkoxymethyl, OH, CN, carboxamide, carboxyl, amino, acylamino, sulfonylamino; R4R4' = fused heterocycle; R5 = R5' = R5'' = H, alkyl, cycloalkyl, halogen, OH, aryl alkoxy, CN, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, acylamino, carbamoyl] were prepd for use as .beta.3 adrenergic receptor agonists (no data), and therefore, potentially useful for treatment of diseases such as **diabetes**, **obesity** and gastrointestinal diseases. Thus, amide II was prepared a multistep synthetic sequence including the preparation of Et (S)-.alpha.-amino-4-methoxy-.alpha.-methylbenzeneacetate starting from 4-methoxyacetophenone and the formation of 1-(4-phenylmethoxy-3-aminophenyl)ethanone starting from 4-hydroxyacetophenone.

ST catecholamine surrogate prepn adrenergic receptor agonist; benzeneacetamide prepn adrenergic receptor agonist

IT Adrenoceptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.3; preparation of catecholamine surrogates useful as .beta.3 adrenergic receptor agonists)

IT 96-72-0, 2-Chloro-5-nitrobenzenesulfonamide 99-03-6, 3-Acetylaniline 99-60-5, 2-Chloro-4-nitrobenzoic acid 99-93-4, 4-Hydroxyacetophenone 100-06-1 100-28-7, 4-Nitrophenylisocyanate 107-10-8, 1-Propanamine, reactions 108-01-0, 2-(Dimethylamino)ethanol 121-51-7, 3-Nitrobenzenesulfonyl chloride 121-52-8, 3-Nitrobenzenesulfonamide 121-90-4, 3-Nitrobenzoyl chloride 122-04-3, 4-Nitrobenzoyl chloride 123-30-8, 4-Aminophenol 288-36-8, 1,2,3-Triazole 288-47-1, Thiazole 591-27-5, 3-Aminophenol 636-98-6, 4-Nitrophenyl iodide 645-00-1, 3-Nitrophenyl iodide 2627-86-3, (-)-.alpha.-Methylbenzylamine 3320-87-4, 3-Nitrophenylisocyanate 3586-12-7, 3-Phenoxyaniline 3958-57-4, 3-Nitrobenzyl bromide 25784-91-2 41252-96-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of catecholamine surrogates useful as .beta.3 adrenergic receptor agonists)

IT 98-18-0P 2015-19-2P 6274-18-6P 6322-56-1P 14347-05-8P 14347-08-1P 14347-15-0P 14347-25-2P 22927-78-2P 27958-77-6P 35582-07-1P 35582-08-2P 62345-76-0P 62882-08-0P 62882-11-5P 104139-11-9P 170687-75-9P 170687-82-8P 170689-16-4P 181513-08-6P 184097-39-0P 193017-26-4P 197643-49-5P 197643-97-3P 197643-98-4P 197643-99-5P 197644-01-2P 197644-02-3P 197644-03-4P 197644-04-5P 197644-05-6P 197644-06-7P 197644-07-8P 197644-08-9P 197644-09-0P 197644-10-3P 197644-11-4P 197644-12-5P 197644-13-6P 197644-14-7P 197644-15-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of catecholamine surrogates useful as .beta.3 adrenergic receptor agonists)

IT 197643-50-8P 197643-54-2P 197643-57-5P 197643-60-0P 197643-63-3P 197643-66-6P 197643-69-9P 197643-72-4P 197643-74-6P 197643-76-8P 197643-77-9P 197643-79-1P 197643-81-5P 197643-83-7P 197643-84-8P 197643-86-0P 197643-88-2P 197643-90-6P 197643-92-8P 197643-94-0P 197643-96-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of catecholamine surrogates useful as .beta.3 adrenergic receptor agonists)

L68 ANSWER 25 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:634222 HCAPLUS
Correction of: 1997:322147
DN 127:220523
Correction of: 127:50484

ED Entered STN: 06 Oct 1997
TI A practical method for the preparation of .alpha.'-chloro ketones of N-carbamate protected-.alpha.-amino acids
AU Chen, Ping; **Cheng, Peter T. W.**; Spegel, Steven H.; Zahler, Robert; Wang, Xuebao; Thottathil, John; Barrish, Joel C.; Polniaszek, Richard P.
CS Discovery Chem., **Bristol-Myers Squibb** Pharm. Res. Inst., Princeton, NJ, USA
SO Tetrahedron Letters (1997), 38(18), 3175-3178
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
CC 27-2 (Heterocyclic Compounds (One Hetero Atom))
GI



I

AB A practical method for the preparation of .alpha.-N-BOC-epoxides from protected amino acid esters based on Kowalski homologation reaction is described. This procedure can be readily performed on a large scale without the use of hazardous reagents and has allowed preparation of epoxide I in multi-kilogram quantities.
ST chloro ketone prepn; amino acid carbamate conversion chloro ketone
IT Ketones, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(.alpha.'-chloro; preparation of .alpha.'-chloroketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
IT 28709-70-8 28875-17-4 53588-99-1 58561-04-9 59936-29-7
80963-10-6 102123-74-0 127132-32-5 165727-45-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
IT 26049-94-5P 93371-30-3P 98737-29-2P 102284-41-3P 103542-47-8P
150831-62-2P 152438-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Albeck, A; Tetrahedron 1994, V50, P6333 HCAPLUS
(2) Askin, D; J Org Chem 1992, V57, P2771 HCAPLUS
(3) Barluenga, J; J Chem Soc, Chem Commun 1994, P969 HCAPLUS
(4) Barrish, J; US 5481011 1996 HCAPLUS
(5) Barrish, J; J Med Chem 1994, V37, P1758 HCAPLUS
(6) Beaulieu, P; Tet Lett 1995, V36, P3317 HCAPLUS
(7) Buckley, T; J Am Chem Soc 1981, V103, P6157 HCAPLUS
(8) Evans, B; J Org Chem 1985, V50, P4615 HCAPLUS
(9) Gordon, E; Biochem Biophys Res Commun 1985, V126, P419 HCAPLUS
(10) Green, B; Synlett 1995, P613 HCAPLUS
(11) Heinsoo, A; Tetrahedron:Asymmetry 1995, V6, P2245 HCAPLUS
(12) Kowalski, C; J Org Chem 1985, V50, P5140 HCAPLUS

(13) Kowalski, C; J Org Chem 1992, V57, P7194 HCAPLUS
(14) Luly, J; Biochem Biophys Res Comm 1987, V143, P44 HCAPLUS
(15) Luly, J; J Org Chem 1987, V52, P1487 HCAPLUS
(16) Ng, J; Tetrahedron 1995, V51, P6397 HCAPLUS
(17) Powers, J; Biochemistry 1973, V12, P4767 HCAPLUS
(18) Powers, J; J Am Chem Soc 1970, V92, P1782 HCAPLUS
(19) Rotella, D; Tet Lett 1995, V36, P5453 HCAPLUS
(20) Segal, D; Biochemistry 1971, V10, P3728 MEDLINE
(21) Thaisrivongs, S; Ann Rep Med Chem 1994, V29, P133 HCAPLUS
(22) Tsuda, Y; Chem Pharm Bull 1987, V35, P3576 HCAPLUS

L68 ANSWER 26 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:322147 HCAPLUS
DN 127:50484
ED Entered STN: 21 May 1997
TI A practical method for the preparation of .alpha.'-chloro ketones of N-carbamate protected-.alpha.-amino acids
AU Chen, Ping; **Cheng, Peter T. W.**; Sperfgel, Steven H.; Zahler, Robert; Wang, Xuebao; Thottahil, John; Barrish, Joel C.; Polniaszek, Richard P.
CS Discovery Chem., **Bristol-Myers Squibb** Pharmaceutical Res. Inst., Princeton, NJ, 0853-4000, USA
SO Tetrahedron Letters (1997), 38(18), 3175-3178
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
CC 27-2 (Heterocyclic Compounds (One Hetero Atom))
OS CASREACT 127:50484
GI



AB A practical method for the preparation of .alpha.-N-BOC-epoxides from protected amino acid esters based on Kowalski homologation reaction is described. This procedure can be readily performed on a large scale without the use of hazardous reagents and has allowed preparation of epoxide I in multi-kilogram quantities.

ST chloro ketone prepn; amino acid carbamate conversion chloro ketone
IT Ketones, preparation
RL: SPN (Synthetic preparation); PREP (Preparation)
(.alpha.'-chloro; preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
IT 28709-70-8 28875-17-4 53588-99-1 58561-04-9 59936-29-7 80963-10-6 127132-32-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
IT 102123-74-0P 165727-45-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
IT 26049-94-5P 93371-30-3P 98737-29-2P 102284-41-3P 103542-47-8P
150831-62-2P 152438-62-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of .alpha.'-chloro ketones of N-carbamate .alpha.-amino acids and preparation of epoxide derivative)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Albeck, A; Tetrahedron 1994, V50, P6333 HCAPLUS
(2) Askin, D; J Org Chem 1992, V57, P2771 HCAPLUS
(3) Barluenga, J; J Chem Soc, Chem Commun 1994, P969 HCAPLUS
(4) Barrish, J; US 5481011 1996 HCAPLUS
(5) Barrish, J; J Med Chem 1994, V37, P1758 HCAPLUS
(6) Beaulieu, P; Tet Lett 1995, V36, P3317 HCAPLUS
(7) Buckley, T; J Am Chem Soc 1981, V103, P6157 HCAPLUS
(8) Evans, B; J Org Chem 1985, V50, P4615 HCAPLUS
(9) Gordon, E; Biochem Biophys Res Commun 1985, V126, P419 HCAPLUS
(10) Green, B; Synlett 1995, P613 HCAPLUS
(11) Heinsoo, A; Tetrahedron:Asymmetry 1995, V6, P2245 HCAPLUS
(12) Kowalski, C; J Org Chem 1985, V50, P5140 HCAPLUS
(13) Kowalski, C; J Org Chem 1992, V57, P7194 HCAPLUS
(14) Luly, J; Biochem Biophys Res Comm 1987, V143, P44 HCAPLUS
(15) Luly, J; J Org Chem 1987, V52, P1487 HCAPLUS
(16) Ng J S; Tetrahedron 1995, V51, P6397
(17) Powers, J; Biochemistry 1973, V12, P4767 HCAPLUS
(18) Powers, J; J Am Chem Soc 1970, V92, P1782 HCAPLUS
(19) Rotella, D; Tet Lett 1995, V36, P5453 HCAPLUS
(20) Segal, D; Biochemistry 1971, V10, P3728 MEDLINE
(21) Thaisrivongs, S; Ann Rep Med Chem 1994, V29, P133 HCAPLUS
(22) Tsuda, Y; Chem Pharm Bull 1987, V35, P3576 HCAPLUS

L68 ANSWER 27 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:262729 HCAPLUS
DN 126:330706
ED Entered STN: 24 Apr 1997
TI Preparation of prodrug esters of phosphonosulfonate squalene synthetase inhibitors
IN **Cheng, Peter T. W.**; Poss, Michael A.
PA **Bristol-Myers Squibb** Company, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07F009-40
NCL 558180000
CC 29-7 (Organometallic and Organometalloidal Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5618964	A	19970408	US 1995-487383	19950607
PRAI	US 1995-487383		19950607		

OS MARPAT 126:330706
GI



I

AB New prodrug esters of salt forms of the phosphonosulfonate squalene synthetase inhibitor I [R = acylthioalkyl, preferably R1C(O)S(CH2)n, R1 = alkyl, arylalkyl, aryl; n = 2-6; X = pharmaceutically acceptable salt] (preparation given), including all stereoisomers, are claimed. These prodrug esters inhibit cholesterol biosynthesis (no data) and therefore are useful in lowering serum cholesterol and in treating atherosclerosis. Preferably, I is .alpha.-[[bis[[[2-(acetylthio)ethoxy]carbonyl]oxy]methoxy]phosphinyl]-3-phenoxybenzenebutanesulfonic acid or a pharmaceutically acceptable salt thereof; in an example, the potassium salt of this compound is prepared in 43% yield from ICH2OCO2CH2CH2SCOMe and m-PhOC6H4(CH2)3CH[P(O)(OH)2]SO3H (prepns. given). Capsule and injectable formulations are given.

ST phosphonosulfonate ester prepn prodrug hypercholesterolemia atherosclerosis; phosphonobenzenebutanesulfonate salt prodrug ester prepn

IT Atherosclerosis
Hypercholesterolemia
(preparation of salts of phosphonosulfonate esters for treating hypercholesterolemia and atherosclerosis)

IT Drug delivery systems
(prodrugs; preparation of salts of phosphonosulfonate esters for treating hypercholesterolemia and atherosclerosis)

IT 9077-14-9, Squalene synthetase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of prodrug esters of phosphonosulfonate squalene synthetase inhibitors)

IT 189444-34-6P 189444-35-7P 189444-36-8P 189444-37-9P 189444-38-0P 189444-39-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of salts of phosphonosulfonate esters for treating hypercholesterolemia and atherosclerosis)

IT 57-88-5, Cholesterol, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(preparation of salts of phosphonosulfonate esters for treating hypercholesterolemia and atherosclerosis)

IT 75-84-3, Neopentyl alcohol 100-51-6, Benzyl alcohol, reactions 507-09-5, Thiolacetic acid, reactions 540-51-2, 2-Bromoethanol 768-94-5, Adamantanamine 22128-62-7, Chloromethyl chloroformate 68737-65-5 157126-72-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of salts of phosphonosulfonate esters for treating hypercholesterolemia and atherosclerosis)

IT 16427-42-2P 41858-09-7P 58304-99-7P 137943-77-2P 157126-15-3P 157126-19-7P 157126-99-3P 157127-01-0P 162691-14-7P 188526-11-6P 189444-40-4P 189444-41-5P 189444-42-6P 189444-43-7P 189444-44-8P 189444-45-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of salts of phosphonosulfonate esters for treating

hypercholesterolemia and atherosclerosis)

L68 ANSWER 28 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:204430 HCAPLUS
DN 126:238373
ED Entered STN: 28 Mar 1997
TI Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
IN **Cheng, Peter T. W.**; Sun, Chong-oing; Poss, Michael A.
PA **Bristol-Myers Squibb** Company, USA
SO U.S., 23 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D321-00
NCL 549228000
CC 28-5 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5610314	A	19970311	US 1995-415799	19950403

PRAI US 1995-415799 19950403
OS CASREACT 126:238373; MARPAT 126:238373
GI



I



II

AB Dioxolenone derivs. I (R = alkyl, aryl; R3 = CO2R1, R1 is H, alkyl, benzyl, diphenylmethyl, para-methoxybenzyl) are prepared from RCOCH2CO2R1 via cyclization of RCOCH(OH)CO2R1 with a cyclization agent in the presence of an amine. I are converted to I (R3 = CH2OH) via reduction of the acid chloride and the latter are brominated to give I (R3 = CH2Br). Thus, I (R = 4-CF3C6H4, R3 = CO2H) was prepared from 4-CF3C6H4COCH2CO2CH2Ph via diazotization with 4-AcNHC6H4SO2N3, treatment of the azo compound with rhodium acetate dimer, cyclization of the hydroxy acid with carbonyldiimidazole in the presence EtN(CHMe2)2, and hydrogenolysis. I (R = 4-CF3C6H4; R3 = CH2Br), prepared from I (R = 4-CF3C6H4; R3 = CO2H) via chlorination with ClCOCOCl in CH2Cl2 containing DMF, reduction with NaBH4 in

EtOH/CH2Cl2 and bromination with CBr4/PPh3 in CH2Cl2, was converted to sulfonate II. II is a prodrug of a squalene synthetase inhibitor.

ST dioxolenone deriv prepn; squalene synthetase inhibitor dioxolenone deriv prodrug

IT Drug delivery systems
(prodrugs; preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

IT 9077-14-9D, Squalene synthetase, inhibitors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

IT 1344-67-8, Copper chloride 5503-41-3, Rhodium diacetate 7440-50-8, Copper, uses
RL: CAT (Catalyst use); USES (Uses)
(preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

IT 75-44-5, Carbonic dichloride 79-37-8, Oxalyl chloride 101-02-0, Triphenyl phosphite 109-02-4, N-Methylmorpholine 110-86-1, Pyridine, reactions 121-44-8, reactions 329-15-7, p-(Trifluoromethyl)benzoyl chloride 503-38-8, Diphosgene 530-62-1, 1,1'-Carbonyldiimidazole 558-13-4, Carbon tetrabromide 603-35-0, Triphenylphosphine, reactions 998-40-3, Tributylphosphine 3249-68-1, Ethyl butyrylacetate 4949-44-4, Ethyl propionylacetate 6148-64-7, Ethyl potassium malonate 7087-68-5, Diisopropylethylamine 7152-15-0, Ethyl isobutyrylacetate 7719-09-7, Thionyl chloride 7719-12-2, Phosphorus trichloride 7726-95-6, Bromine, reactions 7737-62-4, Ethyl 3-oxoheptanoate 7789-60-8, Phosphorus tribromide 16940-66-2, Sodium borohydride 17476-04-9, Lithium tri(tert-butoxy)aluminum hydride 32315-10-9, Triphosgene 33725-74-5, Tetrabutylammonium borohydride 55107-14-7, Methyl 4,4-dimethyl-3-oxopentanoate 188526-11-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

IT 2158-14-7P, 4-Acetamidobenzenesulfonyl azide 4949-45-5P, Benzyl 3-oxopentanoate 5006-35-9P 66696-91-1P 77902-92-2P 86005-12-1P 86978-73-6P 94250-56-3P 106263-53-0P 188525-84-0P 188525-85-1P 188525-86-2P 188525-88-4P 188525-89-5P 188525-90-8P 188525-92-0P 188525-93-1P 188525-95-3P 188525-96-4P 188525-97-5P 188525-99-7P 188526-00-3P 188526-01-4P 188526-03-6P 188526-04-7P 188526-05-8P 188526-07-0P 188526-08-1P 188526-09-2P 188526-10-5P 188526-12-7P 188526-13-8P 188526-14-9P 188526-15-0P 188526-16-1P 188526-17-2P 188526-18-3P 188526-19-4P 188526-20-7P 188526-21-8P 188526-22-9P 188526-23-0P 188526-24-1P 188526-25-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

IT 188525-87-3P 188525-91-9P 188525-94-2P 188525-98-6P 188526-02-5P 188526-06-9P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dioxolenone derivs. as prodrugs for squalene synthetase inhibitors)

L68 ANSWER 29 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:415302 HCAPLUS
ED Entered STN: 16 Jul 1996
TI A practical method for the preparation of .alpha.'-chloroketones of N-protected-.alpha.-aminoacids.
AU Chen, Ping; **Cheng, Peter T. W.**; Spergel, Steven H.; Zahler,

Robert; Wang, Xuebao; Thottathil, John; Barrish, Joel C.; Polniaszek, Richard
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Book of Abstracts, 212th ACS National Meeting, Orlando, FL, August 25-29 (1996), ORGN-397 Publisher: American Chemical Society, Washington, D. C. CODEN: 63BFAF
DT Conference; Meeting Abstract
LA English
AB A method for the preparationof .alpha.-N-carbamate-protected epoxides from protected amino acid esters based on the Kowalski homologation reaction is described. This procedure can be readily performed on a large scale without the use of hazardous reagents. [Equation Omitted].

L68 ANSWER 30 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:241879 HCAPLUS
DN 125:157770
ED Entered STN: 25 Apr 1996
TI Amino Diol HIV Protease Inhibitors. Synthesis And Structure-Activity Relationships Of P1/P1' Compounds: Correlation between Lipophilicity and Cytotoxicity
AU Chen, Ping; **Cheng, Peter T. W.**; Alam, Masud; Beyer, Barbara D.; Bisacchi, Gregory S.; Dejneka, Tamara; Evans, Adelaide J.; Greytok, Jill A.; Hermsmeier, Mark A.; et al.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Journal of Medicinal Chemistry (1996), 39(10), 1991-2007 CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
CC 1-3 (Pharmacology)
Section cross-reference(s): 34
GI



I

AB A series of novel amino diol inhibitors of HIV protease based on an amino diol (I) with structural modifications were prepared in order to reduce the cytotoxicity of I. The authors observed a high degree of correlation between the lipophilicity and the cytotoxicity of this series of inhibitors. Appropriate substitution at the para position of the Ph group of I resulted in the identification of equipotent (both against the enzyme and in cell culture) compds. which had significantly decreased cytotoxicity.
ST amino diol HIV protease inhibitor prepn; structure amino diol antitumor prepn; lipophilicity cytotoxicity amino diol prepn
IT Lipophilicity
Neoplasm inhibitors
(preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)
IT Molecular structure-biological activity relationship

(aspartic proteinase-inhibiting, preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT Molecular structure-property relationship
(lipophilicity, preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT Molecular structure-biological activity relationship
(neoplasm-inhibiting, preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT 144114-21-6, Retropepsin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitors; preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT 162539-73-3 162540-08-1 162540-10-5 162540-58-1 175233-85-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT 161302-38-1DP, derivs. 161302-40-5P 162538-18-3P 162538-24-1P
162538-25-2P 162539-54-0P 162539-57-3P 162539-80-2P 162539-95-9P
162540-49-0P 162540-61-6P 162540-84-3P 162540-90-1P 162540-93-4P
162540-97-8P 162541-02-8P 162541-04-0P 162541-14-2P 175233-59-7P
175233-60-0P 175233-61-1P 175417-50-2P 175417-51-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT 105-36-2, Ethyl bromoacetate 109-00-2, 3-Hydroxypyridine 288-32-4, Imidazole, reactions 500-22-1, 3-Pyridinecarboxaldehyde 540-51-2, 2-Bromoethanol 547-64-8, Methyl lactate 587-33-7, L-m-Tyrosine 622-08-2 1826-67-1, Vinylmagnesium bromide 2130-96-3 3417-91-2 13734-34-4 98737-29-2 169701-45-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

IT 1615-14-1P, 1H-Imidazole-1-ethanol 3694-86-8P 4326-36-7P 16677-29-5P 17450-34-9P 37535-57-2P 53346-03-5P 70448-03-2P 90819-30-0P 112766-18-4P 144825-44-5P 161453-37-8P 162536-42-7P 162536-45-0P 162536-46-1P 162536-84-7P 162537-86-2P 162537-87-3P 162537-99-7P 162538-00-3P 162538-01-4P 162538-15-0P 162538-16-1P 162538-17-2P 162538-23-0P 162539-58-4P 162540-95-6P 162541-27-7P 162541-31-3P 162541-35-7P 162541-58-4P 162542-02-1P 162542-03-2P 175233-62-2P 175233-63-3P 175233-64-4P 175233-65-5P 175233-66-6P 175233-67-7P 175233-68-8P 175233-69-9P 175233-70-2P 175233-71-3P 175233-72-4P 175233-73-5P 175233-74-6P 175233-75-7P 175233-76-8P 175233-77-9P 175233-78-0P 175233-79-1P 175233-80-4P 175233-81-5P 175233-82-6P 175233-83-7P 175233-84-8P 175233-86-0P 175233-87-1P 175233-88-2P 175233-89-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino diol HIV-protease inhibitors and correlation between lipophilicity and cytotoxicity)

L68 ANSWER 31 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:71589 HCAPLUS
DN 124:233145
ED Entered STN: 02 Feb 1996
TI Process for preparing N-protected amino acid .alpha.-halomethyl ketones

and alcohols from N-protected amino acid esters
IN Chen, Ping; **Cheng, Peter T. W.**; Spergel, Steven H.; Barrish, Joel C.; Thottathil, John K.; Zahler, Robert; Polniaszek, Richard P.; Wang, Xuebao
PA **Bristol-Myers Squibb** Company, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D301-02
ICS C07D303-12; C07D303-36
NCL 549514000
CC 34-2 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5481011	A	19960102	US 1994-355373	19941213
CA 2163062	AA	19960614	CA 1995-2163062	19951116
CA 2163062	C	19990209		
FI 9505955	A	19960614	FI 1995-5955	19951212
AU 9540360	A1	19960620	AU 1995-40360	19951212
AU 690768	B2	19980430		
EP 719769	A2	19960703	EP 1995-309025	19951212
EP 719769	A3	19960731		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 73644	A2	19960930	HU 1995-3544	19951212
HU 215249	B	19981130		
CN 1132203	A	19961002	CN 1995-121316	19951212
JP 08225557	A2	19960903	JP 1995-324201	19951213
PRAI US 1994-355373		19941213		

OS CASREACT 124:233145; MARPAT 124:233145
GI







AB The present invention relates to a novel method useful for the conversion of amino acids to halomethyl ketones, which are then converted to amino

acid epoxides. Such epoxides are important intermediates for the synthesis of inhibitors of renin and HIV protease, which are particularly useful in the treatment and/or prevention of HIV infection (AIDS). More specifically, a process is claimed for preparing an amino epoxide I wherein R4 and R5 are independently selected from hydrogen, lower alkyl, aryl, aralkyl substituted lower alkyl, or R4 and R5 are taken together with the carbon atom to which they are bonded to form a substituted or unsubstituted carbocyclo group, which comprises: (a) reacting an amino ester II wherein Z is a carbamate group having the formula R7O2C, wherein R7 is selected from lower alkyl or arylalkyl, and wherein R6 is selected from lower alkyl or benzyl, with at least 2 molar equivalents of a compound of formula LiCHX1X2 wherein X1 and X2 are independently selected from chloro, bromo, iodo or fluoro, provided at least one of X1 or X2 is bromo or iodo, to form a halomethyl ketone III wherein X is selected from X1 or X2; and (b) converting III to the amino epoxide. Thus, e.g., treatment of Boc-L-phenylalanine Et ester (1.17 g; 4 mmol) and chloroiodomethane (1.16 mL; 4 mmol) in 22 mL of THF at -78.degree. with lithium diisopropylamide afforded chloro ketone IV; reduction of IV with NaBH4 afforded chlorohydrin V (51%); ring closure of V (KOH/EtOH) afforded epoxide VI (85%).

ST halomethylation amino acid ester; ketone halomethyl amino acid prepn redn; alc halomethyl amino acid prepn cyclization; epoxide amino acid prepn

IT Halomethylation
(consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 102123-74-0P 152438-62-5P 165727-45-7P 174801-33-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 98737-29-2P 162536-84-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 593-71-5, Chloroiodomethane 53588-99-1, Boc-L-phenylalanine ethyl ester 127132-32-5, Boc-L-O-benzyltyrosine ethyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 109-63-7, Boron trifluoride etherate
RL: CAT (Catalyst use); USES (Uses)
(reduction catalyst; consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 16940-66-2, Sodium borohydride
RL: RCT (Reactant); RACT (Reactant or reagent)
(reducing agent; consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 109-99-9, THF, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

IT 617-86-7, Triethylsilane
RL: RCT (Reactant); RACT (Reactant or reagent)
(stereoselective reducing agent; consecutive conversion of N-protected amino acid esters to N-protected amino acid .alpha.-halomethyl ketones, alcs., and amino epoxides)

L68 ANSWER 32 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:755738 HCAPLUS
DN 124:8354
ED Entered STN: 24 Aug 1995
TI .alpha.-Hydroxyamide derived aminodiols as potent inhibitors of HIV protease
AU Ahmad, Saleem; Ashfaq, Aaila; Alam, Masud; Bisacchi, Gregory S.; Chen, Ping; **Cheng, Peter T. W.**; Greytok, Jill A.; Hermsmeier, Mark A.; Lin, Pin-Fang; et al.
CS **Bristol-Myers Squibb** Pharm. Res. Inst., Princeton, NJ, 08543, USA
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(15), 1729-34
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 15
GI



I

AB A novel series of HIV protease inhibitors has been prepared Replacement of the P2 carbamate of compound I (R = CO2CMe3) [IC50 = 125 nM] with an .alpha.-hydroxy amide moiety results in a significant increase in anti-HIV protease activity [e.g., I, R = 1-hydroxy-2,2-dimethylcyclopentylcarbonyl; IC50 = 15 nM]. Furthermore, isomers with (R) absolute configuration at the P2 site show greater inhibitory activity than the corresponding (S)-isomers. A proposed binding mode based on mol. modeling is used to rationalize the structure-activity relationships.
ST aminodiol hydroxyamide prepn inhibitor HIV protease
IT Virus, animal
(human immunodeficiency 1, preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)
IT 161302-38-1 162538-55-8 162540-34-3 162540-38-7 162540-75-2
162541-00-6 162541-09-5 162541-10-8 162541-17-5 162677-84-1
162678-02-6 162678-03-7 162678-10-6 162678-11-7 162678-15-1
171228-69-6 171228-70-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)
IT 161302-39-2P 162541-03-9P 162677-82-9P 162678-07-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)
IT 144114-21-6, Retropepsin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)

IT 79-50-5 100-46-9, Benzylamine, reactions 594-56-9 617-35-6, Ethyl pyruvate 1826-67-1, Vinylmagnesium bromide 4541-32-6, 2,2-Dimethylcyclopentanone 13031-04-4 98737-29-2 128018-44-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)

IT 1184-93-6P 4026-21-5P 15833-82-6P 100841-12-1P 162536-41-6P 162538-49-0P 170996-47-1P 170996-48-2P 170996-49-3P 170996-50-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)

IT 684-07-1P 21641-92-9P 22146-57-2P 170996-45-9P 170996-46-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxyamide derived aminodiols as potent inhibitors of HIV protease)

L68 ANSWER 33 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:445266 HCAPLUS
DN 123:82913
ED Entered STN: 28 Mar 1995
TI Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency
AU Bisacchi, G. S.; Ahmad, S.; Alam, M.; Ashfaq, A.; Barrish, J.; **Cheng, P. T. W.**; Greytok, J.; Hermsmier, M.; Lin, P. F.; et al,
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(5), 459-64
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
CC 25-21 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 75
AB A series of BOC-modified analogs of the aminodiol HIV protease inhibitor BMS-182193 was prepared and tested for inhibitory activity against the enzyme and the virus in cell culture. Some hydroxy-modified analogs showed enhanced potency against the protease.
ST amine diol HIV protease; virucide amine diol HIV protease; structure BMS 182193 aminodiol HIV protease; activity BMS 182193 aminodiol HIV protease
IT Molecular structure
Virucides and Virustats
(preparation of BMS-182193 derivs. as HIV protease inhibitors)
IT Virus, animal
(human immunodeficiency 1, preparation of BMS-182193 derivs. as HIV protease inhibitors)
IT Molecular structure-biological activity relationship
(virucidal, preparation of BMS-182193 derivs. as HIV protease inhibitors)
IT 161302-38-1DP, 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-11-oxo-3,9-bis(phenylmethyl)-, 1,1-dimethylethyl ester, [3S-(3R*,4S*,8S*,9R*)], derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(BMS-182193; preparation of BMS-182193 derivs. as HIV protease inhibitors)
IT 144114-21-6, Retropepsin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(HIV-1 protease; preparation of BMS-182193 derivs. as HIV protease inhibitors)

IT 162538-49-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of BMS-182193 derivs. as HIV protease inhibitors)

IT 162539-41-5P 162539-44-8P 162539-47-1P 162539-48-2P 162539-88-0P 162539-97-1P 162539-99-3P 162540-03-6P 162540-07-0P 162540-18-3P 162540-60-5P 162677-86-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of BMS-182193 derivs. as HIV protease inhibitors)

IT 98737-29-2 162538-06-9 162538-40-1 165331-68-0 165331-69-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of BMS-182193 derivs. as HIV protease inhibitors)

IT 162536-81-4P 162538-43-4P 162539-42-6P 165331-65-7P 165331-67-9P 165524-61-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of BMS-182193 derivs. as HIV protease inhibitors)

IT 165331-66-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of BMS-182193 derivs. as HIV protease inhibitors)

L68 ANSWER 34 OF 34 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:11984 HCAPLUS
DN 123:143351
ED Entered STN: 08 Nov 1994
TI Amino Diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR
AU Barrish, Joel C.; Gordon, Eric; Alam, Masud; Lin, Pin-Fang; Bisacchi, Gregory S.; Chen, Ping; **Cheng, Peter T. W.**; Fritz, Alan W.; Greytok, Jill A.; et al.
CS **Bristol-Myers Squibb** Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA
SO Journal of Medicinal Chemistry (1994), 37(12), 1758-68
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
CC 25-4 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 34
GI



I

AB A series of HIV protease inhibitors containing a novel C2 sym. amino diol core structure were prepared from amino acid starting materials. The ability of the amino diols to inhibit HIV replication in cell culture is comparable to their ability to inhibit the isolated enzyme, a result compatible with good cell membrane penetration by this class of compds. Optimization of the structure-activity in this series led to amino diol I [Ki = 100 nM;

ED50 (HIV-1) = 80 nM]. I is a selective inhibitor of HIV protease vs. other aspartyl proteases such as human renin, human cathepsin D, and porcine pepsin. In addition, I is equipotent against HIV-1 and HIV-2 in cell culture and demonstrates similar activity in infected T-lymphocytes and PBMCs. After i.v. and oral administration in rats, I displayed significant oral bioavailability (ca. 40%) and a promising plasma elimination half-life (4 h).

ST aminohydroxyphenylbutylamine prepn protease inhibitor; HIV inhibitor bisaminohydroxyphenylbutylamine prepn

IT Virus, animal
(human immunodeficiency 1, inhibitors, bis[amino(hydroxy)phenylbutyl]amines)

IT Virus, animal
(human immunodeficiency 2, inhibitors, bis[amino(hydroxy)phenylbutyl]amines)

IT 161302-38-1P 162538-12-7P 162538-18-3P 162538-22-9P 162538-39-8P
162538-45-6P 162538-55-8P 162539-07-3P 162539-13-1P 162539-20-0P
162539-23-3P 162539-64-2P 162677-30-7P 162677-32-9P 162677-36-3P
162677-37-4P 162677-38-5P 162678-23-1P 165727-43-5P 165727-44-6P
166019-57-4P 166019-58-5P 166019-61-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis, and preliminary SAR of amino diol HIV protease inhibitors)

IT 144114-21-6, Retropepsin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(design, synthesis, and preliminary SAR of amino diol HIV protease inhibitors)

IT 13734-34-4, N-tert-Butoxycarbonyl-L-phenylalanine 99113-30-1
107202-43-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(design, synthesis, and preliminary SAR of amino diol HIV protease inhibitors)

IT 60398-41-6P 94670-70-9P 98737-29-2P 98760-08-8P 102123-74-0P
107202-62-0P 128018-44-0P 130944-47-7P 156474-21-4P 156474-22-5P
160232-54-2P 162536-41-6P 162536-42-7P 162536-72-3P 162536-73-4P
162536-74-5P 162537-01-1P 162538-06-9P 162538-15-0P 162538-21-8P
162538-40-1P 162538-98-9P 162538-99-0P 162539-06-2P 162539-11-9P
162539-12-0P 162541-31-3P 162541-33-5P 162541-42-6P 165727-45-7P
165727-46-8P 165727-47-9P 165727-48-0P 165727-49-1P 165727-50-4P
165727-51-5P 165727-52-6P 165727-53-7P 166019-59-6P 166019-60-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis, and preliminary SAR of amino diol HIV protease inhibitors)

=> b home
FILE 'HOME' ENTERED AT 15:13:22 ON 13 JUL 2004

=>